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Abstract 
Platelets are cytoplasmic fragments present in large numbers within the bloodstream 
that contain a multitude of proteins. For a long time, platelet function was believed to 
be limited to the essential functions of haemostasis and thrombosis. However, it has 
become clear in the last decade that platelets play significant roles in both innate and 
adaptive immunity, inflammatory responses including leukocyte migration, tissue 
regeneration and angiogenesis. Parallelling the revelation of the diverse physiological 
functions of platelets, however, has been the association of exacerbated platelet 
function with numerous thrombotic and chronic inflammatory diseases. Until our 
knowledge of platelet biology is more comprehensive, the prevention of platelet-
associated pathologies will remain a challenge of inhibiting pathology-associated 
platelet reactions whilst preserving those essential for normal function. The aims of 
this thesis, therefore, were to examine in detail the following three platelet-associated 
biological processes: (i) The role of platelets in tumour cell metastasis, in particular, the 
kinetics and interrelationship of the pro-metastatic role of platelets and the anti-
metastatic role of NK ceils, and the relevant contributions to the metastatic process of 
platelet P-selectin and endothelial P-selectin. (ii) The determinants and mechanisms of 
antibody-mediated platelet elimination, as seen in the medical condition known as 
immune thrombocytopenic purpura (ITP), and the role of inhibitory self-recognition 
systems in this process, (iii) The factors influencing platelet and erythrocyte lifespan by 
establishing approphate experimental and analytical methodologies. 
The results of work described in Chapter 3 have demonstrated that the lung metastasis 
of both B16F1 melanoma cells and 4T1.2 breast cancer cells is promoted by platelets 
and inhibited by NK cells. Moreover, in the B16F1 metastasis model, platelets were 
demonstrated to promote lung metastasis by a process that is independent of NK cells 
and, likewise, the action of NK cells was unaltered in the presence or absence of 
platelets. Additionally, the role of platelets and NK cells in the metastatic process were 
shown to be chronologically distinct with the pro-metastatic action of platelets occurring 
within 1 hr, and the anti-metastatic action of NK cells occurring between 1 hr and 24 hr 
following tumour cell injection. Intriguingly, unlike B16F1 melanonna lung metastasis, 
B16F1 liver metastasis appeared not to be reliant upon platelets, in fact, in the absence 
of platelets liver metastasis was increased most likely due tumour cells, unable to 
adhere to the lung capillary bed without the assistance of platelets, being swept into 
downstream organs. Furthermore, the pro-metastatic roles of both platelet-derived and 
endothelial-derived P-selectin in lung metastasis, and endothelial-derived P-selectin in 
liver metastasis, was demonstrated. P-selectin may, therefore, represent a key target 
for therapies aimed at preventing tumour metastasis in multiple organs. 
In Chapter 4, it was demonstrated in a mouse model of ITP using rat mAbs specific for 
various murine platelet surface proteins, that ITP induction was dependent upon the 
platelet protein targeted by the antibody and the antibody isotype, it was not 
determined by the density of mAb binding or the level of platelet antigen saturation. 
Additionally, the mechanism of platelet elimination in this model of ITP occurred 
phncipally via FcyR-mediated phagocytosis but was also shown to occur, in a limited 
number of instances, through complement-mediated destruction or through an FcyR-
and complement-independent process of platelet fragmentation. An exploration into the 
role of the self-recognition protein pair CD47:SIRPa in this model of ITP revealed that 
some antibodies that were incapable of inducing ITP in WT mice were capable of 
inducing ITP in CD47-deficient mice. Furthermore, administration of an activating mAb 
specific for SIRPa in-vivo not only prevented, but reversed rat lgG1 mAb-induced, 
FcyR-mediated ITP. This treatment effect was isotype specific, however, as SIRPa 
mAb treatment was unable to prevent ITP induced by rat lgG2b mAbs suggesting that 
SIRPa inhibits the signalling capacity of low-affinity rather than high-affinity FcyRs. The 
results of these studies give a greater understanding of the pathogenic pathways of 
ITP and how self-recognition systems may be manipulated to prevent antibody-
mediated ITP. 
The aims of work presented in Chapter 5 were to establish an in-vivo platelet and 
erythrocyte labelling method using CFSE, determine the most appropriate 
mathematical model for lifespan analysis, and apply both to the study of factors that 
control platelet and erythrocyte lifespans. Control and platelet-deficient c-mpi-/- and 
BCI-XL mutant mice were injected with CFSE and platelet and erythrocyte fluorescence 
followed over time. Data sets were analysed using linear, exponential, multiple-hit and 
lognormal mathematical models. It was found that in-vivo CFSE labelling of platelets 
and erythrocytes requires no post-collection processing, proved to be stable, non-toxic 
and non-immunogenic, and the lifespans obtained were highly reproducible. 
Mathematical modelling revealed the lognormal model gave a robust fit to control and 
extreme data sets when either extrinsic or intrinsic factors determined lifespan. Using 
these methods, platelet lifespans were found to be significantly shortened in 
thrombopoietin-receptor deficient mice independent of blood loss, and the anti-
apoptotic protein BCI-XL was shown to play a role in prolonging erythrocyte lifespans. 
Thus, the simultaneous study of platelet and erythrocyte lifespans using in-vivo CFSE 
labelling with lognormal modelling yielded insights into common intrinsic and extrinsic 
platelet and erythrocyte lifespan determinants and provides an improved methodology 
for use in this field of research. 
The experimental data presented in this thesis has shed some light on three aspects of 
platelet biology, namely, proving their NK cell independent role in the promotion of 
tumour cell metastasis that closely resembles their role in assisting leukocyte 
migration; identifying not only likely determinants and mechanisms of antibody-
mediated platelet destruction but also an inhibitor of this process that may have 
therapeutic potential; and the development of robust methods that may be used to 
better understand those factors influencing the production, lifespan and senescence of 
platelets. As with most research, whilst the results presented in this thesis have 
answered some questions, they have also raised many more upon which future 
research may be based. 
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Chapter 1 
Literature Review 
1.1 Introduction 
Cancer is one of the greatest contributors to morbidity and nnortality in developed 
countries with estimates that 1 in 3 males and 1 in 4 females within the Australian 
population will be diagnosed with cancer before the age of 75 (Australian Institute of 
Health and Welfare 2010). Approximately 40% of those individuals will succumb to 
their disease within 5 years despite treatment (Australian Institute of Health and 
Welfare 2008). The principle cause of cancer-associated mortality is metastasis, the 
spread of cancer from the initial site of occurrence, known as the primary, throughout 
the body forming secondary tumours. 
Metastasis occurs via the bloodstream, known as the haematogenous route, or via the 
lymphatic vessels. Due to the nature of the circulatory system, haematogenous 
metastasis results in the dissemination of metastasising tumour cells to multiple organs 
with the most common sites being the liver, lungs, bone and brain (National Cancer 
Institute; Liotta 1992). It is these multiple secondary sites of tumour growth that 
present the greatest threat to life and the greatest challenge for treatment. Hence, 
elucidating the mechanisms of metastasis and designing therapies to prevent its 
occurrence are imperative to the overall goal of reducing cancer-related deaths. 
The relationship between an increased risk of thrombosis (blood clots) and malignant 
cancer has been long recognised, being first described by Bouillard in 1823 and later 
by Trousseau in 1865 (Bouillard and Bouillaud 1823; Trousseau 1865). These initial 
observations stimulated a great amount of research into the many components of 
coagulation and their role in metastatic disease. Platelets were first demonstrated to 
promote metastasis by Gasic et al in 1968 (Gasic et al. 1968). Many studies 
performed since then have confirmed the pro-metastatic role of platelets with the 
purported mechanisms of action including the formation of a thrombus around the 
tumour cell thus affording protection from haemodynamic stresses, linking tumour cells 
to the vascular endothelium via adhesion molecules, assisting the migration of tumour 
cells across the blood vessel wall through the releases of deradative enzymes, and the 
provision of growth and angiogenic factors enabling the establishment of secondary 
tumours (Karpatkin and Pearlstein 1981; Karpatkin 2002; Erpenbeck and Schon 2010). 
The evidence was sufficiently compelling for clinical trials of various anti-platelet agents 
to be conducted in individuals with cancer. Conflicting results, however, have cast a 
shadow of doubt over this potential avenue of therapy (AkI et al. 2007; Kuderer et at. 
2007). Other laboratory-based research has suggested the only role for platelets in 
metastasis is the formation of a protective cloak around the tumour cells thus 
preventing immune-cell mediated tumour-cell killing (Nieswandt et al. 1999; Palumbo et 
al. 2005). 
The full repertoire of platelet activities in health and disease is still being unravelled. 
For a long time, platelet function was believed to be limited to haemostasis (the arrest 
of bleeding) and thrombosis, however, it has become clear in the last decade that 
platelets play a significant role in immunity, inflammation, wound healing, and 
angiogenesis (new blood vessel formation). The molecular events involved in these 
platelet functions are complex and still being determined. 
This thesis revisits the role of platelets in haematogenous tumour cell metastasis and, 
thus, the following sections provide background information on the diversity of platelet 
functions, the ultra-structural and molecular characteristics of the haematogenous 
metastatic process with a comparison made to that of leukocyte migration, and the 
evidence for and against a role for platelets in haematogenous metastasis. The 
chapter concludes with a summary of the aims of the PhD project. 
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1.2 Platelet Structure and Function 
Although platelets were Initially thought to have a role only in thrombosis and 
haemostasis, they have subsequently been shown to participate in wound healing, 
angiogenesis and immune-related activities such as defence against pathological 
microorganisms, and activation and assisted migration of immune cells. The following 
sections briefly review the structure and functions of platelets. 
1.2.1 Platelet Structure 
Platelets circulate within the bloodstream and consist of small, discoid, anucleate, 
cytoplasmic fragments released by megakaryocytes from within the bone marrow or 
the lung capillary bed (Zucker-Franklin and Philipp 2000). In the resting state, the 
surface of the platelet contains numerous pores that function as entrances to the open 
canalicular system, an elaborate internal, tubular, membraneous network. Within the 
platelet cytoplasm are mitochondria, some endoplasmic reticulum and 3 types of 
storage granules - a granules, dense granules and lysosomes. The contents of 
platelet granules are considerable and listed in Table 1.1 (Reed 2002). 
Alpha-granules are the largest and most numerous of the platelet secretory granules 
making up approximately 10% of the platelet volume and numbering 50-80 per platelet. 
The contents of a-granules are either synthesised by the megakaryocyte and 
packaged prior to platelet formation, or endocytosed by the megakaryocyte or platelet. 
Significant heterogeneity exists in the content of a-granules and subpopulations of 
granules have been observed within the a-granules (Blair and Flaumenhaft 2009). In 
comparison, dense granules constitute approximately 1% of platelet volume and 
Table 1.1: Platelet granule contents 
a-granules Membrane-bound Pro-angiogenic & Pro-inflammatory & 
proteins Wound Repair Immune Modulating 
P-selectin Vascular endothelial GF- Factors 
a l l | « (Gpllb-llla) A Platelet-derived GF 
(xVp3 Vascular endothelial GF- CXCL-1,-4, -5, -7, -8, -12 
GpVI C CCL-2, -3, -5 
Fc receptors Basic fibroblast GF Transforming GF-(5 
PECAM-1 (CD31) Platelet-derived GF p-thromboglobulin 
Gplb-IX-V Epidermal GF CD40L 
CD9 Insulin-like GF-1 
CD36 Hepatocyte GF Antimicrobial Host 
Gluts Angiopoietin Defence 
Fibrocystin L CXCL12 CXCL4, CXCL7, CCL5 
CD109 M M P s - 1 , 3 & 9 Thymosin f>4 
Gas6 C3, C4 precursor 
Adhesion & p thromboglobulin Factor D 
Coagulation Osteonectin IgG 
vWF Protease nexin-ll 
Tissue factor Heparanase Complement 
Fibrinogen Regulators 
Fibronectin Angiogenesis Inhibitors Platelet factor H 
vitronectin Thrombospondin-1 C1 inhibitor 
Factor V + multimerin CXCL-4 (PF4) p i H globulin 
Factor XI Angiostatin 
Factor XIII Endostatin Protease Regulation 
Factor VIII Tissue inhibitors of MMPs (x1-antitrypsin 
Prothrombin -1 & - 4 (x2-macroglobulin 
HMW kininogens 
Plasminogen activator- Coagulation Inhibitors 
inhibitor-1 (PAI-1) Antithrombin 
«2-antiplasmin C1 inhibitor 
Histidine-rich glycoprotein Tissue factor pathway 
Protease nexin-ll inhibitor 
Protein S 
Protease nexin-2 
Plasmin and plasminogen 
Dense Platelet Activation Ions Wound healing & 
granules ADP Phosphate Vasodilation & 
ATP Pyrophosphate Constriction 
Serotonin Calcium Serotonin 
Magnesium Histamine 
Nucleotides 
GTP Membrane proteins 
GDP LAMP 3 (CD63) 
LAMP 2 
P-selectin 
Lysosomes Membrane Proteins Degradative Enzymes 
LAMP 1 Acid hydrolases (x13) 
LAMP 2 Cathepsin D 
LAMP 3 (CD63) Cathepsin E 
Mezzano et al. 2008; Blair and Flaumenhaft 2009) 
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number approximately 7 per platelet. Lysosome numbers are very few (Reed 2002; 
Blair and Flaumenhaft 2009). 
1.2.2 Platelet Function in Thrombosis and Haemostasis 
Due to their small size and shape, platelets are marginalised by the blood flow to the 
lumenal surface of the blood vessels where they are most likely to come into contact 
with damaged endothelium (Plow and Ginsberg 1999). Intact endothelium secretes 
several factors that inhibit coagulation and platelet activation. Those factors preventing 
platelet activation include nitric oxide, prostaglandin U and adenosine diphosphatase. 
When the endothelium is damaged, however, the secretion of these factors is down-
regulated and the non-thrombogenic nature of the endothelium is reversed (Karsan 
and Harlan 1999). The reaction of platelets to exposed subendothelial matrix is 
complex with the underlying mechanisms varying according to the prevailing shear 
forces (Jackson 2007). The following sections describe, in a simplified way, the 
reaction of platelets when they interact with components of the subendothelial matrix 
exposed through injury. 
1.2.2.1 Platelet Adhesion 
Platelets express on their surface several receptor proteins that bind to components of 
the extracellular matrix (Table 1.2 lists the major platelet receptors and their ligands). 
The receptors with the greatest roles in platelet adhesion are Gplb-IX-V, GpVI, Gpla-lla 
and Gpllb-lila (Plow and Ginsberg 1999; Lopez and Berndt 2002). 
The initial contact between platelets and the subendothelial matrix involves the 
formation of platelet membrane tethers extending from the point of adhesion to the 
endothelium. These tethers may be transient and entail Gplb-IX-V binding to vWF 
which triggers a conformational change in Gpllb-llla to an active state enabling it to 
bind fibronectin and vWF (Jackson 2007). Whilst the signalling induced by Gplb-IX-V 
binding to vWF results in Gpllb-llla activation, it does not induce granule secretion. 
More stable adhesive interactions with the endothelium are mediated by GpVI or Gpla-
lla binding to collagen and it is these interactions that induce sufficient signalling to 
induce granule secretion (Plow and Ginsberg 1999; Lopez and Berndt 2002). 
1.2.2.2 Platelet Activation, Spreading and Aggregation 
Platelets may be activated by platelet adhesion receptors binding their ligands (e.g., 
GpVI to collagen), agonists released from nearby platelets binding their G-coupled 
protein receptors on platelets (e.g. ADP and thromboxane A2), or soluble substances 
produced as a result of injury interacting with their platelet receptors (e.g. thrombin and 
adrenaline). The complete process of platelet activation includes cytoskeletal 
rearrangement and shape change, calcium mobilisation, integrin activation and granule 
secretion. 
Following adhesion and activation, platelets spread on the damaged endothelial 
surface essentially forming a pavement. The additional membrane provided by the 
open canalicular system and a -granules results in a 2- to 4-fold increase in platelet 
surface area following activation (Blair and Flaumenhaft 2009). Following the release of 
granule contents, in particular ADP and thromboxane, and the generation of thrombin, 
additional platelets are recruited and activated and may either bind to the endothelium 
or to the initially adherent platelets thus forming a 3-dimensional thrombus. These 
platelet-platelet interactions are dependent upon Gplb-IX-V and Gpllb-llla (Patel et al. 
2003; Furie and Furie 2004; Jackson 2007). 
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Table 1.2: Major platelet receptors 
Receptor Family Receptor Liqands 
Integrin - p3 Family 
aiibPs (Gpllb-llla) 
50,000 - 80,000 
copies 
Fibrinogen, von Willebrand factor 
(vWF), fibronectin, vitronectin and 
thrombospondin 
WvPs 
50-100 copies 
Fibronectin, fibrinogen, laminin, 
collagen, PECAM-1, vitronectin, 
osteopontin, bone sialoprotein? " 
Integrin - pi Family 
aaPi (Gpla-lla) 
2,000-4,000 copies 
Collagen 
asP, (Gplc-lla) 
<1000 copies 
Fibronectin 
aeP, (Gplc'-lla) 
<1000 copies 
Laminin 
C-type lectin-like CLEC-2 Podoplanin 
EGF repeat containing 
receptor 
PEAR1 Not yet identified 
Immunoglobulin Superfamily 
GpVI 
-1000 copies 
Collagen 
FCYRIIA (human) IgG 
FCERI (human) igE 
JAM-1 JAM-1 on other platelets or 
endothelium 
ICAIVL-2 
-3,000 copies 
aLP2on leukocytes or other platelets 
PECAM-1 (CD31) PECAM-1 (CD31) on other 
platelets, leukocytes or 
endothelium, a^Pj heparan sulfate 
proteoglycans 
CD47 Thrombospondin, SIRPa 
" The role of platelet (XvPs is unknown, however, on other cell types the ligands for (XvPs include 
those listed. 
Table 1.2: Major platelet receptors (continued) 
Receptor Family Receptor Ligands 
Leucine-Rich Repeat Family 
Gplb-IX-V 
30-40,000 copies 
vWF, P-selectin, Mac-1, thrombin, 
HMW kininogen, Factors XI and XII 
Selectins P-selectin " PSGL-1, Gplb 
Tyrosine Kinase Receptors c-mpi Thrombopoietin 
TNF-Receptor Superfamily CD40 CD40 ligand (CD40L) 
CD40L CD40 on endothelium and immune 
cells, Gpllb-llla on platelets, and a5pi 
on endothelial cells 
PARI (human) Thrombin, granzyme A, trypsin, 
plasmin 
Seven Transmembrane 
Receptors PARS (mice) Thrombin 
PAR4 (humans & 
mice) 
Thrombin, trypsin, cathepsin G 
P2Yi and P2Y,2 ADP 
TXA2/PGH2 Thromboxane 
PGI2, PGD2 and 
PGE, 
Prostaglandin I2, Prostaglandin D2, 
Prostaglandin E2 
PAF - receptor Platelet-activating factor 
LA - receptor Lysophosphatidic acid 
Chemokine 
receptors 
CXC & CC chemokines 
V,a receptor Vasopressin 
A2a receptor Adenosine 
P2-Adrenergic 
receptor 
Adrenaline 
5-HT2A receptor Serotonin 
D3 and D5 receptors Dopamine 
Table generated from data presented in by (Clemetson 2002; Tomiyama et al. 2002; Nanda et 
al. 2005; von Hundelshausen and Weber 2007; May et al. 2009) 
1.2.2.3 Thrombus Stabilisation 
The binding of fibrinogen and vWF by Gpllb-llla receptors (up to 80,000 per platelet), in 
addition to the formation of the fibrin meshwork through cleavage of fibrinogen 
by thrombin, results in the stabilisation of platelet aggregates and the formation of a 
haemostatic plug (Woulfe et al. 2002). Additional proteins involved in thrombus 
stability include glycoprotein VI, PEAR1, P-selectin and interactions between Eph 
kinases and ephrins (Merten and Thiagarajan 2000; Goto et al. 2002; Prevost et al. 
2002; Herrera-Galeano et al. 2008). Figure 1.1 depicts the role of platelets in 
thrombosis and haemostasis. 
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3 - Platelet spreading on damagea surface ' 
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thrombus formation. Leukocytes and erythrocytes 
are also incorporated into the growing thrombus, 1 
Figure 1.1: Platelet function in thrombosis and haemostasis 
1.2.3 Platelet Function In Tissue Repair and Angiogenesis 
The wound-healing effects of platelets are well recognised. Preparations of platelet 
releasate are used in several clinical scenarios, such as the healing of chronic ulcers in 
diabetics, bone fractures and periodontal surgery amongst others, as they have been 
found beneficial in promoting tissue regeneration (Nurden et al. 2008; Blair and 
Flaumenhaft 2009). 
Following injury, a host of activities take place that ultimately result in the repair of 
injured tissue. These activities include thrombosis and haemostasis (reviev\/ed in 
section 1.2.2), the removal of damaged cells by phagocytosis, the remodelling of the 
extracellular matrix (ECM), and the growth of new tissue and its associated 
vasculature. Platelets release a multitude of factors that contribute to each of these 
steps including chemokines, cytokines, degradative enzymes, and growth factors that 
promote cell division, growth and differentiation . Of equal importance, platelets also 
release factors that regulate these processes thus ensuring they are 'switched- off' 
when the repair process is complete (Blair and Flaumenhaft 2009). The activators and 
regulators of wound repair released by platelets are included in Table 1.1. 
1.2.4 Platelet Function in Inflammation and Immunity 
In addition to their functions in haemostasis and wound healing, platelets have 
significant roles in the promotion of an inflammatory response and in antimicrobial 
defence. Due to their relative abundance in the bloodstream, platelets are capable of a 
rapid response to stimuli and accumulate at sites of infection in response to 
chemotactic signals. Platelets promote inflammation at the site of injury or infection by 
producing the key inflammatory cytokine, IL-1p, through rapid mRNA translation; by 
expressing CD40L that induces an inflammatory response in, and matrix degradation 
by nearby endothelial cells; by increasing vascular permeability through the release of 
histamine and serotonin from dense granules and through the production of 
prostaglandins D2 and E2; and by enhancing leukocyte recruitment through the release 
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of numerous chemokines and cytokines from a-granules (see Table 1.1) (Henn at al. 
1998; Klinger 2002; May et al. 2002; Weyrich and Zimmerman 2004). 
Platelets also provide protection from invading micro-organisms through direct action 
against pathogens, or indirectly by assisting other components of the immune system. 
They are capable of binding to antibody-bound pathogens via Fc receptors (in humans, 
not mice), and to complement-coated pathogens via complement receptors. Through 
the expression of CD40L, platelets have been demonstrated to promote adaptive 
immunity by activating dendritic cells. They can also recognise pathogen-associated 
molecular patterns via platelet Toll-like receptors. Following binding, platelets 
internalise micro-organisms or antigens into phagosomes. Alternatively, the binding of 
pathogens may stimulate platelet activation and the release of toxic oxygen 
metabolites and proteins capable of killing bacteha, fungi and protozoa as well as 
encapsulating the pathogen within a thrombus (Klinger 2002; Weyrich and Zimmerman 
2004; Elzey et al. 2005; von Hundelshausen and Weber 2007). 
Platelets also cooperate with other components of the immune system in the clearance 
of pathogens through the promotion of complement activity and the recruitment, 
activation and assisted migration of effector cells of both the innate and adaptive 
immune systems (Yeaman and Bayer 2002; Weyrich and Zimmerman 2004; von 
Hundelshausen and Weber 2007). 
1.3 Tumour Metastasis 
Tumour cell types display a preference for certain tissues to which they will 
metastasise, for example, prostate cancer frequently metastasises to the bone, 
whereas colon cancer metastasises to the liver and lung, and uveal melanoma 
generally metastasises to the liver (Nguyen et al. 2009). Furthermore, tumour 
metastasis may occur via the lymphatic or haematogenous pathways with some 
cancers appearing to have a predilection for one over the other, while other cancers 
take advantage of both routes (Cao 2005). The following sections discuss the factors 
believed to influence the location of metastatic spread of tumour cells and the 
mechanisms of haematogenous metastasis. Lymphatic metastasis will not be 
considered as it is a distinct field of research and was not investigated in this body of 
work. It is worth mentioning, however, that tumour cells invading the lymphatic system 
may eventually enter the bloodstream via the lymphatic ducts, where lymph is 
deposited into the blood, and thence become widely dispersed (Wong and Hynes 
2006). 
1.3.1 Determinants of Tissue Preference for Metastatic Spread 
Two dominant theories have been proposed for the mechanisms dictating the pattern 
of metastatic spread of tumour cells. The two theories are not mutually exclusive and 
each is supported by significant experimental evidence. The following sections discuss 
each of the proposed theories. 
1.3.1.1 Mechanical Forces and Vascular Anatomy 
One of the earliest theories proposed by Rudolf Virchow in 1858 and reinforced by 
James Ewing in 1928 is that the final destination of circulating tumour cells is 
determined by the dynamics of blood flow and the anatomy of the vasculature (Virchow 
1858; Ewing 1928). Indeed, the majority (60%) of metastases can be predicted on the 
basis of the anatomy of the vasculature alone (Llotta 1992). The basis of the theory is 
that tumour cells will be carried within the venous system draining the primary tumour 
and carried to the first capillary bed that is encountered. As tumour cells usually have a 
greater diameter than the lumen of the capillaries, the tumour cells are arrested at 
these sites and subsequently metastasise to nearby tissue. The dynamics of the blood 
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flow within the capillaries will also force a small proportion of tumour cells through the 
narrow vessels on to the next capillary bed. The pattern of colorectal carcinoma (CRC) 
metastasis is consistent with this theory. As blood returns from the colon, the first 
capillary bed encountered is within the liver and this is the organ most frequently 
affected by CRC metastasis. The next capillary bed encountered is within the lungs, 
the second most likely site of CRC metastasis (Chambers et al. 2002; Nguyen et at. 
2009). Similarly, in a detailed study of the pattern of metastatic spread of B16 
melanoma cells in mice, both initial and secondary metastases occurred in the first 
capillary bed encountered with there being no evidence of organ selectivity (Alterman 
efa/. 1985). 
Based on the data outlined above and numerous autopsy studies, it has been widely 
accepted that the initial and predominant determining factor of the pattern of metastatic 
spread is the anatomy of the vasculature downstream of the primary tumour site with 
size restrictions within capillary beds trapping circulating tumour cells (Chambers et al. 
2002; Nguyen et al. 2009). 
1.3.1.2 Seed and Soil Hypothesis 
In 1889, Steven Paget proposed the 'Seed and Soil' hypothesis for the organ 
preference of tumour cell metastasis following the study of numerous breast cancer 
patients (Paget 1889). He found that the preference for liver metastasis in breast 
cancer could not be explained by vascular anatomy and blood flow alone. He wrote 
"When a plant goes to seed, its seeds are carried in all directions, but they can only live 
and grow if they fall on congenial soil." He proposed that the liver, therefore, must be 
"receptive" to the metastasising breast cancer cells whereas other organs are not. 
Much research in this area has revealed that the gross structure of, and surface 
molecules on, endothelium varies between organs and influences the metastatic 
pattern of certain tumour types (Pauli et at. 1990; Nguyen et al. 2009). Furthermore, 
reciprocal interactions between tumour cells and cells of the target organ determine 
whether tumour cells will adhere, extravasate, migrate, survive and grow (Chambers et 
al. 2002; Ben-Baruch 2008). 
An extension of the 'Seed and Soil' hypothesis, proposed in 2005, is that soluble 
factors released by cells of the primary tumour prepare specific tissues for the 
attachment and invasion of circulating tumour cells. Thus, based on this hypothesis, 
the primary tumour establishes a "pre-metastatic niche" (Kaplan et al. 2005; Psaila and 
Lyden 2009). 
1.3.2 Mechanisms of Haematogenous Metastasis of Tumour Cells 
The processes involved in haematogenous metastasis are complex and include 
numerous steps. For the purpose of clarity, the metastatic process will be broken down 
into two sections, namely, (i) detachment from the primary tumour and migration into 
the bloodstream and (ii) extravasation from the bloodstream and invasion of a distant 
organ. 
1.3.2.1 Detachment from Primary Tumour and Migration into Bloodstream 
Metastasis was initially believed to occur as a result of increasing tumour size and 
pressure forcing tumour cells into the bloodstream. However, following intense 
research, it has become clear that metastasis is an active process involving changes in 
cell behaviour beyond those of tumourigenesis (Liotta 1992). The behavioural changes 
associated with metastatic tumour cells include detachment from the primary tumour 
mass, invasiveness, resistance to apoptosis and migration to other locations within the 
body. This phenotypic switch is consistent with that seen in some normal biological 
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processes and has been termed the 'epithelial to mesenchymal transition' (EMT) 
(Guarino et al. 2007; Tse and Kalluri 2007; Kalluri and Weinberg 2009). 
1.3.2.1.1 Epithelial to Mesenchymal Transition (EMT) 
EMT is associated with developmental processes including implantation, 
embryogenesis and organ development; inflammatory processes including wound 
healing and tissue regeneration; and tumour cell progression to a metastatic 
phenotype. Figure 1.2 depicts the morphological and molecular changes associated 
with EMT. 
EMT is believed to constitute one of the key events transforming a tumour cell to the 
metastatic phenotype and is induced, in the case of many carcinomas, by hepatocyte 
growth factor (HGF), epidermal growth factor (EOF), platelet-derived growth factor 
(PDGF) and transforming growth factor-beta (TGF-(3) released from the tumour stroma 
(Kalluri and Weinberg 2009). In the epithelial state, cell-cell interactions are 
maintained by specific adhesion molecules such as E-cadherin and syndecan and cell-
ECM interactions are mediated by integrins. However, during the transition of a tumour 
cell to a mesenchymal and metastatic phenotype these proteins are lost through down-
regulation, mutations affecting function, or an increase in protease cleavage 
(Sanderson 2001; Guarino et al. 2007; Tse and Kalluri 2007; Kalluri and Weinberg 
2009). 
Once separated from the tumour mass, an individual tumour cell can migrate through 
tissues, a process which involves repeated cycles of the following series of events:-
(i) pseudopod formation at the leading edge of the migrating cell 
(ii) focal contact between the ECM and cell adhesion molecules 
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cells 
E-cadherin 
Cytokeratin 
ZO-1 
Laminin-1 
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Figure 1.2: Morphological and Molecular Changes Associated with Epithelial to Mesenchymal Transition 
from Kailuri R. and Weinberg, RA. J. Clin. Invest, 2009 
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(iii) recruitment and release of proteases at the focal contact points with digestion 
of ECM components 
(iv) contraction of the cell cytoskeleton, and 
(v) detachment of the rear of the cell. 
This multi-step process of migration has been observed in non-neoplastic as well as 
neoplastic cells. Detailed studies on the migratory patterns of cells within tumours 
have revealed that migration may occur not only as single cells, but also collectively as 
chains, sheets or clusters of cells (Fhedl and Wolf 2003). 
Numerous factors within the tumour microenvironment have been demonstrated to 
influence the migratory behaviour of tumour cells and include chemokines (autocrine 
motility factor, stromal-derived factor-1), growth factors (EGF, lysophosphatidic acid, 
insulin-like growth factor-1), cleavage products of the ECM and matrix 
metalloproteases (MMPs). 
Chemo-attractants may be generated in the process of migration following the 
digestion of the ECM, or they may be secreted by nearby cells. Platelets and 
macrophages are major sources of EGF that has downstream effects on cell 
proliferation, differentiation and survival. It has also been suggested that platelets and 
macrophages may establish a chemotactic gradient encouraging tumour cell migration 
into the vasculature. In support of this notion, the chemotaxis of carcinoma cells 
towards blood vessels has been demonstrated in response to EGF, with 
overexpression of the EGF receptor being demonstrated in a variety of tumour cells 
and associated with a poor prognosis. Furthermore, metastatic ability can be induced 
in non-metastatic tumour cells through the exogenous expression of the EGF receptor 
(Condeelis and Segall 2003; Friedl and Wolf 2003; Herbst 2004). Interestingly, all of 
the growth factors released by the tumour stroma and demonstrated to induce EMT in 
carcinoma cells are also released by platelets. 
The tumour-associated vasculature is very leaky and, therefore, may not represent a 
major barrier to tumour escape. Once tumour cells cross the blood vessel wall, 
however, they encounter the high mechanical stress associated with the shear forces 
generated by blood flow. Using intravital imaging, comparisons have been made of the 
ability of poorly metastatic and highly metastatic carcinoma cell lines to enter the 
bloodstream. The poorly metastatic tumour cells were fragmented by the shear forces 
within the bloodstream, whereas tumour cells derived from the highly metastatic 
carcinoma remained intact. The robust nature of the highly metastatic carcinoma cells 
under shear force was attributed to an increased expression of cytokeratins and a 
resistance to apoptosis induction (Condeelis and Segall 2003). 
1.3.2.1.2 The Association between Inflammation and Cancer 
The previous section alludes to a role for inflammation in metastasis promotion through 
the induction of EMT by platelets and components of the immune system. There is, in 
fact, a growing body of evidence suggesting that inflammation, mediated by platelets 
and immune cells, is essential for tumour progression. 
Inflammation is an orchestrated response to tissue injury or infection. The role of 
platelets in tissue repair and inflammation was reviewed in sections 1.2.3 and 1.2.4. 
Other key players in the inflammatory process which may play a role in EMT and 
metastasis include thrombin, a product of the coagulation cascade, which promotes 
monocyte adhesion to endothelial cells (DiCorleto and de la Motte 1989). It is also a 
potent mitogen and has recently been demonstrated to induce migration of retinal 
pigment epithelial cells by stimulating the expression of chemokines (Palma-Nicolas et 
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a/. 2010). Neutrophils recruited to the sites of injury or inflammation by platelets 
release additional pro-inflammatory cytokines to enhance the recruitment and 
activation of additional effector cells, including monocytes and macrophages. 
Following their activation, macrophages take over as the predominant source of tissue 
repair factors controlling cell proliferation, angiogenesis, ECM restructuring and 
phagocytosis of damaged cells. Mast cells also play a major role by contributing 
inflammatory mediators and growth factors to the wound site. 
The inflammation associated with wound healing is self-limiting due to the rapid 
production of anti-inflammatory cytokines that supercede the pro-inflammatory 
cytokines. Dysregulation of this highly controlled response, or continued exposure of 
the tissue to injury, however, can lead to a chronic inflammatory state. The persistence 
of inflammation is believed to have the potential to promote tumourigenesis in pre-
neoplastic cells. Additionally, the conditions associated with chronic inflammation may 
induce cancer progression through the promotion of an EMT in tumourigenic cells 
(Coussens and Werb 2002; Grivennikov and Karin 2010). 
1.3.2.2 Extravasation and Invasion of Distal Organs by Tumour Cells 
Once inside the vasculature, metastasising tumour cells must withstand the 
mechanical stresses created by the immense force of blood flow within the varying 
diameters of the blood vessels, escape destruction by circulating cells of the immune 
system, attach to the wall of a distant capillary bed resisting the inherent shear forces, 
migrate through the vessel wall and proliferate to establish a viable secondary tumour. 
This process as a whole represents a significant challenge to tumour cells as 
numerous studies demonstrate that less than 10% of cells entering the circulation 
succeed in establishing a secondary tumour (Liotta et al. 1974; Liotta 1992; Meyer and 
Hart 1998; Geiger and Peeper 2009). At which stage, or stages of the metastatic 
process the majority of cells fail is a matter of debate. In vivo microscopy studies have 
provided insights into the ultrastructural events associated with tumour cell 
extravasation. The subsequent section therefore reviews the findings of 
videomicroscopy studies of tumour cell metastasis. 
1.3.2.2.1 Ultrastructural Analysis of the Extravasation of Tumour Cells 
A morphological study of the fate of 3 different mouse tumour cell lines (Lewis lung 
carcinoma, 16c mammary adenocarcinoma and B16 melanoma) injected into the tail 
vein of mice demonstrated the following common steps of lung invasion (Crissman et 
al. 1988): 
(i) In less than 1 minute: Tumour cells were seen to arrest within the lung capillary bed 
following contact with endothelial cells. A size restriction within the vessel appeared to 
have an impact upon the initial lodgement of the tumour cells within the vessel. This 
initial lodgement was temporary, however, as those tumour cells that were unable to 
initiate an interaction with the endothelium passed through the capillary bed, 
(ii) Within 2 min: Platelet activation and aggregation around the tumour cell was 
observed. A small number of platelets were observed in contact with tumour cells prior 
to their interaction with the endothelium, although the platelets appeared not to be 
involved in the initial contact with the vessel wall. Platelet aggregation was seen to 
continue for 1-4 hours with thrombus formation eventually causing vessel occlusion. 
Those platelets in close association with the tumour cells were observed to undergo 
shape change and degranulation, and the tumour cells were observed to develop 
extensions that became intimately associated with, and projected into, the platelet 
thrombus. The degree of interaction between the tumour cells and the endothelial cells 
increased over time. The platelet thrombus remained until the tumour cells had 
established contact with the sub-endothelial matrix. 
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(Hi) 4 hours: Endothelial cell separation was observed, with cytoplasmic extensions of 
the tumour cells reaching the subendothelial matrix. Marked thinning of the endothelial 
cytoplasm was seen adjacent to tumour cells and the authors concluded that 
endothelial cells play an active role in this step, little destruction of endothelial cells 
being observed. The tumour cells then appeared to disrupt inter-endothelial cell 
junctions and gain access to the basement membrane, 
(iv) 8-24 hours: The tumour-cell associated thrombus dissolved during this period and 
flow was re-established within the vessel. Tumour cells were also found attached to the 
subendothelial matrix. 
(v) 24 hours: Tumour cell division was noted at at this time point with the development 
of intravascular nodules. The proliferating tumour cells caused further displacement of 
nearby endothelial cells and maintained their attachment to the basement membrane. 
(vi) 3-8 days: The basement membrane of the capillary was dissolved under tumour 
nodules by the tumour cells and extravasation was achieved. No single tumour cells 
were observed to penetrate the basement membrane. 
(vii) Obsen/ed interactions between tumour cells and circulating immune cells 
Particular attention was paid to interactions between tumour cells and cells of the 
immune system prior to extravasation. A slight increase in the number of lymphocytes 
associating with the tumour cells was seen in the first 24 hours post injection, however, 
there were no direct interactions observed. An increased number of polymorphonuclear 
cells were seen to associate with Lewis lung carcinoma cells during the first 24 hours 
with occasional degenerative changes in the tumour cells observed (Crissman et al. 
1988). 
A subsequent series of detailed in vivo video-microscopy studies used a variety of 
models of murine carcinoma, sarcoma and melanoma and examined liver and lung 
metastasis using a novel cell accounting procedure (Chambers et at. 2001). These 
studies revealed that tumour cells were highly efficient at survival within the circulation 
and that more than 80% of tumour cells injected intravenously extravasated through 
the capillary bed of a distant organ. In contrast, they were inefficient at survival, growth 
and persistence following extravasation, with only -8% of injected tumour cells 
establishing a macroscopic secondary tumour. The observed outcomes for 
extravasated tumour cells were death through apoptosis or immune destruction, 
dormancy or successful proliferation (Chambers et al. 2001). 
The authors of this work found that the majority of tumour cells were arrested in organs 
due to size restrictions within the first capillary bed encountered and the ability to 
extravasate was common to tumour cells with both high and low metastatic capacity. 
In contrast to the previous study by Crissman et al., they did not observe initial growth 
of tumour cells within the blood vessels (Chambers et al. 2001). 
1.3.2.3 Comparison of Molecular Events Associated with Leukocyte and 
Tumour Cell Extravasation 
In vivo microscopy studies, along with those examining the process of tumour cell 
extravasation at the molecular level, reveal remarkable similarities to those of 
leukocyte extravasation in response to inflammation or injury (Miles et al. 2008).The 
following section, therefore, provides a comparison at the molecular level of leukocyte 
and tumour cell extravasation including adhesion and attachment to the vessel wall, 
transendothelial migration, and migration through the pericyte layer, basement 
membrane and underlying tissue. In section 1.3.2.3.4 our current understanding of the 
ultrastructural and molecular mechanisms of tumour cell metastasis to the liver are 
reviewed and compared with leukocytes. The process of leukocyte extravasation is 
depicted in Figure 1.3 and Table 1.3 lists the adhesion proteins implicated in tumour 
cell metastasis along with their purported mechanisms of action. 
1.3.2.3.1 Adhesion and Attachment to the Blood Vessel Wall 
In the case of inflammation, the endothelium is activated by the release of cytokines, 
such as IL-1, -6, -8, -12 and TNF-a by tissue-resident macrophages. It is conceivable 
that establishment of a pre-metastatic niche by tumour cells results in similar changes 
to the endothelium. Endothelial cell activation results in the expression of P- and E-
selectin on their lumenal surface. Leukocytes flowing past a site of inflammation or 
injury, adhere to and roll along the endothelial surface of the blood vessel. This initial 
contact may be mediated by the following interactions: 
(i) P- selectin on activated endothelial cells binding to sialyl Lewis^ or sialyl Lewis® 
carried by PSGL-1 on leukocytes; 
(ii) E-selectin on activated endothelial cells binding to sialyl Lewis^°'® carried by PSGL-
1, or to L-selectin on leukocytes; 
(iii) L-selectin on leukocytes binding endothelial cell-heparan sulfate proteoglycans 
(HSPG); 
(iv) CD44 on leukocytes binding hyaluronic acid (HA) on the endothelium and 
(v) the a4pi integrin on endothelial cells binding to L-selectin on leukocytes (Liu and 
Kubes 2003; Bonder etai 2006; Parish 2006; Ruffell and Johnson 2009). 
During the process of rolling, leukocytes come into close proximity to chemokines, 
such as IL-8, produced by tissue-resident macrophages and presented by endothelial 
heparan sulfate to leukocyte receptors. This process activates leukocyte |31 and (32 
integrins, such as a4pi (VLA-4), aL|32 (LFA-1) and aMp2 (Mac-1), which mediate firm 
adherence of leukocytes to the endothelium via interactions with members of the 
immunoglobulin superfamily, such as ICAM-1, ICAM-2, VCAM-1 and PECAM-1 
(Luscinskas etai 1994; Parish 2006). 
Contact between tumour cells and the endothelium has been shown to occur through 
size restriction, however, this contact also seems to involve molecular interactions 
common to leukocyte-endothelial adhesion. Thus, P-, E- and L-selectin, CD44, HA, 
a4pi , aLp2, ICAM-2, VCAM-1 and PECAM-1 have all been demonstrated to promote 
metastasis in experimental models. Tumour cells often express sialyl Lewis^ or sialyl 
Lewis®, carried by mucins, that interact with the selectin family members (Wahrenbrock 
et al. 2003). They may also aberrantly express CD44, thus enabling tumour cell rolling 
on P-selectin (Hanley et al. 2006), adhesion to fibrin (Alves et al. 2009) and adhesion 
and migration through interaction with HA on the endothelium (Mummert et al. 2003; 
Ponta et al. 2003). Alternatively, HA expressed on the surface of tumour cells may 
bind to endothelial CD44 or ICAM-1 (Zhang et al. 1995). Furthermore, tumour cells 
have been found to express the integrins a4pi and aLp2 thus potentially mediating 
binding to cell adhesion molecules on the endothelium following activation (Taichman 
et al. 1991; Wang et al. 2005). It should be noted that the above findings were 
dependent upon the tumour cell type studied and are unlikely to be common to all 
tumour cell types. 
1.3.2.3.2 Transendothelial Migration (TEM) 
Both leukocytes and tumour cells commence migration across the vessel wall by first 
crossing the endothelium. This may occur between endothelial cells (paraceliular 
pathway) or through endothelial cells (transcellular pathway). Both of these pathways 
require significant morphological changes within the leukocyte/tumour cell and the 
endothelial cells that, in the case of leukocytes, are initiated by integrin:immunoglobulin 
superfamily member binding (Carman et al. 2007; Hidalgo and Frenette 2007; 
Nakhaei-Nejad et al. 2007; Aghajanian et al. 2008). A protrusive leading edge rich in 
the integrin aL|32 is formed on the leukocyte with a contractile rear and ventral 
membrane protrusions. Endothelial cells form protrusions at the cell surface, rich in the 
integrin ligands VCAM-1 and ICAM-1, that are believed to promote firm adhesion 
between the leukocyte and endothelium (Nourshargh et al. 2010). 
Leukocytes crawl along the endothelial surface probing for a migration permissive site. 
Once found, the bulk of the leukocyte follows the membrane protrusion to the basal 
side of the endothelial surface. The action of leukocyte crawling is associated with 
ICAM-1, VCAM-I and E-selectin clustering and stimulates signalling events within 
endothelial cells that result in the reduction of endothelial cell junctions, in preparation 
for paracellular migration, or the formation of intracellular pores, in preparation for 
transcellular migration (Nourshargh et al. 2010). 
VE-cadherin is important in maintaining contact between endothelial cells and must be 
temporarily inactivated through tyrosine phosphorylation to permit leukocyte, and 
presumably, metastatic tumour cell migration. Cytoskeletal contraction within the 
endothelial cells also assists in the creation of a permissible space. Several proteins 
present in endothelial junctions have been shown to assist transendothelial leukocyte 
migration and include PECAM-1, ICAM-2, junctional adhesion molecules (JAM-A, JAM-
B, JAM-C), CD99 and endothelial-cell selective adhesion molecule (ESAM). The 
mechanism of transcellular migration is not fully understood but is known to involve the 
formation of a vesiculovacuolar organelle around the leukocyte that transports its 
contents to the abluminal side of the endothelial layer. The vesicle-associated 
membrane protein (VAMP) has been implicated in this process (Nourshargh et al. 
2010). 
Our understanding of tumour cell TEM is not as extensive as that of leukocytes. It has 
been demonstrated, however, that the interactions between integrins on the tumour 
cells and their immunoglobulin superfamily member receptors on the endothelium, the 
down-regulation of cadherin expression by endothelial cells and cytoskeletal 
reorganisation within both endothelial and tumour cells are all integral to the process of 
tumour cell TEM (Miles et at. 2008). 
1.3.2.3.3 Migration through the Pericyte Layer, Basement Membrane and Underlying 
Tissue 
Following transendothelial migration, leukocytes and tumour cells must cross the 
pericyte layer and the basement membrane of the blood vessel. Migration across the 
pericyte layer may occur via the transcellular or paracellular routes, however little is 
understood about the underlying mechanisms. The basement membrane consists of a 
dense network of laminin, collagen type IV and heparan sulfate proteoglycans and is 
manufactured by endothelial cells and pericytes (Parish et at. 2001; Parish 2006; 
Nourshargh et al. 2010). It represents a significant barrier to the migrating lymphocyte 
and tumour cell. There is no consensus regarding the process of leukocyte migration 
across the basement membrane although there is evidence for the existence of 
permissive sites for migration within the basement membrane (Nourshargh et al. 2010). 
Additionally, there is significant evidence to suggest that both leukocytes and 
endothelial cells remodel the basement membrane through the release of proteases 
(including matrix metalloproteases (MMP), serine-, cysteine- and aspartic proteases) 
and heparanase thus generating a migratory pathway (Hulett et al. 2000). Unpublished 
data from the Parish Laboratory (in collaboration with Professor Michael Hickey, 
Monash University) using intra-vital microscopy in an in vivo inflammatory model 
demonstrated that the heparanase inhibitor PI-88 did not prevent leukocyte adhesion to 
the blood vessel wall but did prevent migration through the vessel wall. 
Proteases and heparanase have also been implicated in tumour cell migration across 
the blood vessel wall. Cancer cells are able to degrade the ECM through the sequential 
actions of enzymes such as MMPs, serine and cysteine proteases and 
Figure 1.3: The Process of Leukocyte Extravasation. 
In response to cytokines produced by tissue-resident macrophages, pre-formed P-selectin is rapidly expressed on the surface of endothelial 
cells. E-selectin may also be expressed following transcription (not shown). The interaction between P-selectin and its ligand, PSGL1, on 
leukocytes initiates rolling on the endothelium which is further stabilised by L-selectin binding to endothelial-cell heparan sulfate proteoglycans 
(HSPGs), such as syndecan. Chemokines, such as CXC-chemokine ligand 8 (CXCL8), produced by tissue-resident macrophages are 
presented by heparan sulfate (HS) to receptors on leukocytes. This process activates leukocyte integrins thus enabling them to bind their 
endothelial ligands, such as aLP2 binding to ICAM-1, and results in more stable leukocyte adhesion. Transendothelial migration may occur via 
the paracellular or transceilular pathways and involves extensive morphological changes within the leukocytes and endothelial cells. Once 
leukocytes have completed transendothelial migration, they interact with chemokines presented by HSPGs such as perlecan in the underlying 
basement membrane. In order to traverse the subendothelial basement membrane, leukocytes deploy various proteases and the heparan-
sulfate-degrading enzyme heparanase to solubilise the basement membrane components. During basement membrane solubilisation, 
heparanase releases growth factors associated with basement membrane HSPGs. 
Key: HS, heparan sulfate; ICAM1, intercellular adhesion molecule 1; CXCL8, GXC chemokine 8 or IL8. 
From Parish, CR. Nature Reviews Immunology 6, 633-643, 2006 .t> 
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Table 1.3: Cell adhesion molecules involved in tumour cell extravasation. 
Protein Family Member Location Role in IVIetastasis Reference 
Selectins L-selectin Leukocytes (Mannori et al. 1995; 
P-selectin Activated 
platelets and 
endothelium 
Tumour cell 
adhesion to 
endothelium 
Kim etal. 1998; 
Borsig et al. 2002; 
Laubli etal. 2006; 
Barthel et al. 2007; 
E-selectin Activated 
endothelium 
Garcia et al. 2007; 
Tremblay et al. 2008; 
Konstantopoulos and 
Thomas 2009) 
Integrins allbps 
(Gpllb-llla) 
Platelets 
Tumour cells 
Tumour cell 
adhesion to 
platelets promoting 
adhesion to 
endothelium 
(Karpatkin et al. 
1988; Chang etal. 
1992; Chen et al. 
1992; Felding-
Habermann et al. 
1996; Chen et al. 
1997; Bakewell et al. 
2003; Patel etal. 
2003; 
Konstantopoulos and 
Thomas 2009) 
otv|^3 
Osteoclasts 
Activated 
endothelium 
Tumour cells 
Tumour 
angiogenesis 
Osteopontin 
binding 
(Samanna et al. 
2006; Somanath et 
al. 2009) 
(VLA-4) 
Leukocytes 
Vascular smooth 
muscle cells 
Tumour cells 
Tumour cell 
adhesion to 
endothelium 
Osteopontin 
binding 
(Taichman etal. 
1991; Bayless etal. 
1998; Wang et al. 
2005) 
(xL[52 
(LFA-1) 
Leukocytes 
Tumour cells 
Tumour cell 
adhesion to 
endothelium 
(Wang et al. 2005) 
Basal surface of 
epithelia 
Tumour cells 
Motility 
Apoptosis 
resistance 
Invasion via laminin 
binding 
(Rabinovitz and 
Mercuric 1996; Chen 
et al. 2009) 
Carbohydrate 
moieties 
Sialyl 
Lewis'' 
Sialyl 
Lewis® 
Leukocytes 
Tumour cells 
Tumour cell 
adhesion to 
endothelium 
through selectin 
binding 
(Takada etal. 1993; 
Kim etal. 1998; 
Gassmann et al. 
2010) 
Table 1.3: Cell adhesion molecules involved in tumour cell extravasation (cont.) 
Protein Family Member Location Role in Metastasis Reference 
Immunoglobulin 
Superfamily 
JAM-C Endothelial cell 
junctions 
Tumour Cells 
Tumour cell 
adhesion to 
endothelium and 
migration 
(Santoso etal. 
2005; Fuse et 
al. 2007) 
VCAM-1 Activated 
endothelium 
Tumour cell 
adhesion via 
interactions with 
<x4pi and sialyl 
Lewis^ 
(Zetter 1993) 
PECAM-1 Endothelial cells 
Platelets 
Macrophages 
Leukocytes 
Osteoclasts 
Tumour Cells 
Angiogenesis 
Thrombus formation 
Tumour cell 
adhesion to 
endothelium via 
homotypic 
interaction or via 
integrins 
(Roos 1991; 
Sheibani and 
Frazier 1999; 
Gong and 
Chatterjee 
2003) 
ICAM-1 Activated 
endothelium 
Leukocytes 
Tumour cell 
adhesion to 
endothelium via 
inteqrins 
(Tang and 
Honn 1994) 
CD44 family Numerous 
variant 
isoforms 
Lymphoid and 
epithelial cells 
Tumour cells 
Adhesion to 
endothelium 
Prevention of 
apoptosis Invasion 
Angiogenesis 
Motility and 
chemotaxis 
Growth factor 
binding 
Promotion of 
receptor tyrosine 
kinase activation 
(Anborgh et 
al.: Kennel et 
al. 1993; 
Wang et al. 
2005; Hanley 
et al. 2006; 
Samanna et 
al. 2006; 
Orian-
Rousseau 
2010) 
Platelet 
glycoproteins 
Gplb-IX-V Receptor for vWF Tumour cell 
adhesion to 
endothelium and 
basement 
membrane 
(Jain et al. 
2007) 
Heparan 
sulphate 
proteoglycans 
Perlecan 
Syndecan-I 
Secreted by 
vascular 
endothelial and 
smooth muscle 
cells 
Expressed by 
tumour cells 
Tumour cell 
invasion, migration, 
growth and 
angiogenesis 
(Cohen et al. 
1994; Jiang et 
al. 2004; 
Khotskaya et 
al. 2009) 
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endoglycosidases. Numerous studies have linked altered MMP expression in different 
human cancers with poor prognosis, with up-regulation of MMPs leading to enhanced 
cancer cell invasion, while synthetic or natural inhibitors of MMPs inhibit metastasis 
(Curran and Murray 2000; Itoh and Nagase 2002). Studies in melanoma cells indicate 
that the binding of the integrin avps to its ligand, osteopontin, increases the expression 
of MMP-2. Furthermore, CD44 and avps were demonstrated to be critical for the 
positioning of activated MMP molecules on the surface of invasive tumor cells 
(Hofmann et al. 2000; Hofmann et al. 2000; Samanna et al. 2006). Similar to MMPs, 
heparanase expression is also elevated in numerous cancer types studied in 
comparison to the surrounding normal tissue and the level of expression correlates 
with metastatic potential (Parish et al. 2001; VIodavsky and Friedmann 2001; Chen et 
al. 2008; Hoffmann et al. 2008; Mikami et al. 2008). In rats injected with the mammary 
adenocarcinoma cell line 13762 MAT, or in mice injected with the B16 melanoma cell 
line, inhibition of heparanase using the inhibitor PI-88 dramatically reduced 
experimental lung metastasis (VIodavsky et al. 1994; Parish et al. 1999). Furthermore, 
the invasion of Matrigel by renal cell carcinoma cell lines, 786-0 and Caki-2, and 
SMMC7721 human hepatocellular carcinoma was inhibited by down-regulating the 
expression of heparanase using antisense oligodeoxynucleotides or small interfering 
RNAs (Zhang et al. 2007; Mikami et al. 2008). Anti-sense oligonucleotides to 
heparanase also inhibited experimental metastasis of human hepatocellular carincoma 
in nude mice (Zhang et al. 2007). 
1.3.2.3.4 Successful Establishment of a Secondary Tumour 
Following invasion of a distant organ, to form a successful secondary tumour, a 
metastasising tumour cell must proliferate, induce angiogenesis and resist immune 
destruction. In one study of metastatic efficiency in the lung, the majority of tumour 
cells that succeeded in extravasation underwent apoptosis soon after arrival (Cameron 
et al. 2000). In another study, of the 80% of injected cells that were found to 
successfully extravasate into the liver, 1 in 40 grew to form micrometastases (defined 
as 4-16 cells), with 1 in 100 of these going on to form macroscopic tumours. Thirty-six 
percent of the injected cells remained as single dormant cells, therefore, not 
undergoing apoptosis or proliferation. From the figures presented in this paper, it would 
appear that ~40% of cells that successfully extravasated did not survive to attain 
dormancy or proliferate into a micrometastasis and, therefore, presumably underwent 
apoptosis or immune-mediated destruction (Luzzi et al. 1998). The growth and survival 
of tumor cells following extravasation or a period of dormancy is determined by factors 
inherent to the tumour cells and also to the microenvironment into which they migrate, 
such as growth factors, hormones, proteins of the ECM and cytotoxic immune cells 
(Nicolson 1993; Bates et al. 1995; Townson and Chambers 2006; Waldhauer and 
Steinle 2008). The failure of tumour cells to grow beyond a microscopic tumour is most 
likely due to the inability to initiate angiogenesis (Naumov et al. 2006). 
1.3.2.3.5 Site-Specific Mechanisms of Leukocyte and Tumour Cell Extravasation 
The majority of studies analysing the mechanisms of leukocyte extravasation have 
been performed in cremasteric and mesenteric post-capillary venules and are, 
therefore, likely to be consistent with what occurs in the majority of locations within the 
body. However, significant differences exist, not only in the structure of the 
endothelium, but also the expression profiles of cell adhesion molecules in various 
organs including the liver, brain, lymphoid tissues and bone marrow (Girard and 
Springer 1995; Karsan and Harlan 1999; Liu and Kubes 2003; Lee and Kubes 2008). 
These differences in tissue-specific extravasation are most evident in leukocyte and 
tumour cell extravasation from the liver microvasculature. Within the liver, venous 
blood from the gastro-intestinal tract enters via the hepatic portal vein into the pre-
sinusoidal venules, and arterial blood enters via the hepatic artery into the hepatic 
arterioles. The two merge within the sinusoids and exit via the post-sinusoidal venules 
into the central vein (Figure 1.4). 
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Leukocyte extravasation from the pre- and post-sinusoidal venules is believed to occur 
as in the cremasteric and mesenteric venules. However, due to the nature of the 
endothelium within the sinusoids, the mechanism of leukocyte extravasation in this 
region is quite different. The sinusoids are comparatively narrow, being as wide as the 
leukocytes themselves. The sinusoidal endothelium is discontinuous, contains pores 
known as fenestrations, and lacks basal lamina and tight junctions. It contains 
numerous bristle-coated micropinocytic vesicles and has a high endocytic activity. 
Sinusoidal endothelium also lacks Weibel-Palade bodies and, therefore, does not 
release P-selectin or vWF upon activation. Sinusoidal endothelium also does not 
express E-selectin, PECAM-1, CD34 or VE-cadherin, however, they do express a 
diversity of oligosaccharides, adhesion proteins and pathogen-associated recognition 
receptors and are highly efficient at receptor-mediated endocytosis. Leukocyte rolling 
does not occur within the sinusoids despite this being the greatest site of leukocyte 
extravasation during inflammation. The extravasation of leukocytes within the 
sinusoids is not only selectin-independent but it also appears to be p2-integrin 
independent. Within the post-sinusoidal venules, on the other-hand, leukocyte 
extravasation does include rolling and does appear to be P- and E-selectin dependent. 
The sinusoidal endothelium constitutively expresses ICAM-1 and the vascular 
adhesion protein VAP-1, both of which promote lymphocyte extravasation. The a4pi -
integrin also appears to be involved in CD4+ T cell recruitment in the sinusoids. The 
liver sinusoids constitutively express HA at high levels and its involvement in neutrophil 
extravasation within the sinusoids via CD44 binding has been demonstrated 
following LS-induced hepatic injury (Braet and Wisse 2002; Liu and Kubes 2003; 
Klintman et al. 2004; McDonald et al. 2008; Vidal-Vanaclocha 2008). 
Bile duct Hepatic portal 
vein 
Portal area Bile ductules 
Figure 1.4: Histology of the Liver 
Venous blood, returning from the gastro-intestinal tract (GIT), enters the liver via the 
hepatic portal vein. It travels from the pre-sinusoidal venules into the sinusoids, then 
exits via the post-sinusoidal venules (not shown) that empty into the central vein. 
Arterial blood, delivered via the aorta from the left ventricle, enters the liver via the 
hepatic artery and travels from the hepatic arterioles into the sinusoids, mixing with the 
venous blood from the GIT, and exits via the central vein. 
From: 
httpJ/www. harford. edu/facultv/WRaDDazzo/BI0204/lecture/bio204lecturematerials. htm 
with minor modification 
The liver is the most common site of metastasis in gastro-intestinal cancers and the 
organ most commonly involved in haematogenous metastasis. This is likely due to its 
position and function within the circulatory system, the dynamics of flow within the liver 
microvasculature, and the structure of the endothelium within the liver (Vidal-
Vanaclocha 2008). The liver filters venous blood returning from the internal organs of 
the abdomen via the portal vein with Kupffer cells ingesting toxic materials such as 
apoptotic cells, microorganisms, chemicals, drugs, and debris found in the blood 
passing through the liver. Metastatic cells derived from primary tumours within the 
abdominal viscera will, therefore, pass through the liver first. Additionally, the liver 
receives approximately 30% of the cardiac output via the hepatic artery. Metastatic 
cells derived from other organs, that have passed through the capillary network of the 
lungs, will reach the liver via the arterial blood supply. The rate of blood flow through 
the hepatic microcirculation is slow due to the extensive sinusoidal capillary network 
and due to the presence in and around the sinusoids of Kupffer and stellate cells. This 
slow flow rate will better enable tumour cells to adhere to the vessel walls of the 
hepatic microcirculation (Vidal-Vanaclocha 2008). 
In vivo videomicroscopy studies on the fate of tumour cells delivered to the portal 
circulation showed that the majority were arrested within the pre-sinusoidal venules 
with few reaching the sinusoids. More than 90% of arrested CRC cells were eliminated 
by NK and Kupffer cells. In another study of liver metastasis using EL-4 lymphoma 
cells and C26 colon adenocarcinoma cells, the larger C26 cells were found to become 
lodged, without evidence of rolling, principally within the pre-sinusoidal venules with 
few entering the sinusoids, whereas the smaller EL-4 cells did adhere to the 
endothelium without interrupting blood flow, and a minority were observed to flow right 
through the hepatic circulation (Ding et al. 2001; Vidal-Vanaclocha 2008). 
The adhesion molecules involved in liver metastasis include P- and E-selectin, CD44 
and the sialyl Lewis" and sialyl Lewis® molecules. In a study using the murine 
carcinoma line H-59, the use of a monoclonal antibody to E-selectin reduced the 
number of liver metastases by 97% (Brodt et al. 1997). The intra-vital microscopy 
study mentioned in the previous paragraph also studied the role of P-selectin in the 
metastasis of EL-4 and C26 cells to the liver. Adhesion of the smaller EL-4 tumour cells 
was decreased in P-selectin-/- mice and in wild-type mice administered an anti-P-
selectin antibody, however, this P-selectin effect on metastasis was not seen with the 
larger C26 cells (Ding et al. 2001). In a study comparing the lymphoma parental cell 
line RWA117-P with the liver-metastatic cell line, RAW117-H10, unlike sialyl Lewis'" the 
presence of sialyl Lewis® was found to be much higher on the liver-metastatic line than 
the parental line and metastasis could be prevented by pre-treatment of the cells with 
sialidase (Kikkawa et al. 1998). Furthermore, the interaction between tumour cell 
CD44 and hepatic endothelial HA in metastasis to the liver of both B16 melanoma and 
Lewis lung carcinoma LL3 tumour cells was demonstrated when a synthetic HA-butyric 
acid molecule was administered prior to the intrasplenic implantation of the tumour 
cells (Coradini et al. 2004). 
1.3.3 The Role of Platelets In Tumour Cell Metastasis 
A wealth of evidence exists in the scientific literature linking platelets with the process 
of tumour cell metastasis. That they do play a role is not in doubt, however, whether 
this role is one of assisting tumour cell adhesion and migration across the blood vessel 
wall or of merely forming a barrier around tumour cells preventing immune cell-
mediated killing has come into question. The following sections discuss the role of 
platelets in leukocyte extravasation and provide a review of the extensive research 
conducted in the area of platelets and tumour cell metastasis. 
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1.3.3.1 Leukocyte-Platelet Interactions as a Model of Haematogenous Tumour 
Metastasis 
Platelets play a significant role in assisting leukocyte migration in response to injury 
and inflammation, a process that may resemble platelet-assisted tumour metastasis 
(Pitchford et al. 2003). Activated platelets express P-selectin on their surface and bind 
PSGL-1 on leukocytes within the circulation. This interaction results in activation of 
leukocyte (32 integrins and secretion of inflammatory cytokines (Wagner and Frenette 
2008). Furthermore, since leukocyte:platelet complexes express a greater number of 
adhesion molecules and ligands than unactivated leukocytes alone, there is a greater 
chance of them interacting with activated endothelium. 
Platelets have also been observed to roll along and adhere to activated endothelium 
via P-selectin (Frenette et al. 1995). A platelet layer forms over the endothelium and 
expresses P-selectin at a density higher than that of activated endothelium and, hence, 
leukocytes may be recruited more efficiently. Platelets also release chemokines, such 
as RANTES (CCL5), which promote leukocyte adhesion to the endothelium (Wagner 
and Frenette 2008). 
Platelets have been demonstrated to play a significant role in the recruitment of 
leukocytes to sites of ischaemia/reperfusion injury. This occurs following the 
resumption of blood flow to an ischaemic organ and is associated with significant 
changes to the microvasculature that reflect changes seen in inflammation. Along with 
these changes, extensive tissue damage occurs, known as ischaemia/reperfusion 
injury, due to the release of reactive oxygen species by leukocytes recruited to the area 
(Salter et al. 2001). Leukocyte recruitment appears to be dependent upon the 
adhesion of platelets to the activated endothelium and the extent of 
ischaemia/reperfusion injury is significantly reduced following platelet depletion (Golino 
et al. 1987). The platelet proteins P-seiectin and Gpllb-llla and the procoagulant 
fibrinogen have been shown to be involved in ischaemia/reperfusion injury through the 
promotion of leukocyte adhesion and transendothelial migration (Massberg et at. 1999; 
Salter ef a/. 2001). 
Platelets have recently been demonstrated to migrate into lung tissue in an 
experimental model of allergic asthma. This migration appeared to precede that of 
leukocytes and was not due to haemorrhage as erythrocyte antigens were not detected 
(Pitchford et al. 2003; Pitchford et al. 2008) Furthermore, endothelial cells have been 
shown to transport platelets transcellularly, in vesiculo-vacuolar organelles, to their 
basal surface (Feng et al. 1998; Feng et al. 2002). Platelets may assist leukocyte 
migration by degrading the basement membrane through the release of matrix 
metalloproteases and heparanase (VIodavsky et al. 1992; Bartlett et al. 1995). The 
haemostatic effects of platelets also minimise bleeding and local tissue damage 
caused by extravasating leukocytes (Wagner and Frenette 2008). 
1.3.3.2 Can Platelets Induce an EMT at the Primary Tumour Site? 
Surprisingly, there is very little information on whether platelets are capable of 
enhancing the metastatic behaviour of tumour cells within the primary tumour. 
Theoretically, there is ample opportunity for platelets to interact with tumour cells at the 
primary tumour site. As a tumour grows it establishes its own blood supply through 
angiogenesis. Typically, tumour-associated blood vessels are ill-formed, tortuous and 
the lumenal surface consists of a mosaic of endothelium and tumour cells (Chang et al. 
2000). Platelet adhesion to the vessel-associated tumour cells and release of granular 
contents has the potential of inducing an EMT, a process that would enhance the entry 
of tumour cells into the haematogenous circulation. 
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In studies determining tine effect of platelet-derived microvesicles (PMV), released 
following platelet activation, on human lung cancer cell lines (A549, CRL 2066, CRL 
2062, HTB 183, HTB 177), and breast cancer cell lines (MDA-231 and BT-549) it was 
demonstrated that the majority of the cell lines migrated towards PMV, with the level of 
reponse correlating with the metastatic capacity. Additionally, following exposure of the 
A549, HTB 177, MDA-231 and BT-549 cell lines to PMV, proliferation was enhanced, 
following activation of the MAPK p42/44 and AKT pathways, and in the A549 cells 
cyclin D2 mRNA was increased, thus increasing the invasive potential of these cells. 
Furthermore, matrix metalloprotease (MMP) expression was strongly upregulated in 
the A549, HTB 177, MDA-231 and BT-549 cells which was associated with enhanced 
chemoinvasion of Matrigel, an effect that could be reversed by the addition of an MMP 
inhibitor (Janowska-Wieczorek et al. 2005; Janowska-Wieczorek et al. 2006). 
Unpublished work from Professor Parish's laboratory has demonstrated, using micro-
array data and in vitro and in vivo studies, that platelets are capable of inducing a more 
aggressive phenotype in tumour cell lines. Using a Matrigel solubilisation assay, it was 
demonstrated that numerous tumour cell lines when exposed to washed, thrombin-
activated platelet membranes were able to solubilise Matrigel proteins to a significantly 
greater extent than the tumour cell lines or platelet membrane preparations alone. 
When the human breast cancer cell line MDA-MB-231 cell line was studied further, the 
extent of Matrigel solubilisation was platelet membrane concentration dependent. 
Additionally, the tumour cells were observed to adopt an invasive phenotype when 
incubated with thrombin-activated platelet membranes (Figure 1.5). In vivo studies 
revealed that MDA-MD-231 and the MM 170 cells were both significantly more 
metastatic when pre-incubated with thrombin-activated platelet membranes. 
Subsequent micro-array data have indicated that invasion-associated genes are 
upregulated in tumour cells following their incubation with activated platelets. 
1.3.3.3 Platelets Can Promote Tumour Cell Extravasation and Invasion 
Elucidating the mechanisms involved in tumour cell extravasation has involved the use 
of in vitro flow-chamber and Matrigel degradation models, as well as in vivo 
experimental metastasis models and intra-vital videomicroscopy. The experimental 
metastasis models usually involve the intravenous injection of tumour cells into the tail 
vein or the splenic or portal circulation of mice (Xue and Gao 1989; Panis et al. 1990; 
Elkin and VIodavsky 2001). Due to the vascular anatomy, the first capillary bed 
encountered is within the lungs following tail vein injection and the liver following portal 
vein/intrasplenic injection. Less commonly, tumour cells are injected into the left 
cardiac ventricle, thus bypassing the lungs, and metastases assessed in the bone 
marrow or brain (Mandybur 1981; Arguello et al. 1988). Following a period of time 
sufficient to enable the growth of macroscopic metastases, the organs of interest are 
removed and the tumour burden enumerated. The role of a specific cell type or protein 
may be determined in this model through the use of knockout or transgenic mice, by 
pre-treating mice with blocking or depleting antibodies, and by the administration of 
peptide mimetics, protein-specific enzymes or pharmaceutical agents. It is 
acknowledged that this model does not replicate the true-to-life situation in that a bolus 
of 1-200,000 tumour cells is unlikely to occur at any one time in the course of 
metastatic disease. Additionally, the endothelium in the experimental animals is 'naive' 
in that soluble factors, possibly released by the primary tumour in order to establish a 
pre- metastatic niche, are absent. In spite of these short-comings, and in the absence 
of a superior model, the experimental metastasis models described enable the 
assessment of the molecular interactions associated with tumour cell extravasation 
within the intact vascular system and its inherent shear forces, and within the complex 
milieu of the haematogenous and immune systems. 
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Figure 1.5: The adoption of an invasive phenotypc by MDA-MB-231 
tumour cclls when cultured on Matrigel in the presence of thrombin-
activated human platelet membranes 
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Many different tumour cell types have been demonstrated to have the ability to induce 
platelet activation and this correlates with their capacity to metastasise in vivo when 
injected intravenously (Karpatkin and Pearlstein 1981). Tumour cells may induce 
platelet activation through several mechanisms including: (i) activation of the 
coagulation pathway through the constitutive expression of tissue factor or cancer 
procoagulant, with the coagulation pathway resulting in the production of the potent 
platelet activator, thrombin; (ii) release of TNF-a or IL-1|3 by tumour cells resulting in 
expression of tissue factor by endothelial cells and associated dowregulation of 
thrombomodulin, thus creating a prothrombotic environment at the vascular wall; (iii) 
direct activation of platelets by tumour cells through the release of agonists, such as 
ADP or thrombin, or by direct binding of tumour cells to platelets (Noble and Pasi 
2010). 
Numerous experimental studies have demonstrated the requirement of platelets for 
successful metastasis of i.v. injected tumour cells. Ultrastructural studies in vivo have 
also demonstrated that tumour cells arrested in the vasculature are surrounded by 
platelets and fibrinogen (Karpatkin and Pearlstein 1981; Erpenbeck and Schon 2010). 
When anti-platelet agents are administered, or when platelet levels are experimentally 
lowered in-vivo, tumour cell metastasis is inhibited (Gasic et al. 1968; Karpatkin and 
Pearlstein 1981; Gasic 1984; Honn et al. 1992; Tzanakakis et al. 1993). Furthermore, 
mice genetically deficient in circulating platelets, the thrombin receptor PAR4, 
fibrinogen or the Gaq protein required for platelet activation have a reduced 
susceptibility to metastasis formation (Palumbo et al. 2000; Camerer et al. 2004; 
Palumbo et al. 2005). In particular, the platelet-specific adhesion proteins Gpllb-llla 
and P-selectin have consistently been shown to promote metastasis. As a result of the 
importance of these two molecules in tumour metastasis and leukocyte migration in 
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ischaemia/reperfusion injury, the following sections discuss the normal function of 
these two proteins and the evidence for their role in tumour cell metastasis. 
1.3.3.4 Role of the Integrin allb^S (Gpllb-llla) in Tumour Metastasis 
Integrins are heterodimeric receptors consisting of a and (3 subunits that are generally 
involved in cell-ECM interactions or cell-cell adhesion. In addition to their adhesive 
function, which is activated by inside-out signalling, they are involved in cell 
communication through outside-in signalling. Several members of the integrin family 
have been implicated in metastasis as shown in Table 1.2. 
The protein allbpS, also known as Gpllb-llla, is the most highly expressed receptor on 
the surface of resting platelets with approximately 50,000 copies/platelet, this number 
increasing to approximately 80,000 upon platelet activation. The role of Gpllb-llla in 
platelet function is to cross-link platelets through the binding of soluble macromolecular 
ligands, thus forming a stable clot. Ligands for Gpllb-llla include fibrinogen, von 
Willebrand factor (vWF), fibronectin, vitronectin and thrombospondin (Hato et al. 2002; 
Collerand Shattil 2008). 
Consistent with other members of the integrin family, until activated through inside-out 
signalling, Gpllb-llla has a low affinity and avidity for its ligands. Inside-out signalling 
through Gpllb-llla may be triggered by other platelet adhesion receptors binding their 
ligands (e.g., Gplb-IX-V binding to vWF or GpVI binding to collagen), by agonists 
released from nearby platelets binding their G-coupled protein receptors (e.g., ADP 
and thromboxane A2), or by substances produced as a result of tissue injury (e.g., 
thrombin and adrenaline). This inside-out signalling modulates within 1 second the 
ligand-binding affinity of Gpllb-llla through conformational change and increases the 
mobility of the protein to allow clustering, thus increasing adhesive function (Hato et al. 
2002; Coller and Shattil 2008). 
Outside-in signalling occurs through a conformational change induced in the 
cytoplasmic domains of Gpllb-llla following ligand binding. The subsequent signalling 
cascades lead to changes in cytoskeletal reorganization thus permitting platelet 
spreading to enhance adhesion, granule secretion and clot retraction (Hato et al. 2002; 
Coller and Shattil 2008). 
There is a significant amount of evidence implicating Gpllb-llla in the promotion of 
tumour cell extravasation. Inhibition of Gpllb-llla adhesion using blocking monoclonal 
antibodies or small molecules significantly reduces the interaction between platelets 
and tumour cells, as well as in vivo experimental metastasis (Bastida et al. 1987; 
Grossi et al. 1987; Amirkhosravi et al. 1999). Similarly, using a mouse strain deficient 
in p3 integrins, bone metastasis of B16 melanoma was significantly inhibited (Bakewell 
et al. 2003). Using bone marrow chimeras, it was demonstrated that the (33 integrins 
exerted their prometastatic effect via platelets, with Gpllb-llla being the dominant (33 
integrin expressed by platelets. Subsequent pharmacological inhibition of Gpllb-llla 
also significantly reduced metastases (Bakewell et al. 2003). In separate studies, 
Gpllb-llla binding to tumour cells was shown to occur via recognition of fibronectin and 
von Willebrand factor in vitro and Gpllb-llla blockade prevented tumour cell-platelet 
interactions in vitro and experimental metastasis in vivo (Karpatkin et al. 1988; 
Amirkhosravi et al. 1999). 
Gpllb-llla expression is normally restricted to platelets, megakarocytes and some 
haemopoietic progenitors, however, numerous tumour cells have been found to 
express Gpllb-llla, and in doing so, increase their metastatic potential through 
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enhanced platelet and endothelial interactions (Chen et al. 1992; Nierodzik et al. 1992; 
Oleksowicz et al. 1995; Chen et al. 1997). Furthermore, the level of expression of 
Gpllb-llla by a variety of B16 melanoma lines correlated with their ability to induce 
platelet activation and to form lung colonies. In addition, the level of Gpllb-llla 
expression increased following stimulation with thrombin, which was associated with an 
increased ability of the tumour cells to adhere to fibronectin and the subendothelial 
matrix (Chang et al. 1992; Wojtukiewicz et al. 1992). 
1.3.3.5 Role of P-selectin in Tumour Metastasis 
The selectin family of adhesion molecules, consisting of P-selectin, L-selectin and E-
selectin, are structurally related, transmembrane glycoproteins that recognise specific 
ligands which are generally sialo-fucosylated carbohydrate structures (Mannori et al. 
1995). 
P-Selectin is stored within the a -granules of platelets and the Weibel-Palade bodies of 
endothelial cells, both of which translocate to the surface within minutes following 
platelet/endothelial cell activation. Constitutive expression of P-selectin has been 
observed on the vascular endothelium of several organs with the highest levels seen in 
the liver and lungs (Eppihimer et al. 1996; Singh et al. 1999). The ligand for P-selectin, 
PSGL-1 (P-selectin glycoprotein ligand-1), is expressed by platelets, leukocytes and 
endothelial cells and carries the sialyl Lewis'^ tetrasaccharide (Moore et al. 1994; 
Frenette et al. 2000). PSGL-1 is capable of binding all 3 selectins, although it binds P-
selectin with the greatest affinity (Guyer et al. 1996; Li et al. 1996). Both platelet- and 
endothelial-derived P-selectin mediate the initial tethering of leukocytes to the vascular 
wall during inflammation and aid stable thrombus formation following vessel wall injury 
(McEver et al. 1995; Furie and Furie 2004). 
Several studies using experimental metastasis to the lung have demonstrated a role for 
P-selectin in the promotion of metastasis through enhancement of tumour ceil 
interactions with the blood vessel wall. This effect is generally attributed to the binding 
of platelet P-selectin to various carbohydrate ligands on the tumour cell surface (Kim et 
al. 1998; Kim et al. 1999; Garcia et al. 2007). In contrast, the relative contribution of 
endothelial P-selectin in tumour cell metastasis to the lung is not dear. As mentioned 
in section 1,3.2.3.4, a study of EL-4 lymphoma metastasis to the liver demonstrated a 
marked P-selectin effect which was attributed to endothelial P-selectin, however, the 
relative contributions of platelet P-selectin and endothelial P-selectin in this model were 
not delineated (Ding et al. 2001). 
It should be noted that unpublished results from Professor Parish's Laboratory 
demonstrated a potential cooperative role for P-selectin and Gpllb-llla in the promotion 
of metastasis by platelets. When incubating the human breast cancer cell line MDA-
MD-231 with washed, thrombin-activated, platelet membranes, it was found that 
interactions between platelet membranes and tumour cells and activation of Matrigel 
solubilisation could be prevented only when antibodies to P-selectin and Gpllb-llla 
were used in combination. Antibodies to Gplba, PECAM-1 and a2p1 were also tested 
in isolation and in combination with the antibody to P-selectin but had no inhibitory 
effects. These results are supported by the findings of Yu et al. who demonstrated that 
the binding of the highly metastatic human hepatoma cell line, MHCC97, to ECM in an 
in vitro adhesion assay was enhanced by platelets and could be significantly reduced 
by mAbs to Gpllb-llla and P-selectin (Yu et al. 2002). 
1.3.3.6 The Pro-Metastatic Effects of the Tumour Cell-Platelet Interaction 
The potential pro-metastatic effects of circulating tumour cells associating with platelets 
include the following (Karpatkin and Pearlstein 1981; Honn et al. 1992; VIodavsky et al. 
1992; Erpenbeck and Schon 2010): 
(i) A platelet-coated tumour cell may be better able to withstand the shear stresses 
within the circulation and more likely to become arrested within the capillary bed. 
(iii) Platelet adhesive proteins may interact with the endothelium creating a stable 
platform for subsequent tumour cell migration. 
(iv) Platelet-derived proteases and heparanase may assist in the migration of tumour 
cells across the vessel wall, particularly the subendothelial basement membrane. 
(v) Platelet-derived growth and angiogenic factors may assist the subsequent growth of 
tumour cells and the establishment of secondary tumours. 
Other research, however, has suggested that the only role platelets play in promoting 
metastasis is the protection of tumour cells from destruction by NK cells through 
physical impedence and the downregulation of NK function by PDGF interacting with 
the inhibitory receptor NKG2D (Nieswandt et al. 1999; Palumbo et al. 2005; Kopp et al. 
2009). 
1.4 Conclusions 
Platelets, despite their small size, contain a remarkable armoury of proteins that not 
only promote thrombosis, haemostasis and tissue repair but also attack invading 
microorganisms, initiate an inflammatory response, and activate cells of the immune 
system. Furthermore, activated platelets attract and bind leukocytes, including NK 
cells, within the circulation assisting their migration across the blood vessel wall. 
The small amount of research conducted on the role of platelets at the primary tumour 
site indicates that they are capable of inducing genes involved in invasion, proliferation 
and angiogenesis. In contrast, the evidence indicating a role for platelets in tumour cell 
extravasation, that parallels their role in leukocyte migration, is substantial. In the light 
of this wealth of evidence, it is hard to conceive that the only role for platelets in the 
metastatic process is to form a protective cloak around tumour cells preventing their 
destruction by NK cells. Platelet adhesion proteins involved in leukocyte migration 
have unequivocally been shown to promote tumour cell metastasis, moreover, L-
selectin, present on leukocytes, including NK cells, has been shown to have an 
independent and synergistic effect with P-selectin in promoting metastasis (Borsig et 
al. 2002; Lejtenyi et al. 2003). Furthermore, leukocytes are readily incorporated into, 
and capable of migrating through, a thrombus (Sheikh et al. 2004; Wohner 2008). The 
timing within the metastatic process of the actions of platelets and NK cells on tumour 
cells has not been determined and may resolve these conflicting data. 
1.5 Experimental Aims of this PhD 
in light of the evidence and controversy regarding the role of platelets in tumour cell 
extravasation detailed above, initially this PhD project planned to address the following 
aims: 
(i) To establish the kinetics of the pro-metastatic role of platelets and the anti-
metastatic role of NK cells in an experimental model of tumour cell metastasis, and to 
determine whether platelets have a role in promoting metastasis beyond that of 
preventing NK cell-mediated tumour cell killing. 
(ii) To determine the relative contributions of platelet-derived and endothelial-derived 
P-selectin in promoting metastasis. 
(iii) To establish an improved methodology enabling the in vivo monitoring of platelet 
production and lifespan for use when trialling anti-platelet therapies or investigating the 
cause of abnormal platelet numbers. 
During the research under these aims, however, it was observed that the use of a mAb 
specific for the platelet protein Gpllb-llla in vivo resulted in the elimination of >95% of 
platelets and, upon reviewing the literature on the mechanisms of antibody-mediated 
platelet depletion (provided in Chapter 4), it was felt that a contribution could be made 
to this field of research. The project aims were extended, therefore, to include the 
following: 
(iv) To investigate the different mechanisms of platelet depletion using monoclonal 
antibodies to a variety of platelet proteins. 
(v) To explore the potential regulatory pathways that determine whether an anti-platelet 
antibody causes platelet depletion or not. 
(vi) To establish whether these regulatory systems can be manipulated to prevent 
antibody-mediated depletion as seen in the medical condition known as immune 
thrombocytopenic purpura (ITP). 
It was hoped that the results of this work would better define the role of platelets and 
NK cells in tumour cell metastasis, the mechanisms and regulation of antibody-
mediated platelet elimination, and provide improved techniques for the study of the 
determinants of platelet production and lifespan. The greater aim of this work was to 
contribute to the significant bank of knowledge on the mechanisms of haematogenous 
metastasis and ITP, and in so doing, aid the quest to find more effective therapies for 
the treatment of both conditions. 
Chapter 2 
Materials and Methods 
The following chapter details the materials and experimental methods used to obtain 
the results described in chapters 3, 4 & 5. 
2.1 General reagents 
2.1.1 Media, buffers and anti-coagulant solutions 
Acid Citrate Dextrose (ACD) 
Sodium citrate 25 g/L, citric acid 14 g/L and glucose 20 g/L in purified, deionised, sterile 
water, pH 4.5. 
Alpha Minimal Essential Medium (alpha MEM) 
Minimum Essential Medium (MEM) Alpha Medium powder (Invitrogen, Carlsbad, CA) 
in purified, deionised, sterile water. 
Bouin's Solution 
Acetic acid 5% (v/v), formaldehyde 9% (v/v), picric acid 0.9% (v/v) in purified, 
deionised, sterile water. 
Buffered Saline Citrate Glucose (BSCG) 
NaCI 6.78 g/L, sodium citrate 4 g/L, Na2HP04 1.2 g/L, KH2PO4O.2 g/L, EDTA 0.34 g/L 
and glucose 2 g/L in purified, deionised, sterile water. 
EDTA (5mM) in PBS 
EDTA 1.46 g/L in phosphate buffered saline 
F15 Medium 
F15 MEM powder (Gibco BRL, Grand Island, NY) 9.61 g/L and NaHCOa 2.2 g/L in 
purified, deionised, sterile water. 
Hank's Balanced Salt Solution 
NaCI 8 g/L, KCI 400 mg/L, MgS04.7H20 100 mg/L, MgCb.eHzO 100 mg/L, CaCb 112 
mg/L, glucose 1 g/L, phenol red 20 mg/L, NaH2P04.2H20 78 mg/L, KH2PO4 60 mg/L in 
purified, deionised, sterile water. 
Phosphate Buffered Saline (PBS) 
NaCI 8 g/L, NaH2P04.2H20 0.35 g/L and Na2HP04.2H20 1.25 g/L in purified, 
deionised, sterile water. 
Penicillin Streptomycin Neomycin (PSN) Antibiotics 
Penicillin G 300 mg/L, streptomycin sulphate 500 mg/L, neomycin sulphate 500 mg/L in 
purified, deionised, sterile water. 
RPMI-1640 
RPMI powder (Gibco BRL, Grand Island, NY), NaHCOs 2 g/L in purified, deionised, 
sterile water. 
Red Blood Cell Lysis Buffer 
7.65 g/L NH4CI and 2.06g/L Tris in purified, deionised, sterile water, pH 7.2. 
Trypsin/EDTA 
0.04% (w/v) Trypsin and 0.02% (w/v) EDTA in purified, deionised, sterile water. 
2.2 Animals 
The strain, phenotype, background and source of all mice used are detailed in Table 
2.1. Approval for all experimental procedures conducted on these mice was obtained 
from the Animal Experimentation Ethics Committee of the Australian National 
University. The mice were housed within PC2 facilities. Daily care and breeding of the 
mice was conducted by the staff of the Animal Services Division, the Australian 
National University or the candidate. 
2.3 Antibodies 
Table 2.2 details the antibodies used. The 1B5 mAb against mouse Gpllb-llla was 
kindly provided by Professor Barry Coller (The Rockefeller University, New York, USA) 
(Lengweiler et al. 1999). All other antibodies were purchased from commercial 
sources. 
Tabic 2.1: Mouse strains usod in experimental procedures 
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^ M o u s c S t r a i n B a c K g r o u n d P h o n o t y p e S o u r c c R o f c r c n c c 
C57BL/6 86 WT Animal Resources Centre, Porh. Australia NA 
C57BL'6 (CD45 1) 66 CD45 1 congenc strain Animal Resources Centre. Perh. Australia NA 
BALB.'c BALB/c WT Animal Resources Centre. Perh, Australia NA 
Dr Mtcnael Hickey Monash University. 
P sclectin /. C57BL'6 Absencc of P-seiectin Mebourne. Australia ^ (Kuligowski of al 2006) 
Lack thrombopoie:in recepior Dr Warren Alexander. WEHI. Melbourne, 
cmp);'- C57BL'6 J 5 15% normal platelot r^umbcrs Australia (Alexander ef al. 1996) 
Mutation in Bel X (Mason ef al 2007) 
Ptt20 BALB/c 30% normal platelet numbers I Dr Ben Kyle, WEHI. Melbourne. Australia 
Absence of C3 component of Professor Marina Botto, Impenal College. (Wessels ef 0/ 1995) 
t , C3 A : C57BL''6 complement system London, UK 
1" 
C57BL'6 or Absencc of common gamma chain Dr Mar1< Hogarth, Burnett Institute. Melbourne. 
- • 1 
(Takaiefa/ 1994) 
FcRv.' j BALBVc of all Tc receptors ^Australia 
i 
Absence of fi; microglobulin Dr Guna Karupiah. JCSMR. ANU. Canberra. (Zijlstra ef a/. 1990) 
f-.M-/- C57BL'6 associated with MHC Class 1 Australia 
B6.129S7 
Cd47 t .m1FpW C57BU6 , Absence of CD47 Jackson Laboratories, Maine, USA (LindPerg of at. 1996) 
B6.129S4 
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(Coxonefa/ 1996) 
l:gam!fri1Myc(/J _|_C57BL''6 Absence of c o n b (Mac 1) 1 Jackson Laboratories, Maine, USA 
N O D S C I C I J L 2 R y Absence of NK. B and T cells 
! 
Jackson Laboratories, USA (Shultz er al. 2005) 
NOD/SC'G NOD , Absence of B and T cells \ Animal Resources Centre. Penh, Austrafia ; NA 
Tabic 2.2: Antibodies Used in Experimental Procedures 
Antigen (CD) Moloculo Spccics Raised in IgG isotypo Clone Source Catalogue No. 
Purified mAbs 
CDI Ib Mac 1/CR3 mouse ra: lgG2a. Ml..'70 BD 553308 
CD31 PECAM 1 mouse ra: IgGI Pec.H3 Emfre: M120 0 
CD41.'61 Gpllbi'llla mouse hamster lgG3 1B5 Barry Co'ler NA 
CD4i;61 Gpllb.'llla mouse ra: lgG1 Leo.AI Emfre: M022 0 
C041.'61 Gpllb.'llla , mouse rat lgG2b L00.H4 Emfre: M021 0 
CD42a GplX ' mouse ra: IgGI Xia B4 Emfre: M051 0 
CD42b Gplbd mouse ra: IgGI Xia G7 Emfre: M042 0 
CD42b Gplb<i mouse ra: lgG2b Xia G5 Emfre: M040 0 
CD42d GpV mouse ra: IgGI GonC2 Emfre: M060 0 
CD42d GpV mouse ra: lgG2a Gon G6 Emfre: M061 0 
C047 lAP mouse ra: tgG2a miap301 BD 555297 
CD49b Gpla mouse ra: IgGI Sam H9 Emfre: Custom made 
CD49b Gpla mouse ra: lgG2b Sam G4 Emfre: M070 0 
CD62L L selcctin mouse ra: lgG2a MEL 14 BD 553148 
C062P P selec'.tn mouse ra: lgG1 RB40 34 BD 553741 
GDI 72a SIRPu mouse ra- IgGI p e 4 BD 552371 
CD200 R 0X2 R mouse ra: lgG2a OX 110 BoLegend 123902 
lso:ypc contro! 
• 4 - -
ra: IgGI A l i o 1 BD 553993 
Iso'.ypc control 
T 
i 
ra: IgGI R3 34 BD 553922 
lso:ype control ra: lgG2a 54447 R&D MAB006 
Iso'.ypc control ra: lgG2b 141945 R&D MAB0061 
lso:ype control han^ster lgG3 C36 239 BD 551386 
FITC Conjugated mAbs 
C062P P Sclcctm Mouse Rat IgGI RB40 34 BD 553744 
C071 Transferrin R Mouse Rat IgGI C2 BD 553266 
CD452 LCA Mouse Mouse lgG2a 104 BD 553772 
CD3 CD3 Mouse Rat lgG2b 17A2 BD 555274 
lso:ype contro! Rat IgGI R3 34 BD 554684 
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Table 2.2: Antibodies Used in Experimental Procedures (continued) 
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2.4 Flow cytometty equipment and software 
Samples were analysed on either a Becton Dickinson FACSort or Becton Dickinson 
LSR Fortessa machine using BD CellQuest™ software (Franklin Lakes, NJ) and 
FlowJo software (Tree Star Inc., Ashland OR). 
2.5 Platelet and erythrocyte enumeration 
Mice were placed in a restrainer and approximately 1 mm of the tail tip removed using 
surgical scissors. 5 (,iL whole blood was collected from the tail vein and thoroughly 
mixed into 45 ^L ACD. To prevent blood loss from the wound of thrombocytopenic 
mice, or when platelet and erythrocyte kinetics were performed, lignocaine gel was 
applied topically for pain minimisation and the tail tip cauterised. 
Platelet and erythrocyte numbers were determined via flow cytometry within 30 min of 
collection using the method of Alugupalli et al (Alugupalli et al. 2001). Briefly, 10 [AL 
blood/ACD was added to 990 M-L PBS containing 10 i^L rainbow fluorescent reference 
beads (Becton Dickinson, Catalogue No. 556291). Platelet and erythrocyte gates were 
determined using their characteristic log forward and log side scatter parameters. 
These parameters were confirmed when establishing the method using antibodies to 
Gpllb-llla (clone MWRegSO) and glycophorin A (clone TER119). Samples were 
passaged through the FACS machine until 1000 reference beads had been collected, 
representing 10 [.iL of the solution. Platelet and erythrocyte numbers were calculated 
per \xL blood by multiplying the number of events in the platelet or erythrocyte gate by a 
factor of 100 (multiplied by 1000 to account for the blood sample dilution factor, and 
divided by 10 as 10 i^L of diluted sample was analysed). 
2.6 Staining of platelets for cell surface markers 
From the tail tip of mice, 5 j,iL samples of whole blood were collected into 100 ^^ L of 
5mM EDTA in PBS. Samples were centrifuged at 350g for 5 min at room temperature 
to pellet RBCs and WBCs. The platelet-rich supernatant from each sample was 
collected and centrifuged at 1210gfor 10 min at room temperature and the supernatant 
removed. Antibodies directed against the surface markers of interest were added, or an 
appropriate isotype control, and incubated in the dark for 30 min at 37°C. Samples 
were washed twice with PBS prior to FACS analysis or addition of a fluorescent-
conjugated secondary antibody. Following incubation with the secondary antibody for 
30 min in the dark at room temperature, 2 wash steps were repeated prior to analysis 
using flow cytometry. 
2.7 Platelet-assisted tumour cell metastasis 
2.7.1 Tumour cell lines, culture, injection and assessment of tumour 
burden 
2.7.1.1 B16-F1 mouse melanoma cell line 
B16-F1 melanoma cells were cultured in F15 medium supplemented with 10% foetal 
calf serum, 0.1% PSN and 1% glutamine and passaged 4 times prior to preparation for 
injection. Cells were washed twice with PBS following lifting with EDTA/Trypsin and 
resuspended in HBSS for injection. A dose of 1-2 x 10® cells in 200 [iL was injected 
into the tail vein of mice. Mice were culled 14 days following injection of tumour cells, 
the lungs +/- livers were then removed and placed into 10% formalin. The preserved 
organs were dissected into separate lobes and tumours counted under a dissecting 
microscope. 
2.7.1.2 Mouse breast cancer cell line -4T1.2 
This cell line was kindly provided by Dr Robin Anderson (Peter MacCallum Cancer 
Institute, Melbourne) and routinely cultured in alpha MEM supplemented with 10% 
foetal calf serum, and 0.1% PSN. Cells were passaged 3 times prior to preparation for 
injection. Cell were washed twice with PBS following lifting with EDTA/Trypsin and 
resuspended in HBSS for injection. A cell dose of 1-2 x 10® in 200 i^L was injected i.v. 
into BALB/c mice. Mice were culled 14 days following tumour cell injection, the lungs 
+/- the livers removed and placed into Bouin's solution. The preserved organs were 
dissected into separate lobes and tumours counted under a dissecting microscope. 
2.7.2 Depletion of platelets in mice 
To deplete mice of platelets, 20 ^g of a mAb specific for mouse Gpllb-llla, clone 1B5, 
was diluted in 150 ^L of PBS and injected i.v. via the tail vein. 
2.7.3 Depletion of NK cells in mice 
To deplete mice of NK cells, 50 (^ L of a rabbit polyclonal anti-asialo GM1 antiserum 
(#986-10001, Wako Pure Chemical Industries, Osaka, Japan) was mixed with 100 ^L 
of 0.9% saline and injected i.v. via the tail vein at the time points indicated. 
To confirm the selective depletion of NK cells, mice were injected with the anti-asialo 
serum or PBS i.v. via the tail vein and the spleens removed 1 hr and 48 hr following 
injection. The spleens were mashed, the cells washed, stained with mAbs specific for 
NK1.1, CD45.2, CDS and B220 in addition to the viability dye Hoechst 33258, then 
analysed using flow cytometry (Figure 3.5). 
2.7.4 Generation of P-selectin bone marrow chimeras 
This experiment was performed on two separate occasions with the bone marrow 
make-up of the chimeras described in Chapter 3, Tables 3.1 and 3.2 
2.7 A A Bone marrow Collection 
Donor mice were euthanased via cervical dislocation and the femurs and tibias 
dissected. The marrow was extracted by flushing the lumen of the bones with RPMI-
1640. The cellular extract was then filtered 3 times through a 70 ^m filter, placed on 
ice and a cell count performed. Cells were centrifuged at 300g for 5 min at 4°C and 
resuspended in PBS at a concentration of 1 x 10^ cells/mL in preparation for injection. 
2.7.4.2 Mouse irradiation and marrow transplantation 
Irradiation of the mice and injection of bone marrow preparations were performed by 
Mrs Debbie Howard. Recipient mice were placed in containers and irradiated with 1000 
rads from a cobalt-60 source. Within 4 hr of irradiation the mice were injected i.v. with 
2x10® bone marrow cells. Mice received prophylactic antibiotic therapy of neomycin 
and polymyxin in their drinking water for 6 wk following irradiation. 
2.7.4.3 Measurement of CD45 allotype 
Four to 6 wk following irradiation, 7 ^L of blood was collected from the tail vein of each 
bone marrow recipient mouse into 20 |a,L of ACD. Following the addition of 150 ^L of 
cold red cell lysis buffer, samples was incubated for 20 min at room temperature. 
Samples were then centrifuged at 300g for 5 min, the supernatant removed, CD45.1-
PE and CD45.2-FITC antibodies added and the samples incubated on ice in the 
dark for 25 min. Samples were washed twice with PBS to remove excess antibody and 
resuspended in PBS for subsequent analysis using flow cytometry. Leukocytes were 
gated using their characteristic log SSC and linear FSC. The percentages of CD45.1-
PE and CD45.2-FITC positive cells were determined for each mouse. 
2.7.4.4 Metastasis experiment in P-selectin chimeras 
Experimental lung metastasis with B16-F1 melanoma cells were conducted in the P-
selectin chimeras as described in section 2.7.1.1 > 6 weeks post irradiation. 
2.8 Immune-mediated depletion of platelets 
2.8.1 Effect of mAbs directed against various platelet antigens on platelet 
numbers 
Mice were injected i.v. with 20 ^g of various antibodies (detailed in Table 2.2) specific 
for the platelet antigens Gpllb-llla, Gplba, GplX, Gpla, GpV and PECAM-1. Platelet 
numbers were determined, as described in Section 2.5 prior to, 2- and 24 hr post mAb 
injection. In a subset of experiments, mice were injected i.v. with 50 ^g of a mAb 
specific for either SIRPa or the CD200R (0X2R) 1 hr prior to, or 1 hr post injection of 
the anti-platelet mAbs. 
2.8.2 Analysis of platelets for degree of mAb binding 
2.8.2.1 In vitro studies 
To determine the extent of anti-platelet mAb binding to the surface of platelets, 200 \iL 
of whole blood was collected from the tail vein of mice into 4 mL of 5mM EDTA in PBS, 
5ml of PBS added, the sample spun at 1210g for 10 min at room temperature and the 
supernatant discarded. The platelet, leukocyte and RBC pellet was resuspended in 
8 mL of PBS and aliquoted. The in vivo dose of mAb administered to mice was 10 
l^g/mL of blood and, therefore, a range of mAb concentrations that equated to 2.5 - 40 
|ig/mL of blood, was added to the samples. The samples were then incubated at 37°C 
for 30 min, washed with PBS prior to the addition of a secondary FITC-conjugated 
antibody directed against rat lgG1 and the samples incubated on ice in the dark for 30 
min prior to washing twice with PBS and analysis using flow cytometry. 
2.8.2.2 In vivo studies 
In the case of anti-platelet mAbs that failed to depleted platelets in vivo their extent of 
binding to platelets was determined by collecting 5 nL of whole blood in duplicate from 
the tail tip of mice into 100 |.iL 5mM EDTA in PBS 2 hr following mAb injection. A 
further 130 (AL of PBS was added to each sample prior to centrifugation at 121 Og for 10 
min at room temperature. The pellet was washed in PBS prior to the addition of a 
FITC-conjugated antibody directed against rat lgG1. The samples were incubated on 
ice in the dark for 30 min prior to washing twice with PBS and analysis using flow 
cytometry. 
2.8.3 Depletion of complement using cobra venom factor (CVF) 
Mice were depleted of C3 by administering an intra-peritoneal injection of 50 \xl of CVF 
(500 ng/mL) (Venom Supplies, Tanunda, South Australia), diluted in 0.9% saline 18 hr 
prior to injection of mAbs directed against platelet antigens. 
2.8.4 Macrophage uptake of antibody-bound platelets 
2.8.4.1 Macrophage isolation 
Peritoneal macrophages were collected from euthanased mice into ice-cold 0.9% 
saline, centrifuged at 400g for 10 min at 4°C, resuspended in PBS and labelled for 20 
min on ice with a mAb to PerCP conjugated mAb specific for CD11b (BD Biosciences, 
cat # 550993). The cells were then washed twice, resuspended in RPMI-1640 
containing 1% PCS and kept on ice. 
2.8.4.2 Platelet isolation, CFSE-labelling and incubation with mAbs 
Platelets were isolated from 1 mL of whole blood collected from 5 mice via retro-orbital 
bleed through heparinized capillary tubes into BSCG. The blood was initially 
centrifuged at 300g for 5 min at room temperature to pellet erythrocytes and 
leukocytes. Platelets were then pelleted from the plasma by centrifugation at 1210gfor 
10 min at room temperature. The platelet pellet was resuspended in 5 mL of PBS and 
5 nL of a 1 mM solution of CFSE in DMSO then added whilst the tube was being slowly 
vortexed. The platelets were incubated with CFSE in the dark for 5 min at room 
temperature prior to 3 washes in PBS/1% PCS and resuspension in 650 ^L of PBS. 
Aliquots (200 ^^ L) of the platelet preparation were then incubated with 3.35 ^g of an 
IgGI mAb specific for GplX, Gpllb-llla or an isotype control for 30 min at 37°C (thus 
maintaining an equivalent platelet:mAb ratio as the in vivo concentration of 10 ^g/mL of 
whole blood), and washed with PBS prior to resuspension in 750 ^L of RPMI-1640 
containing 1% PCS. A platelet count was performed on the residual platelet preparation 
via PACS analysis as described in section 2.5. 
2.8.4.3 Co-Incubation of macrophages and antibody-bound platelets 
Platelets and macrophages were co-incubated at a ratio of 20:1, respectively, for 1 hr 
at 37°C prior to analysis by flow cytometry. CD11 b+ cells were gated and analysed for 
the level of CFSE fluorescence. 
64 9/- 2; ivJcte ' - a n d Methods 
2.8.5 Platelet disintegration in vitro following incubation with antibodies 
directed against platelet antigens. 
Whole blood (100 ^L) from the tail tips of mice was collected into 2 mL of BSCG, 
diluted with 5 mL of PBS, centrifuged at 1210g for 10 min at room temperature, the 
pellet resuspended in 5mL of PBS and centrifuged again. The platelet, leukocyte and 
RBC pellet was resuspended in 1 mL of Hanks solution and aliquoted in 200 jo-L 
volumes. To each sample 0.2 jxg of the anti-platelet antibody of interest was added 
(thus maintaining an equivalent platelet:mAb ratio as the in vivo concentration of 10 
l^g/mL of whole blood), the samples were incubated at 37°C for 30 min and washed 
twice with PBS prior to resuspension in Hanks solution. Each sample was further 
aliquoted into two wells and a FITC conjugated mAb specific for P-selectin or an 
isotype control added (2.5 i^g/mL) Following incubation in the dark for 30 min at room 
temperature and two subsequent washing and centrifugation steps, the samples were 
analysed using flow cytometry. 
2.9 Platelet and erythrocyte lifespan studies In mice using 
CFSE-labellIng 
2.9.1 In vivo CFSE labelling 
Carboxyfluorescein diacetate succinimidyl ester (CFSE - Molecular Probes, Carlsbad 
CA) was dissolved in DMSO to prepare a stock solution of 10 mM. Immediately prior 
to injection into the lateral tail vein, 50 ^L of stock CFSE was mixed with 100 \xl of 
PBS. The solution was injected slowly over ~30 seconds. 
2.9.2 Platelet and erythrocyte lifespan analysis 
To determine the lifespan of platelets in mice, blood samples were collected at 1, 24, 
48, 72, 96 and 120 hr following injection of CFSE as described in section 2.5. To define 
the platelet population from background debris when platelet numbers were low, such 
as in the c-mpl-l- and Plt20 mutant mice, a PE-conjugated anti-mouse Gpllb-llla 
antibody (clone MWRegSO) was added to the ACD at a concentration of 2 ng/mL. 
Samples were analysed as described in Section 2.5 with PE positive platelets gated for 
subsequent CFSE labelling analysis. 
To determine the lifespan of erythrocytes in mice, blood samples were collected at 1, 5, 
10, 20, 30, 40 and 50 days following CFSE injection as described in section 2.5. 
Erythrocytes were gated based upon their characteristic log forward and side-scatter 
parameters for subsequent CFSE labelling analysis. 
To determine the extent of CFSE labelling of platelet and erythrocyte populations at 
each time point, fluorescence was measured on the FL-1 channel of the flow 
cytometer, with the percentage of CFSE positive platelets and erythrocytes being 
followed over time to determine lifespan, and the total cumulative number of CFSE 
negative platelets and erythrocytes followed over time to determine bone marrow 
production rates. See Figure 5.1 for more details of analytical method used. 
2.9.3 CFSE immunogenicity studies 
To determine the immunogenicity of CFSE, mice were injected with a second dose of 
CFSE 12 weeks after the first dose. Erythrocyte kinetics were repeated and compared 
with results from the initial erythrocyte lifespan studies in these mice. 
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2.9.4 CFSE toxicology studies 
To determine whether i.v. injection of CFSE caused any hepato- or nephrotoxicity, one 
mouse was injected with 155 ^L of PBS (PBS control), two mice were injected with 92 
[xL of DIVISO mixed with 63 ^L of PBS (DMSO control), and two mice were injected with 
50 f-iL of lOmmM CFSE stock in 42 ^L of DMSO and 63 [xl of PBS. One mouse from 
each experimental group was culled 24 hr post CFSE injection and the kidneys and 
livers were collected and fixed in 10% formalin. The remaining mice were culled 10 
days post CFSE injection and the organs removed and fixed. The organs were 
paraffin-embedded, sectioned and H&E stained prior to examination by an independent 
anatomical pathologist. 
2.9.5 Comparison of old and young erythrocytes 
Age-associated changes in erythrocytes were also studied using in vivo CFSE 
labelling. Following the injection of mice with CFSE, blood samples were collected, as 
described in Section 2.5, on day 10 and day 40 post CFSE injection. A comparison 
was made of the mean forward scatter (Mean FSC) and the co-efficient of variation of 
the side scatter (CV of SSC) of newly generated versus aged erythrocytes. Aged 
erythrocytes were defined as erythrocytes that were CFSE-bright 40 days following 
CFSE injection. Newly generated erythrocytes were defined as erythrocytes that were 
CFSE-dull 10 days following CFSE injection (Figure 5.6). 
2.9.6 Mathematical modelling of platelet and erythrocyte lifespan data 
This work was done in collaboration with Professor Miles Davenport, University of New 
South Wales and Dr Deborah Cromer, Oxford University, UK. Dr Cromer was 
responsible for modelling the lifespan data generated by the candidate. 
2.9.6.1 Lifespan modelling methods 
In order to estimate the platelet and red cell lifespans from the experimental data it was 
assumed that the percentage of CFSE labelled cells within each mouse was fitted by 
either a linear or exponential curve, or by a curve derived from a lognormal distribution 
which was termed the 'lognormal model' (Murphy and Francis 1969; Dowling et al. 
2005). A linear distribution would arise if all cells had exactly the same lifespan. An 
exponential distribution would generally arise if the death of platelets occurs at a 
defined "rate", possibly as a result of an external event. A log-normal distribution is 
likely to arise when the majority of platelets have a particular lifespan, which can vary 
slightly from its mean value. 
It was assumed that cell lifespans have a distribution given by a function f(r) (and 
therefore that a proportion, fir), of cells have a lifespan of r t ime units). If F% of such 
cells were labelled initially with CFSE, the percentage of labelled cells one would 
observe in circulation f time units after labelling is given by: 
^ «/ . 
S{t) = - J 1 - f m d r ds (S1) 
where C is a normalising constant (Murphy and Francis 1969). 
For a linear distribution: 
[1 x = L 
— . 
10 otherwise 
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where L gives the lifespan of cells. The number of CFSE labelled cells observed in 
circulation at time x after labelling is: 
Sidt) = 
F(L-x) . 
X < L 
I (S2) 
0 otherwise 
For an exponential distribution: 
fexp(T) = ae'", 
where a gives the decay rate of the cells. The number of CFSE labelled cells observed 
in circulation x time units after labelling is then given by 
Sexp(0 = Fe-'^ . (S3) 
Note that since fexpir) represents the lifespan distribution of cells there is a factor of a at 
the front to ensure that the area under the curve is equal to one. Sexp(f) gives the 
observed number of labelled cells present at time t after labelling and has the familiar 
constant term at the front. 
For a log-normal distribution: 
. (U()-mf 
V2 JZSt 
where m and s are defined in terms of t l ie mean, and the standard deviation, a, 
of cell lifespans via 
- I 
= a n d a = - 1 ) . 
The number of CFSE labelled cells one would observe in circulation x time units after 
labelling is given by 
Sinit) = y (S4) 
where Xi = m + s^/2 and X2 = (Dowling et at. 2005). 
Syfl 
Equations S2, S3 and S4 were fitted to experimental platelet and red blood cell data to 
determine average cell lifespans. Matlab®'s non-linear least squares estimator 
isqnoniin was used to perform the fitting. 
2.9.6.2 Statistical analysis 
Comparisons were performed using the Student's t-test when the standard deviation 
(SD) of the two groups was comparable (calculated with the F-test), and the Mann 
Whitney test or non-parametric t-test was used when the SD between the two groups 
was significantly different. Significance of the t-tests or Mann Whitney test is given as 
a 2-tailed P-value. Statistical software used included Microsoft Excel (Version 11.2.3) 
and InStat (Version 3.0). 

Chapter 3 
Platelets and P-selectin control tumour cell 
metastasis in an organ-specific manner and 
independently of NK cells 
3.1 Abstract 
The pro-metastatic role of platelets has long been recognised with many mechanisms 
having been proposed such as platelets shielding tumour cells from destruction by 
intravascular natural killer (NK) cells and P-selectin expressed by activated platelets 
aiding the interaction of blood-borne tumour cells with the endothelium. The following 
chapter describes the results of investigations into the kinetics of the pro-metastatic 
role of platelets and the anti-metastatic role of NK cells in experimental models of 
4T1.2 breast cancer lung metastasis and B16F1 melanoma lung and and liver 
metastasis. Furthermore, the relevant contributions of platelet P-selectin and 
endothelial P-selectin in B16F1 melanoma lung and liver metastasis were determined. 
The results of this work have demonstrated that the lung metastasis of both B16F1 
melanoma cells and 4T1.2 breast cancer cells is promoted by platelets and inhibited by 
NK cells. Moreover, in the B16F1 metastasis model, the prometastatic role of platelets 
and the antimetastatic role of NK cells were shown to be chronologically distinct, and 
that platelets promote lung metastasis by a process that is independent of NK cells. 
Intriguingly, unlike B16F1 melanoma lung metastasis, B16F1 liver metastasis appeared 
not to be reliant upon platelets. Furthermore, the pro-metastatic roles of both platelet-
derived and endothelial-derived P-selectin in lung metastasis, and endothelial-derived 
P-selectin in liver metastasis, was demonstrated. P-selectin may, therefore, represent 
a key target for therapies aimed at preventing tumour metastasis in multiple organs. 
3.2 Introduction 
Metastasis poses the greatest threat to life following a diagnosis of cancer and the 
greatest challenge for successful treatment. Tumour cells may spread from the primary 
tumour into the lymphatics or the bloodstream or both, however, for dissemination to 
organs such as the liver, lung and brain, tumour cells must ultimately enter the 
bloodstream (Wong and Hynes 2006). The process of haematogenous tumour cell 
metastasis includes the migration of tumour cells from the primary tumour, 
intravasation, survival within the bloodstream, adhesion to and migration across the 
blood vessel wall, and survival and growth within a distant organ into a secondary 
tumour. The likelihood of a tumour cell successfully completing the metastatic process 
is low, being <10% (Liotta 1992). At what stage or stages of the metastatic process 
tumour cells fail, however, is a matter of debate. 
Platelets have long been implicated in haematogenous metastasis with the first 
experiments definitively demonstrating an association being published in 1968 (Gasic 
et al. 1968). Since then a multitude of studies have demonstrated that platelets, and 
adhesion proteins expressed by platelets, promote tumour cell metastasis {for a recent 
review see Erpenbeck and Schon 2010) through mechanisms analogous to the role 
platelets play in assisting leukocytes across the blood vessel wall in inflammation 
(Pitchford et al. 2003; Pitchford et al. 2005; Wagner and Frenette 2008). The proposed 
mechanisms by which platelets promote metastasis include: (i) the formation of a 
thrombus around the tumour cells within the bloodstream - this has several potential 
advantages including prolonging the survival of tumour cells within the bloodstream 
from shear stresses and immune cell attack, increasing the effective size of the tumour 
cell thus enhancing the likelihood of arrest in downstream capillary beds due to a size 
restriction, and inducing ischaemic changes in endothelial cells following arrest; (ii) the 
promotion of adhesion to the blood vessel wall via platelet-specific proteins including P-
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selectin and Gpllb-llla; (iii) the release from platelets of permeability factors and 
degradative enzymes to assist tumour cell migration across the blood vessel wall; and 
(iv) the release from platelets of angiogenic and other growth factors to assist in the 
establishment of a secondary tumour (Karpatkin 2002; Erpenbeck and Schon 2010), 
Other research has suggested, however, that the only role platelets play in promoting 
metastasis is to shield tumour cells from NK cell attack (Nieswandt et al. 1999; 
Palumbo et al. 2005), and to impair NK cell function via the inhibitory effects of platelet-
derived TGF-p on the NK cell activating receptor NKG2D (Kopp e^ al. 2009). 
The role of NK cells in detecting and destroying cancerous cells has been extensively 
studied. In vitro studies have shown that NK cells are capable of killing human- and 
animal-derived tumour cells without prior sensitisation (Herberman et al. 1975; 
Kiessling et al. 1978). Additionally, in experimental metastasis models conducted in 
mice genetically deficient of NK cells or experimentally depleted of NK cells, a 
substantial increase in tumour metastases was observed (Gorelik et al. 1984; 
Nieswandt et al. 1999; Kim et al. 2000; Palumbo et al. 2005), whilst enhancing NK cell 
function decreased metastases (Hanna and Fidler 1980; Riccardi et al. 1980). The 
cytolytic function of NK cells against stressed or cancerous cells, mediated principally 
by perforin/granzyme mediated apoptosis, is regulated by the balance of signals 
transmitted by killer inhibitory- and killer activating- receptors. NK cells also release 
immunoregulatory cytokines which stimulate the anti-tumour actions of the adaptive 
immune system (Smyth et al. 2002; Vivier et al. 2008). 
Platelets express numerous proteins that are involved in thrombus formation and 
leukocyte migration and many of these have also been implicated in tumour cell 
metastasis. In particular, the adhesion molecule P-selectin, that is expressed by 
activated platelets and endothelium and has a pivotal role in leukocyte migration, has 
been strongly implicated in the metastatic process. An assumption has been made, 
however, that platelet-derived P-selectin is responsible for the promotion of tumour cell 
metastasis, with the potential contribution of endothelial-derived P-selectin being 
largely ignored. Furthermore, in the face of the wealth of experimental evidence 
indicating that platelets promote the adhesion to and migration across the blood vessel 
wall of metastasising tumour cells, it is hard to conceive that the role of platelets in 
tumour cell metastasis is limited to the inhibition of NK cell effector function. The aims 
of the work described in this chapter, therefore, were to confirm the key role played by 
platelets in tumour cell metastasis, investigate the relationship between the pro-
metastatic activity of platelets and the anti-metastastic action of NK cells and determine 
the importance of both endothelial-derived and platelet-derived P-selectin in tumour 
cell metastasis. 
3.3 Results 
3.3.1 Establishing the optimum experimental metastasis assay and 
platelet depletion procedure 
The experimental metastasis assay took some time to establish, with the predominant 
problem being an unacceptable variation in the number of metastases between mice 
within the same experimental group. This is a significant problem experienced by 
many groups (personal communication. Professor Israel VIodavsky), however, it was 
possible to overcome when the following measures were taken: (i) the vial containing 
the tumour cell preparation was gently but thoroughly mixed with a pipette immediately 
prior to being drawn into a syringe and (ii) the volume of tumour cell suspension drawn 
up into a syringe each time was sufficient for one mouse only, not for several mice as 
is recommended (Elkin and VIodavsky 2001), this step alone dramatically decreasing 
the degree of variation in metastatic foci observed in recipient mice. 
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The optimum tumour cell number for the experimental metastasis assay was 
determined by injecting C57BL/6 mice with varying numbers of B16F1 melanoma cells 
i.v. via the tail vein (Figure 3.1). Two weeks later the mice were culled, the lungs 
removed and the number of lung metastases in each individual lobe ascertained under 
a dissecting microscope. In choosing the cell number to inject, consideration was 
given to the welfare of the mice, the tumour cell number that would reliably give 
sufficient tumours to obtain meaningful results, and to adhere as closely as possible to 
the 'true-to-life' conditions of metastasis by using as low a cell number as possible. A 
tumour cell number of 1 x 10^ tumour cells/mouse was initially chosen, however, in 
some experiments this cell number proved too low to produce sufficient numbers of 
metastases and hence the cell number was increased in subsequent experiments to 2 
X 10^ tumour cells/mouse. In experiments where NK cells were depleted, the tumour 
burden in mice was greatly enhanced and, therefore, the tumour cell number was 
reduced in these experiments to 1 x 10^ tumour cells/mouse. 
Following the establishment of the experimental metastasis assay in mice, the 1B5 
hamster monoclonal antibody specific for the mouse platelet glycoprotein, Gpllb-llla, 
was obtained as a means of determining the role of platelets in tumour cell metastasis 
(Lengweiler et al. 1999). Intravenous administration of 20 i^g of the 185 mAb per 
mouse resulted in the depletion of >95% of the platelet population (Figure 3.2A and B). 
The platelet depleting effect occurred within 5 min of mAb administration, lasted for 
approximately 40 hr and was followed by a thrombocytosis which at 120 hr resulted in 
an approximate 2-fold increase in platelet numbers above baseline levels (Figure 3.2C 
and D). The 1B5 antibody proved useful in tumour metastasis experiments as a means 
of depleting platelets rapidly and reliably at different stages of the metastatic process 
and, thereby, determining the role of platelets at different stages of the tumour 
metastatic process. 
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Figure 3.1 - Determining the optimum tumour cell number for use in 
experimental lung metastasis assays. C57BL/6 mice (n=5) were injected i.v. with 
various numbers of B16F1 melanoma cells then culled 14 days later and the lungs 
extracted and fixed in formalin. The number of tumours within each lung lobe was 
counted under a dissecting microscope. The results of 2 experiments using 1 x 1 0 ® 
cells/mouse are shown to demonstrate the reproducibility of the assay. The mean and 
SEM are presented. In subsequent experiments, tumour cell numbers of 1-2.0 x 10® 
cells/mouse were used. 
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Figure 3.2 - Rapid and transient depletion of platelets in vivo using a hamster mAb (1B5) 
specific for mouse platelet glycoprotein Gpllb/llla. Whole blood was collected from C57BL/6 
mice and analysed via flow cytometry (A) at baseline and (B) 2 hr following i.v. injection of 20 ^g of 
the 1B5 mAb. Platelet populations were identified based on their characteristic log forward- and side-
scatter parameters (red gated area) and platelet numbers were determined by the inclusion of a 
known concentration of reference beads in each sample, (C-D) C57BL/6 mice were injected with the 
1B5 mAb and platelet numbers monitored over a period of (C) 60 mins (n=1) and (D) 7 days (n=3). 
3.3.2 Platelets are required for the lung metastasis of B16F1 melanoma 
and 4T1.2 breast cancer cells 
In order to determine the role of platelets in the lung metastasis of B16F1 melanoma 
and 4T1.2 breast cancer cells, C57BL/6 and BALB/c mice were injected with 20 ^g of 
the 1B5 mAb or an isotype control 1-3 hr prior to the injection of 1 x 10® B16F1 
melanoma cells or 2 x 10® 4T1.2 cells, respectively. Fourteen days later the lungs 
were removed and tumour burden determined. When C57BL/6 mice were injected with 
the 1B5 mAb, which resulted in >95% reduction in platelet numbers, prior to B16F1 
melanoma cell administration, tumour metastases were undetectable compared to the 
control mice (Figure 3.3). Similarly, when BALB/c mice were injected with the 1B5 
mAb, which resulted in a similar reduction in platelet numbers (>95%), prior to the 
injection of the 4T1.2 cells, a highly significant reduction in lung metastases was seen 
in comparison to the control mice (i.e., metastases 6% level of control mice, p < 0.05) 
(Figure 3.3). 
To confirm that the antimetastatic effects observed were due to a lack of platelets 
rather than a non-specific effect of the depleting antibody, the metastasis experiments 
were repeated in two mouse strains genetically deficient in platelets. In the case of the 
B16F1 melanoma, tumour cells were injected into C57BL/6 c-mpl-l- mice (contain 
£15% normal platelet numbers) whereas the 4T1.2 tumour cells were injected into 
BALB/c Plt20 mutant mice (contain -30% normal platelet numbers). In the c-mpl-l-
mice a significant reduction in lung metastases was observed in comparison to their 
heterozygous {c-mpl+l-) littermates (i.e., metastases 17% level of control mice, p<0.05) 
(Figure 3.3). in contrast, with the Plt20 mutant mice, no significant change in tumour 
metastasis numbers was observed compared with the wild type BALB/c mice (Figure 
3.3). Collectively these data suggest that a substantial depletion in circulating platelets 
(&85%) is required for tumour lung metastasis to be inhibited. 
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Figure 3.3: Substantial platelet depletion is required to reduce the lung metastasis of 
B16F1 melanoma and 4T1.2 breast cancer cells in mice. Two approaches were used to 
determine the role of platelets in the haematogenous metastasis of B16F1 melanoma and 4T1.2 
breast cancer cell lines (1) C57BL/6 and BALB/c mice were depleted of platelets (>95%) using 
the Gpllb/llla mAb (1B5) 3 hr prior to i.v.injection, via the tail vein, of 1 x 10® B16F1 melanoma or 
2 X 10® 4T1.2 cells, respectively, (ii) C57BL/6 c-mpl-l- mice (-15% of normal platelet numbers) 
and their c-mpl+/- littermates (normal platelet numbers), and BALB/c Plt20 mutant mice (~30% 
normal platelet numbers) were injected i.v. with 1 x 10® B16 cells or 2 x 10® 4T1.2 cells, 
respectively. Lungs were removed 14 days following tumour cell injection and the number of 
metastases counted. Significant reductions in metastasis numbers relative to controls are shown 
as *ps0.05. 
3.3.3 Platelets are only required at a very early stage of B16F1 melanoma 
lung metastasis 
The kinetics of platelet involvement in B16F1 melanoma lung metastasis was 
determined by depleting platelets from mice using the 1B5 mAb to Gpllb-l l la at varying 
time points before and after injection of B16F1 melanoma cells (Figure 3.4). These 
experiments showed that the depletion of platelets 3 hr prior to the injection of B16F1 
tumour cells resulted in an almost total absence of lung metastases in all mice, 
whereas platelet depletion 1 hr, 3 hr and 24 hr following the injection of B16F1 
melanoma cells did not reduce the number of lung metastases in comparison to 
experimental controls (Figure 3.4). 
140 
120 
100 
CO V (0 
2 m 
2 V 
O) c 
3 
Control 1B5 mAb 
3 hr 
Ere-B16F1 
1B5 mAb 
1 hr 
post-B16F1 
1B5 mAb 
3hr 
post-B16F1 
1B5 mAb 
24 hr 
post-B16F1 
Figure 3.4: Platelets are only required at a very early stage of B16F1 
melanoma metastasis. C57BL/6 mice (n=4-5) were depleted of platelets 
using the 1B5 mAb to Gpllb/llla at 3 hr prior to- and 1 hr, 3 hr and 24 hr 
post-injection of 1 - 2 x 10^ B16F1 melanoma cells via the tail vein. The 
results were obtained from several experiments, each experiment including 
a control group. Lung metastases were determined as described in Figure 
3.2. 
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3.3.4 NK cells strongly Inhibit metastasis and mask the influence of 
platelets on liver and lung metastasis 
Experiments were undertaken to determine whether B16F1 melanoma metastasis is 
susceptible to NK cell control using two different experimental models. NOD/SCIDYC-/-
mice, which are genetically deficient in NK cells (and are also lymphocyte deficient), 
NOD/SCID controls (NK cell sufficient but lacking T and B cells) and antibody depletion 
of NK cells in C57BL/6 mice using a rabbit anti-asialo GM1 polyclonal antibody. 
Preliminary experiments showed that splenic NK cells were depleted by -80% 1 hr 
following injection of the anti-asialo GM1 pAb whereas NKT, T and B cell splenic 
numbers were not affected (Figure 3.5). A similar level of NK cell depletion (77%) was 
observed 48 hr following the injection of the anti-asialo GM1 pAb. 
C57BL/6 mice were depleted of NK cells by the i.v. injection of an anti-asialo GM1 pAb 
48 hr prior to the injection of 1 x 10® B16F1 melanoma cells. NOD/SCIDyc-/- and 
NOD/SCID mice were also injected with 1 x 10® B16F1 melanoma cells. Two weeks 
later the mice were dissected for collection of the lungs. It was noticed upon dissection 
that there was also a significant number of liver metastases that were not usually seen 
in NK cell sufficient mice and, therefore, the livers were also removed for assessment 
of tumour burden. C57BL/6 mice depleted of NK cells by the anti-asialo GM1 pAb were 
found to have a highly significant 33-fold increase in lung metastases (p<0.0005), and 
a significant 54-fold increase in liver metastases (p<0.05) compared to untreated 
control mice (Figure 3.6A). Similarly, NOD/SCIDyc-/- mice were found to have a much 
higher tumour burden in the liver (58-fold higher than controls, p<0.005) and the lungs 
(3-fold higher than controls, p<0.05) than the NOD/SCID controls (Figure 3.6A). It 
should be noted that based on a macroscopic examination, except for sporadic renal 
metastases, there was no evidence of tumour metastases in other organs of NK cell 
depleted C57BL/6 and NK cell deficient NOD/SCIDyc-/- mice. 
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Figure 3.5: Injection of an anti-asialo GIVI1 pAb selectively depletes the majority of 
splenic NK cells within 1 hr. C57BL/6 mice (n=3) were injected with 50 of an anti-asialo 
GM1 pAb i.v. then 1 hr later spleens were removed, cells extracted, stained with mAbs 
specific for CD45.2, NK1.1, CD3 and B220, and then analysed using flow cytometry. (A) 
Gating strategy used to detect the different viable leukocyte populations in spleens from 
untreated mice and (B) in spleens from mice treated with the anti-asialo GM1 pAb. (C) A 
comparison of splenic leukocyte populations 1 hr following treatment with the anti-asialo GM1 
pAb. Significant reduction in NK cells relative to controls is shown as ***ps0.0005. 
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Figure 3.6: The metastasis of B16F1 melanoma and 4T1.2 breast cancer cells is inhibited by 
NK cells. (A) Tumour metastases In C57BL/6 mice depleted of NK cells by l.v injection of an anti-
asialo GM1 pAb 48 hr prior to tumour cell injection and in NOD/SCIDyc-/- mice (n=5) genetically 
deficient in NK cells. Mice were injected with 1 x 10^ B16F1 melanoma cells i.v. via the tail vein. (B) 
Tumour metastases in BALB/c mice (n=5), depleted of NK cells by i.v injection of an anti-asialo 
GM1 pAb 48 hr prior to the injection of 2 x 10^ 4T1.2 breast cancer cells i.v. via the tail vein. 
Fourteen days after tumour cell injection the lungs and livers were collected from all mice and 
tumours counted. Significant changes in numbers of metastases relative to controls are shown as 
"psO.OS, **ps0.005, *"P£0.0005 and **"*psO.000005. 
To assess whether the metastasis of 4T1.2 tumour cells is also susceptible to NK cells, 
BALB/c mice were injected i.v. with the anti-asialo GM1 pAb to deplete NK cells 48 hr 
prior to the i.v. injection of 2 x 10® 4T1.2 cells. Two weeks later the lungs and livers 
were collected and assessed for tumour burden. The NK-cell depleted mice had a 
dramatically higher tumour burden in their lungs than the control mice (47-fold higher 
than controls, p<0.000005), however, liver metastases were not found in either group 
of mice (Figure 3.6B). 
The respective roles of platelets and NK cells in the metastatic process was then 
assessed by depleting C57BL/6 mice of NK cells 48 hr prior to B16F1 melanoma 
injection and/or platelets 24 hr prior to tumour cell injection. Two weeks later the 
number of metastases in the liver and lungs was determined. When compared with 
untreated control mice, mice depleted of platelets had no detectable lung metastases 
and liver metastases appeared but were sporadic and few in number (Figure 3.7). In 
contrast, in mice depleted of NK cells there was a dramatic increase in both lung (46 
fold, p<0.005) and liver (66±11 tumours versus 0 in controls) metastases (Figure 3.7). 
In mice depleted of both NK cells and platelets, there was a 48% decrease in lung 
metastases compared with mice depleted of NK celts alone (p<0.05), which was 
accompanied by a concomitant 42% increase in liver metastases (p<0.05) (Figure 3.7). 
Overall these studies imply that NK cells dramatically mask the metastatic potential of 
tumour cells and that platelets may assist lung but not liver metastasis. 
3.3.5 The anti-metastatic effect of NK-cells occurs later and independent 
of platelets 
In order to resolve the relationship between the pro-metastatic action of platelets and 
the anti-metastatic role of NK cells we investigated the kinetics of the anti-metastatic 
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Figure 3.7: Interplay between platelet and NK cell depletion on B16F1 melanoma lung and 
liver metastasis. C57BL/6 mice (n=5} were depleted of NK cells (anti-asialo GM1 pAb) 48 hr 
prior to and/or platelets (Gpllb-llla specific mAb 1B5) 1 day prior to l.v. injection of 1 x 10^ 
B16F1 melanoma cells. Fourteen days later the mice were culled and lungs and livers collected 
for determination of metastasis numbers. Significant changes in metastasis numbers are shown 
as *ps0.05. This experiment was also performed using 2 x 10^ B16F1 cells and identical 
metastasis trends were observed. 
effect of NK cells. Thus, C57BL/6 mice were depleted of NK cells 48 hr prior to, and 1 
hr or 24 hr following the i.v. injection of 2 x 10^ B16F1 melanoma cells. Two weeks 
later the liver and lungs were collected and metastases counted. When the NK cell-
depleting antibody was administered 48 hr before or 1 hr after tumour cell injection 
there was a comparable dramatic enhancement in lung and liver metastasis. In 
contrast, this enhancement in tumour metastasis did not occur if the NK cell depleting 
pAb was given 24 hr after the tumour cells (Figure 3.8A). These data imply that NK 
cells exert their action after tumour cells lodge in the vasculature of target organs. 
Since NK cell depletion is rapid (<1 hr. Figure 3.5), it appears that NK cells exert their 
anti-metastatic effect between 1 hr and 24 hr following tumour cell injection. 
To determine whether the kinetic profile of NK cell inhibition of tumour metastasis 
changes in the absence of platelets, the above experiment was repeated in mice that 
were additionally depleted of platelets 24 hr prior to i.v. injection of 1 x 10® B16F1 
melanoma cells (Figure 3.88). The outcome of this experiment was very similar to 
when platelets were present (Figure 3.8A), supporting the view that NK cells exert their 
anti-metastatic effect independent of platelets. 
3.3.6 Endothelial P-selectin plays a critical role in lung and liver 
metastasis 
Having demonstrated that the mechanism by which platelets promote metastasis was 
not through the inhibition of NK cell function, experiments were performed to determine 
the contribution of the adhesion protein P-selectin (P-sel), but more specifically the 
relative contributions of platelet-derived and endothelial-derived P-sel, to the metastatic 
process. 
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Figure 3.8: NK cell control of B16F1 lung and liver metastasis occurs between 1 and 24 
hr after tumour cell injection in a platelet independent manner. (A) Lung and liver 
metastasis in C57BL/6 mice (n=5), depleted of NK cells by i.v injection of an anti-asialo GM1 
pAb 48 hr pre- and 1 hr and 24 hr post-injection of 2 x 10^ B16F1 melanoma cells i.v. via the 
tail vein. (B) As above, however, all mice were depleted of platelets by the injection of an 
anti-Gpllb-llla mAb (1B5) 24 hr prior to the injection of 1 x 10^ 816 melanoma cells. 
Significant reductions in metastasis numbers relative to NK depletion 48 hr pre-B16F1 tumour 
cell injection are shown as *ps0.05, **ps0.005 and ***ps0.0005. 
The role of P-sel in the metastasis of B16F1 tumour cells to the lung was determined 
following the i.v. injection of C57BL/6 wild type mice and C57BL/6 P-sel-/- mice with 1 
or 2 X 10® B16F1 melanoma cells. Lung metastases in P-sel-/- mice were found to be 
63% lower than in control wild type mice (Figure 3.9A), a reduction that was highly 
significant (p<0.00005). 
As P-sel is expressed by both platelets and endothelial cells, P-sel bone marrow 
chimeras were generated in two separate transplant experiments. Congenic C57BL/6 
mice expressing the CD45.1 allotype of the leukocyte common antigen were used as 
bone marrow donors or recipients thus introducing an easily measured marker of donor 
marrow engraftment as C57BL/6 mice carry the CD45.2 allotype. In the first transplant 
experiment platelet P-sel positive (P+) endothelium P-sel negative (E-) mice were 
generated by transplanting P-sel-/- mice (CD45.2) with wild type C57BL/6 (CD45.1) 
marrow; P -E+ mice were generated by transplanting C57BL/6 (CD45.1) mice with P-
sel-/- marrow (CD45.2); and the control group (P+E+) consisted of wild type C57BL/6 
(CD45.2) mice transplanted with C57BL/6 (CD45.1) marrow (Table 3.1). A second 
transplant experiment was performed to demonstrate reproducibility of the initial results 
and to ensure that residual host P-sel+ platelets were as low in number as possible. 
Thus, the platelet-deficient c-mpl-l- strain (CD45.2) was transplanted with P-sel-/-
marrow (CD45.2), thereby generating P-E+ mice. A control group for these mice was 
generated using c-mpl-l- mice (CD45.2) as recipients of C57BL/6 (CD45.1) bone 
marrow. In this experiment, P+E- mice were generated by using P-sel-/- mice 
(CD45.2) as recipients of wild type C57BL/6 (CD45.1) bone marrow and the control 
group (P+E+) for these mice, as in the first experiment, consisted of wild type C57BL/6 
mice (CD45.2) transplanted with C57BL/6 (CD45.1) marrow (Table 3.2). 
Table 3.1 - Extent of Donor Marrow Engraftment and Platelet Numbers in 
P-selectin Bone Marrow Chimeras (Transplant Experiment 1) 
Group ® BM Recipient BM Donor % Leukocyte 
CD45.1 
Allotype'' 
Platelet 
Numbers/fiL'' 
(x10®) 
P+E+ C57BL/6 
(CD45.2) 
C57BL/6 
(CD45.1) 
82 ± 0.2 1.09 ±0.01 
P-E+ C57BL/6 
(CD45.1) 
P-Sel -/-
C57BL/6 
(CD45.2) 
20.6 ±0.4 1.18 ±0.03 
P+E- P-Sel -/-
C57BL/6 
(CD45.2) 
C57BL/6 
(CD45,1) 
80.1 ±0.7 1.06 ±0.01 
Table 3.2 - Extent of Donor Marrow Engraftment and Platelet Numbers in 
P-Selectin Bone Marrow Chimeras (Transplant Experiment 2) 
Group® BM Recipient BM Donor % Leukocyte 
CD45.1 
Allotype'' 
Platelet 
Numbers/nL'' 
(x10®) 
P+E+ C57BL/6 
(CD45,2) 
C57BL/6 
(CD45.1) 
83.3 ±0.4 1.37 ±0.03 
P+E- P-Sel -/-
C57BL/6 
{CD45,2) 
C57BL/6 
(CD45.1) 
78.6 ±0.5 1.28 ±0.03 
P+E+ c-mpi -/-
C57BL/6 
(CD45.2) 
C57BL/6 
(CD45.1) 
73.9 ± 0.7 1.22 ±0.02 
P-E+ c-mpI -/-
C57BL/6 
(CD45.2) 
P-Sel -/-
C57BL/6 
(CD45.2) 
<1.0±0.1 1.49 ± 0.04 
a 'P' = Platelets; 'E' = Endothelium;'+' = P-Sel positive; ' - ' = P-Sel negative 
b Extent of donor marrow engraftment was measured by determining tlie proportion of CD45.1 + 
vs CD45.2+ leukocytes in whole blood, with the leukocyte phenotype and platelet numbers/|.tL 
being measured in whole blood via flow cytometry 4 wk following irradiation and bone marrow 
transplantation. 
Platelet numbers and the extent of engraftment of donor bone marrow were 
determined in the P-sel chimeras 4 weeks following transplantation by measuring the 
C45.1+ versus CD45.2+ status of blood leukocytes by flow cytometry. Platelet 
numbers were also determined using flow cytometry and the results are presented in 
Tables 3.1 and 3.2. It was found that bone marrow engraftment, based on CD45 
allotypes, was -80%. 
The various bone marrow chimeras were injected i.v. with 2 x 1 0 ® B16F1 melanoma 
cells and the lungs removed 2 weeks later for metastasis enumeration. The data from 
the two separate bone marrow chimera metastasis experiments are presented in 
Figure 3.9B. The selective absence of P-selectin on platelets substantially (77% Expt 1 
and 78% Expt 2) and significantly (p<0.005 and p<0.05, respectively) reduced the 
number of lung metastases compared to control bone marrow chimeric mice. Similarly, 
the selective absence of endothelial P-selectin resulted in a comparable (69% Expt 1 
and 74% Expt 2) and significant (p<0.05 and p<0.005, respectively) reduction in the 
ability of B16F1 tumour cells to metastasise to the lungs (Figure 3.9B). 
Collectively these data indicate that both platelet and endothelial P-selectin are 
required for the lung metastasis of B16F1 melanoma cells. 
The P-selectin knockout and bone marrow chimera experiments described above 
provided data on the role of platelet and endothelial P-selectin in B16F1 melanoma 
lung metastasis but in these experiments liver metastases were undetectable. In order 
to ascertain the role of P-selectin in B16F1 melanoma metastasis to the liver, C57BL/6 
wild-type and P-selectin-/- mice were depleted of NK cells, thus providing conditions 
that increased the number of detectable liver metastases, and injected 48 hr later with 
2x10® B16F1 melanoma cells. Two weeks later the lungs and livers were removed 
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Figure 3.9: P-selectin on both platelets and endothelium is involved in the lung metastasis of 
B16F1 melanoma cells. (A) WT C57BL/6 (n=24) and P-selectin-/- (n=22) mice were injected i.v. with 
1x10® B16F1 melanoma cells. Fourteen days later the lungs were removed and tumours counted. 
Data pooled from 2 experiments. (B) P-selectin bone marrow chimeras (n=5/group) were generated 
where the platelets (P-E+) or endothelium (P+E-) were P-selectin deficient. For more details see 
Tables 3.1 and 3.2. Following donor marrow engraftment, mice were injected i.v. with 2 x 10® B16F1 
melanoma cells. Fourteen days later the lungs were removed and tumours counted. Panel B 
represents data from two separate transplantation and metastasis experiments. Significant reductions 
in metastasis numbers relative to WT (P+E+) controls are shown as *p£0.05, **ps0.005 and 
****ps0.00005. 
and tumours counted. As seen in previous experiments with NK cell sufficient mice 
(Figure 3.9A), the number of lung metastases in the NK cell depleted P-sel-/- mice was 
reduced by 49% compared with NK cell depleted WT controls (p<0.005). The number 
of liver metastases in the NK cell depleted P-sel-/- mice was also found to be 
substantially (37%) and significantly reduced (p<0.05) (Figure 3.1 OA). 
Previous data in this chapter suggests that platelets are probably not required for 
B16F1 liver metastasis (Fig. 3.7), implying that platelet P-sel does not play a role in 
liver metastasis. The question remained as to whether endothelial P-sel was required 
for liver metastasis and, in order to examine this possibility, C57BL/6 wild type and P-
sel-/- mice were depleted of NK cells and platelets 48 hr and 2 hr, respectively, prior to 
the injection of 1 x 10® B16F1 melanoma cells. Fourteen days later the lungs and livers 
were removed and tumours counted. The platelet-depleted P-sel-/- mice were found 
to have significantly fewer liver (52%, p<0.05) and lung (65%, p<0.05) metastases than 
their platelet-depleted wild type controls (Figure 3.108), supporting the conclusion that 
endothelial P-selectin is just as important for B16F1 melanoma liver metastasis as lung 
metastasis. 
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Figure 3.10: Endothelial P-selectin is involved in B16F1 melanoma metastasis to both 
the liver and lung. (A) WT C57BL/6 and P-selectin-/- mice were depleted of NK cells by 
injection of an anti-asialo GM1 pAb 48 hr prior to injection of 2 x 10^ B16F1 melanoma cells. 
Fourteen days later the lungs and livers were removed and tumours counted. (B) As in (A), 
however mice were additionally depleted of platelets by the injection of an anti-Gpllb/llla mAb 
(1B5) 2 hr prior to injection of 1 x 10^ B16F1 melanoma cells. Significant reductions in 
metastasis numbers relative to controls are shown as *ps0.05 and **ps0.005. 
3.4 Discussion 
The key findings of the work described in this chapter are that (i) platelets promote 
B16F1 melanoma and 4T1.2 breast cancer lung metastasis, (ii) the pro-metastatic 
effect of platelets is brief, lasting for only up to 1 hour following tumour cell entry into 
the circulation, (iii) the anti-metastatic action of NK cells occurs after the pro-metastatic 
actions of platelets and is not inhibited by platelets, (iv) platelets do not appear to be 
necessary for B16F1 melanoma liver metastasis, unlike B16F1 melanoma lung 
metastasis and (v) endothelial P-seiectin plays an important role in both B16F1 
melanoma lung and liver metastasis. 
Studies on the kinetics of the prometastatic effect of platelets demonstrated that the 
time frame during which platelets are required for metastasis is very short in duration 
and early in the metastatic process. Essentially, platelets only play a role in the first 
hour following entry of tumour cells into the bloodstream. Beyond that, their assistance 
is not required for successful metastasis (Figure 3.4). These results support the 
broadly accepted model of the role of platelets in metastasis, namely, that platelets 
mediate the initial interaction of tumour cells with the blood vessel wall via platelet 
adhesion proteins binding to their endothelial ligands (Erpenbeck and Schon 2010). 
The susceptibility of B16F1 melanoma and 4T1.2 breast carcinoma metastasis to NK 
cell inhibition was dramatically demonstrated using either the NOD/SCID7C-/- mouse 
strain, which is genetically deficient in NK cells, or mice depleted of NK cells using an 
anti-asialo GM1 pAb (Figure 3.6). It was found that in both these models, depletion of 
NK cells resulted in a very substantial increase in lung metastases (3-33 fold). 
Interestingly, liver metastases were not usually seen in the B16F1 experimental lung 
metastasis model, however, in the absence of NK cells the number of liver metastases 
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was dramatically increased. The appearance of B16F1 tumour metastases in the liver 
of NK depleted mice, indicates that a significant proportion of B16F1 melanoma cells 
pass through the lung capillary beds to the left cardiac ventricle from where they are 
dispersed to multiple organs including the liver. In NK cell sufficient mice, these tumour 
cells are efficiently eliminated from the liver, however, in NK cell deficient mice the 
extent of tumour cell infiltration into hepatic tissue is revealed. Metastases were 
occasionally seen in the kidney in NK cell depleted mice, however, cerebral 
metastases could not be detected, nor was there any evidence of altered neurological 
function in any of the mice injected with B16F1 or 4T1.2 tumour cells (data not shown). 
Unlike B16F1 melanoma, liver metastases were not seen with 4T1.2 tumour cells in NK 
cell depleted mice. This observation may indicate that the 4T1.2 tumour cells are 
incapable of extravasating into, or surviving within, the hepatic environment. In support 
of this conclusion, a previous study of the metastatic tendency of this cell line following 
mammary gland injection, showed a predilection for the lungs, bone and lymph nodes 
with no liver metastases being found (Leiekakis et al. 1999). 
The pro-metastatic effects of platelets and the anti-metastatic effects of NK cells were 
probed for evidence of an interrelationship by depleting mice of platelets, NK cells or 
both prior to the injection of B16F1 melanoma cells (Figure 3.7). The key finding of this 
experiment was that in mice depleted of both platelets and NK cells, there was a 48% 
reduction in the number of lung metastases compared to mice depleted of NK cells 
only. This result indicates firstly, that platelets promote B16F1 melanoma metastasis in 
the absence of NK cells and, secondly, that a substantial number of tumour cells were 
capable of extravasating in the absence of platelets, a result that was revealed only 
when NK cells were depleted, and may be due to the involvement of endothelial 
adhesion molecules or physical entrapment within small vessels. Furthermore, in the 
absence of platelets and NK cells, a concomitant 42% increase in liver metastases was 
observed, most likely due to a greater number of tumour cells passing through the 
lungs due to a reduced ability to bind to the blood vessel wall. To further demonstrate 
the independence of the pro-metastastic role of platelets from the anti-metastatic role 
of NK cells, the kinetics of the NK cell effect on metastasis was studied in the presence 
and absence of platelets (Figure 3.8). Mice were depleted of NK cells 48 hr prior to-
and 1 hr or 24 hr post-B16F1 melanoma cell injection. The experiment was repeated 
in mice that were additionally depleted of platelets 24 hr prior to B16F1 cell injection. 
The results of these two experiments were essentially the same in that the anti-
metastatic effect of NK cells was seen to occur between 1 and 24 hr following tumour 
cell injection, whether or not mice were injected with the platelet depleting mAb (Figure 
3.8). Collectively, these results unequivocally demonstrate that, in the B16F1 
experimental metastasis model, platelets promote lung metastasis by a mechanism 
that is independent of NK cells. Furthermore, the roles of platelets and NK cells in the 
metastatic process were demonstrated to be chronologically distinct, with platelets 
acting to promote metastasis within the first hour of tumour cell entry into the 
bloodstream and NK cells exerting their anti-metastatic effects between 1 and 24 hr 
after tumour cell injection. Additionally, these experiments suggest that platelets play 
little or no role in B16F1 melanoma liver metastasis. 
Some of these findings contrast with those of Nieswandt et al and Palumbo et al, both 
of whom examined lung metastasis in platelet-, NK cell- or platelet and NK cell-
deficient mice (Nieswandt et al. 1999; Palumbo et al. 2005). Nieswandt et al studied 
the lung metastasis of CFS1/LacZ tumour cells and B16F10 melanoma cells in mice 
depleted of NK cells 1 week prior to the injection of tumour cells using the TM-|31 mAb 
to the interleukin 2 receptor |3 chain expressed constitutively by NK cells and activated 
T cells (Caligiuri et al. 1990), To deplete platelets, mice were injected with a polyclonal 
rabbit anti-mouse platelet serum 24 hr prior to tumour cell injection. In the absence of 
NK cells the number of lung metastases of the CFSI/LacZ fibrosarcoma increased 
approximately 18-fold and B16F10 melanoma approximately 2-fold. In contrast, in our 
experiments with B16F1 melanoma, a 47-fold increase in lung metastasis was 
observed in NK cell depleted mice compared to control mice implying that the B16F10 
melanoma cell line is not as susceptible to NK cell killing as the B16F1 melanoma cell 
line. Similar to our studies, Nieswandt et al noted the appearance of significant 
numbers of liver metastases in NK cell depleted mice injected with B16F10 melanoma 
cells, although these were not quantified. Consistent with our studies of B16F1 
melanoma and 4T1.2 breast cancer lung metastasis, in the absence of platelets, lung 
metastasis of both CFS1 and B16F10 cells was virtually eliminated. In contrast to our 
findings, when mice were depleted of both platelets and NK cells, Nieswandt et al 
concluded that the prevalence of lung metastases was not significantly different to that 
seen in mice depleted of NK cells only. When examining their data for B16F10 
melanoma, however, there was a reduction of ~25% in the mean number of lung 
metastases in the mice depleted of platelets and NK cells compared to mice depleted 
of NK cells alone, although the standard deviation in the number of metastases seen in 
the NK cell depleted mice was considerable which prevented this result from reaching 
statistical significance. 
In a related study Palumbo et al depleted NK cells using an anti-asialo GM1 serum 
and, also, used the Gaq mutant mouse strain to study the role of platelets in tumour 
metastasis. The Gaq protein is involved in the activation of phospholipase C and 
increases in Ca2+ and protein kinase C activity in most cells. As Gaq is required for 
platelet activation this mouse strain has normal platelet numbers, however, thrombus 
formation is severely compromised (Offermanns et al. 1997; Palumbo et al. 2005). The 
ability of Lews lung carcinoma (LLC) cells and B16-BL6 melanoma cells to metastasise 
to the lung was virtually eliminated in Gaq-/- mice compared to controls and, through 
bone marrow transplantation, this effect on metastasis was demonstrated to be due to 
bone-marrow derived cells. The authors attribute the pro-metastatic effect of Gaq to 
platelets but concede that the contribution of leukocytes to the metastatic process was 
not determined. Using quantitative analysis of residual nuclear radiolabelled LLC cells, 
the metastasis promoting effect of Gaq was shown to occur between 5 and 24 hr 
following intravenous injection of tumour cells. This result is, therefore, substantially 
different to our finding, i.e., that platelets act to promote metastasis within 1 hr following 
tumour cell entry into the bloodstream. A significant difference between the 
experimental models used by ourselves and Palumbo et al. was that platelets were 
absent in our model whereas platelets were present but had a signalling defect 
preventing their activation in the experiments conducted by Palumbo et al. The 
measurement of residual tissue radioactivity was also used to demonstrate that 24 hr 
following tumour cell injection Gaq-/- mice depleted of NK cells did not show a 
decrease in LLC lung metastases when compared to wild-type mice depleted of NK 
cells. The validity of results obtained using radionuclear labelled tumour cells are, 
however, questionable as the radioactivity measured does not give an indication of the 
number of cells going on to form tumours nor the reutilisation of radioactivity by 
neighbouring cells. Furthermore, Chambers et al have conducted several in vivo 
microscopy studies examining the process of lung and liver metastasis using both 
nuclear- and cytoplasmic-labelling of tumour cells and have found that, in comparison 
to cytoplasmic labelling, radioactive nuclear labelling rendered tumour cells more 
vulnerable to destruction in vivo. They found a significant decline in the number of 
nuclear-labelled tumour cells over the first 24 hr following i.v. injection of the tumour 
cells. When using cytoplasmic labelling, however, greater than 80% of injected tumour 
cells were demonstrated to successfully extravasate (Chambers et al. 2001). 
Our studies into the kinetics of B16F1 lung metastasis indicate that the pro-metastatic 
effect of platelets occurs <1 hr after tumour cell injection (Figure 3.4) whereas the anti-
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metastatic effects of NK cells occurs >1 hr after tumour cell entry into the bloodstream 
(Figure 3.8). In vivo microscopy studies of tumour cell extravasation, conducted by 
Crissman et ai, have revealed that in less than 1 minute following injection, tumour 
cells contact endothelial cells of the lung capillary bed, with blood vessel size 
restrictions influencing the initial lodgement. This lodgement was, however, temporary 
and those tumour cells unable to initiate an interaction with the endothelium passed 
through the capillary bed. Also, within 2 min following tumour cell injection, platelets 
were seen to associate with the tumour cells with the formation of thrombi in which 
cellular extensions of tumour cells were noted. The thrombus remained until tumour 
cells established contact with the subendothelial matrix. At 4 hr following tumour cell 
injection, endothelial cell separation was observed, with cytoplasmic extensions of the 
tumour cells reaching the subendothelial matrix (Crissman et al. 1988). Chambers et 
at. demonstrated in their in vivo microscopy studies of the metastatic process of 
several tumour cell lines, that the greatest inefficiency in metastasis was seen to occur 
following extravasation (Chambers et al. 2001). The studies of B16F1 melanoma lung 
and liver metastasis presented in this chapter demonstrated that NK cells accounted 
for an -98% reduction in the number of metastases, which occurred between 1- and 24 
hr following tumour cell injection and was unchanged in the absence of platelets. Our 
results demonstrate, therefore, that the anti-metastatic effect of NK cells is not due to 
platelets either shielding tumour cells from NK cell attack or mediating molecular 
inhibition of NK cell effector function and, taken with the findings of Crissman et al and 
Chambers et al, would suggest that NK cells destroy tumour cells following their 
adhesion to the vasculature. It is possible that the interaction between tumour cells and 
the blood vessel wall activates the endothelium with the subsequent release of 
cytokines, such as TNF-a, that recruit NK cells. Such a sequence of biological events 
may account for the 1-hour delay observed before the onset of NK cell destruction of 
tumour cells. 
Having demonstrated the NK cell independent role of platelets in tumour cell 
metastasis, the adhesion protein P-selectin, found in platelets and the endothelium, 
was investigated in the B16F1 melanoma experimental metastasis model using P-sel-/-
mice. Consistent with previous research (Kim et at. 1998), the absence of P-selectin 
was found to significantly diminish lung metastasis. To determine the relative 
contributions to the metastatic process of platelet-derived and endothelial-derived P-
selectin, the experimental B16F1 melanoma lung metastasis assay was performed in 
P-selectin deficient chimeric mice generated through bone marrow transplantation. 
These experiments revealed that both endothelial-derived and platelet-derived P-
selectin contribute to the metastatic process to a similar extent. 
To determine the role of P-selectin in B16F1 melanoma extravasation in the liver, wild 
type and P-selectin-/- mice were depleted of NK cells prior to the injection of B16F1 
tumour cells into the tail vein, thereby preventing NK-cell mediated destruction of 
tumour cells. As seen previously, lung metastasis was significantly reduced in the 
absence of P-selectin, however, a significant reduction was also seen in liver 
metastases. As other experiments described in this chapter demonstrated that 
platelets were not required for B16F1 melanoma metastasis to the liver (Figure 3.7), 
endothelial-derived P-selectin was considered the predominant contributor to this 
process. To confirm this, the experiment was repeated but all mice were additionally 
depleted of platelets thus eliminating platelet-derived P-selectin. Under these 
circumstances endothelial P-selectin was indeed found to have a significant role in 
promoting metastasis to the liver and, consistent with the results obtained with the 
bone marrow chimeras, endothelial P-selectin was also found to promote B16F1 
melanoma lung metastasis. 
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Resting platelets do not express P-selectin on their surface. The initial interactions 
between circulating tumour cells and platelets via P-seiectin are reliant, therefore, upon 
prior platelet activation. Many tumour cell types are able to generate the protein 
thrombin, a potent pro-coagulant and activator of platelets, and thence have the 
capacity to recruit platelets via P-selectin:mucin interactions (VanDeWater et al. 1985; 
Rickles et al. 2003). Tumour celhplatelet interactions may also occur via other 
protein:ligand pairs in the process of haematogenous metastasis. Podoplanin is a 
sialomucin-like glycoprotein that has been identified on several tumour cells and 
interacts with the receptor CLEC-2 on platelets to induce their activation and promote 
experimental tumour metastasis (Suzuki-lnoue 2011). Additionally, the integrins 
Gpllb/llla on platelets and aV|33 on tumour cells have both been shown to participate in 
platelet:tumour interactions and to promote tumour metastasis in experimental animal 
models (Felding-Habermann et al. 1996; Trikha et al. 2002). 
The endothelium of the liver and lungs constitutively express P-selectin and at levels 
higher than all other organs (Eppihimer et al. 1996; Singh et al. 1999), possibly to 
promote leukocyte migration and sun/eillance as these organs are exposed to high 
levels of pathogens, either inhaled or ingested. It is not surprising that the liver and 
lungs are susceptible to invasion by metastasising tumour cells given their locations 
within the circulatory system, the constitutive expression of P-selectin, and the fact that 
many tumour cells express mucins containing sialyl Lewis" and sialyl Lewis® that bind 
P-selectin (Kim et al. 1999). When relating the findings herein to those of Crissman et 
al obtained with in vivo videomicroscopy, it is possible that endothelial P-selectin plays 
a role in the initial temporary contact between tumour cells and the endothelium. This 
initial interaction would then be significantly strengthened by proteins on activated 
platelets, such as P-selectin, CLEC-2 and Gpllb-llla, and proteins of the coagulation 
cascade, such as fibrin. In the absence of platelets, however, the interaction between 
tumour cells and the endothelium within the lung capillary bed would appear insufficient 
to support extravasation by a significant proportion of cells as is evident from the 
substantially reduced lung metastases occurring in platelet-depleted mice. In the liver, 
however, where the velocity of blood flow is comparatively slow, the interaction 
between endothelial adhesion proteins and tumour-cell ligands would appear sufficient 
to arrest tumour cells enabling their subsequent extravasation, with platelets not being 
required to aid endothelial adhesion. Numerous adhesion proteins expressed on 
tumour cells and by the endothelium have the potential to assist in the arrest of tumour 
cells and are detailed in Table 1.3. 
Whilst the results of our experiments demonstrated that platelets are not required for 
B16F1 melanoma metastasis to the liver, it is possible that platelets play a minor role, 
which is difficult to quantify as platelet depletion appears to result in fewer tumour cells 
lodging in the lung vasculature and consequently more tumour cell entering the liver. 
To overcome this problem would require bypassing the lung capillary bed by injecting 
tumour cells directly into the left cardiac ventricle, hepatic artery or spleen in the 
presence and absence of platelets. The problem with this approach, however, is 
controlling post-injection internal haemorrhage in platelet-depleted mice. 
In summary, the results of this work have demonstrated that the lung metastasis of 
both B16F1 melanoma cells and 4T1.2 breast cancer cells is promoted by platelets and 
inhibited by NK cells. Moreover, in the B16F1 metastasis model, the prometastatic role 
of platelets and the antimetastatic role of NK cells were shown to be chronologically 
distinct, and that platelets promote lung metastasis by a process that is independent of 
NK cells. Intriguingly, unlike B16F1 melanoma lung metastasis, B16F1 liver metastasis 
appeared not to be reliant upon platelets. The pro-metastatic roles of both platelet-
derived and endothelial-derived P-selectin in lung metastasis, and endothelial-derived 
P-selectin in liver metastasis, was demonstrated. P-selectin may, therefore, represent 
a key target for therapies aimed at preventing metastasis in multiple organs. 
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Chapter 4 
The fate of antibody-coated platelets: Can self-
recognition systems be manipulated 
to treat ITP? 
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4.1 Abstract 
Immune thrombocytopenic purpura (ITP) is a condition affecting all age groups and is 
characterised, in the majority of cases, by the binding of auto-antibodies to platelet 
surface proteins targeting them for elimination. The resulting low platelet numbers 
renders the individual susceptible to life-threatening haemorrhage. The following 
chapter describes the results of investigations into the various mechanisms of 
antibody-mediated platelet depletion in a mouse model of ITP and the paradox of why 
some anti-platelet antibodies do not induce ITP. Furthermore, the role of self-
recognition inhibitory proteins on phagocytes in ITP development was investigated for 
potential treatment avenues. The results of this work have demonstrated that ITP 
induction was dependent upon the platelet protein targeted by the antibody and the 
antibody isotype, it was not determined by the density of mAb binding or the level of 
antigen saturation. Additionally, the mechanism of platelet elimination occurred 
principally via FcyR-mediated phagocytosis but was also shown to occur through 
complement-mediated destruction or through an FcyR- and complement-independent 
process of platelet fragmentation. An exploration into the role of the self-recognition 
protein pair CD47:SIRPa in this model of ITP revealed that some antibodies that were 
incapable of inducing ITP in WT mice were capable of inducing ITP in CD47-deficient 
mice. Furthermore, administration of an activating mAb specific for SIRPa in vivo not 
only prevented, but reversed rat lgG1 mAb-induced, FcvR-mediated ITP. This 
treatment effect was isotype specific, however, as SIRPa mAb treatment was unable to 
prevent ITP induced by rat lgG2b mAbs suggesting that SIRPa inhibits low-affinity 
rather than high-affinity FcyRs. The results of these studies give a greater 
understanding of the pathogenic pathways of ITP and how self-recognition systems 
may be manipulated to prevent antibody-mediated ITP. 
4.2 Introduction 
As detailed in Chapter 3, administration to mice of the hamster mAb, 1B5, specific for 
murine Gpllb-llla results in >95% depletion of platelets for a 36 hr period (Figure 3.2). 
Upon reviewing the literature on the mechanisms of antibody-coated platelet clearance, 
we found several significant findings that had not been followed up or interconnected 
and believed a contribution could be made to this field of research. The initial intention 
was to determine whether antibodies to platelet adhesion proteins could be used as 
therapeutic agents to prevent not only tumour cell metastasis, but also leukocyte 
migration in inflammation-mediated pathologies, such as asthma or reperfusion injury. 
This interest soon expanded to include potential therapeutic options for individuals with 
ITP. 
In certain medical conditions and during pregnancy, platelets may be erroneously 
targeted by the immune system for destruction. When platelets are destroyed at a rate 
greater than that of production, affected individuals are left with low platelet numbers, a 
state known as thrombocytopenia, with the antibody-mediated form of this disorder 
being known as immune thrombocytopenic purpura (ITP). Individuals with severe ITP 
may experience extensive bruising, nose-bleeds, bleeding into the gums and oral 
mucosa and/or a purpuric (purple) rash due to microscopic bleeding into the skin. 
They are also at significant risk of a life-threatening internal haemorrhage. 
ITP is considered a primary medical disorder when the diagnostic process has 
excluded any coexisting causative pathologies known to be associated with 
thrombocytopenia (e.g., human immunodeficiency virus or hepatitis C infection, 
systemic lupus erythematosis, hypothyroidism, lymphoma, leukaemia, anti-
phospholipid syndrome and inherited disorders causing thrombocytopenia) or therapy-
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related explanations for low platelet numbers (i.e., recent treatment with drugs such as 
quinidine, heparin, abciximab and many more) (Kereiakes et al. 1996; Cines and 
Blanchette 2002; Nurden et al. 2004). The incidence of ITP is estimated to be 1 new 
case per 10,000 individuals per annum and may occur at any age, although 50% of 
cases present in childhood. The disease course differs significantly between paediatric 
and adult cases. In children the majority of cases are of rapid onset, often there is a 
history of recent viral infection or immunisation, the disease course lasts from 3-12 
months and usually resolves spontaneously. In adults, however, the condition has a 
slower onset, bleeding tends to be more severe and the disease course is more likely 
to be chronic, essentially life-long (Cines and Blanchette 2002; Cines and Blanchette 
2006; Cooper and Bussel 2006; Provan et al. 2009). 
Antibodies were demonstrated to be the pathological agent in the majority of ITP cases 
when transfusion of the plasma or IgG-rich fractions of plasma from patients with ITP 
into healthy individuals induced thrombocytopenia (Harrington et al. 1951; Shulman et 
al. 1965). The most commonly targeted platelet proteins for autoantibodies found in the 
serum of patients with ITP are Gpllb/llla, Gplb/IX, Gpla/lla, GpV and GpIV, and it is not 
unusual for patients to have antibodies specific for several platelet proteins present in 
their serum (Cines and Blanchette 2002). The pathophysiology of ITP has until recently 
been considered to be due to the accelerated clearance of auto-antibody coated 
platelets by Fcy-receptors on macrophages. However, more recently it has been shown 
in some individuals that the autoantibodies produced also induce apoptosis of 
megakaryocytes within the bone marrow, hence platelet production is reduced 
alongside accelerated platelet destruction (Chang et al. 2003; HouwerzijI et al. 2004; 
McMillan et al. 2004; HouwerzijI et al. 2006). 
Treatment strategies differ between adults and children and also depend upon the 
severity of platelet depletion. The majority of paediatric cases are not treated unless 
platelet numbers are very low due to the likelihood of spontaneous resolution and the 
significant side-effects of therapy. For the duration of the thrombocytopenia, however, 
children must modify their behaviour to reduce the risk of injury and possible 
haemorrhage. In adult and paediatric cases with active bleeding, corticosteroid therapy 
is often given as an immunosuppressant. Corticosteroids also reduce bleeding through 
a direct effect on blood vessels. Pooled donor intravenous immunoglobulin (iVIg) is 
given as it appears to have several therapeutic actions including FcR blockade, 
neutralisation of autoantibodies, and engagement of the inhibitory FC7R, FcyRIIB, on 
macrophages (Samuelsson et al. 2001; Crow et al. 2006). More recently, agonists of 
the thrombopoietin receptor have been approved for use to boost platelet production by 
the bone marrow (Nurden et al. 2009). If the disease is refractory to these first-line 
treatment approaches, there are numerous second-line options including alternative 
immunosuppressive agents or splenectomy (Cines and Blanchette 2002; Chong 2009; 
Provan et al. 2009). 
It is not uncommon for treatment failures to occur, perhaps reflecting the heterogeneity 
of ITP pathophysiology, and the side-effects of current treatment strategies carry 
significant risks and cause considerable morbidity (Cooper and Bussel 2006). It would 
stand to reason, therefore, that a comprehensive understanding of all possible 
mechanisms of immune-mediated platelet destruction is required before treatments 
can be administered with a reasonable expectation of success. 
Previous studies in mice demonstrated that the antigen targeted by the antibody 
determines the mechanism of platelet depletion (Nieswandt et al. 2000). This group 
found that antibodies to Gpllb-llla caused FcyR-mediated clearance of platelets whilst 
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antibodies to Gplba induced an FcyR-independent mechanism of depletion. Equally 
intriguing were the findings that antibodies to GplX, GpV and CD31 did not cause 
significant platelet depletion (Nieswandt et al. 2000; Poujol et al. 2003), Additional 
studies from the same laboratory and their collaborators demonstrated that the 
administration of IVIg did not prevent platelet depletion following the administration of 
Gplba-specific mAbs whereas it did prevent depletion following administration of Gpllb-
llla-specific mAbs (Webster et al. 2006), thus confirming the FcR-independent 
mechanism of platelet depletion induced by the Gplba-specific mAb. 
Equally intriguing were the findings of accelerated platelet clearance in mice deficient 
of the immune effector cell inhibitory protein, SIRPa, or the widely expressed SIRPa 
ligand, CD47. (Yamao et al. 2002; Olsson et al. 2005). In an in vitro phagocytosis 
assay, Olsson et al. also demonstrated enhanced phagocytosis of IgG opsonised 
CD47 deficient platelets compared to WT platelets. Furthermore, the addition of a 
SIRPa-specific mAb increased the rate of WT platelet clearance to match that of CD47 
deficient platelets. Unfortunately, the anti-platelet mAb (6A6) used in these studies is of 
unknown antigen specificity (Olsson et al. 2005). 
When investigating the use of mAbs to deplete platelets for tumour metastasis studies 
(Chapter 3), we became aware of the intriguing findings of Nieswandt et al and Olsson 
et al., particularly the inability of mAbs specific for certain platelet surface proteins to 
induce ITP. These findings prompted us to hypothesise that mAbs to platelet antigens 
that caused platelet depletion may be interfering with the interaction between CD47 
and SIRPa and, if so, the system may be manipulated to prevent platelet depletion 
following antibody binding in ITP or when anti-platelet antibodies are administered as a 
therapeutic agent. 
The aims of the work presented in this Chapter, therefore, were to: 
(i) Investigate the different mechanisms of platelet depletion using rat IgGI and lgG2b 
mAbs specific for a variety of murine platelet surface proteins. 
(ii) Explore the potential regulatory pathways that determine why some anti-platelet 
antibodies do not cause platelet depletion. 
(iii) Establish whether these regulatory systems can be manipulated to prevent 
antibody-mediated platelet depletion (ITP). 
4.3 RESULTS 
4.3.1 Induction and severity of ITP is platelet antigen and IgG subclass-
dependent and is unrelated to the level of antibody binding 
Initially a range of rat IgGI mAbs specific for the murine platelet surface proteins 
Gplba, Gpllb-llla, Gpla, GpV, GplX and PECAM-1 were examined for their ability to 
induce ITP in C57BL/6 mice (Figure 4.1A, Table 4.1). Three different effects on platelet 
numbers were observed over a 24 hr period following mAb administration. First, a rapid 
depletion (within 2 hr of injection) of >50% of platelets was seen with the IgGI mAbs 
specific for Gplba and Gpllb-llla. Second, a slow but significant depletion in platelet 
numbers was seen with the Gpla-specific mAb and, to a lesser extent, the GpV-specific 
mAb. Third, little or no depletion of platelets was observed with the IgGI mAbs specific 
for GplX and PECAM-1 (Figure 4.1A, Table 4.1). BALB/c mice were also injected with 
the rat IgGI antibodies specific for Gplba, Gpllb-llla, Gpla, GpV and PECAM-1 (Table 
4.1). The platelet depletion induced by the Gplba- and Gpllb-llla-specific IgGI mAbs 
was very similar to that seen in C57BL/6 mice, indicating the effects were not strain 
specific. However, a greater level of platelet depletion was observed in BALB/c mice 
with the mAbs specific for Gpla and GpV, with the PECAM-1-specific mAb also 
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Figure 4.1 - Monoclonal antibodies against Gplba, Gpllb-llla, Gpla and possibly 
GpV, but not GplX or PECAM-1, can induce ITP in C57BL/6 mice. Data shown for (A) 
rat IgGI and (B) rat lgG2a and lgG2b mAbs against mouse platelet surface molecules. 
Baseline platelet numbers were assessed in C57BL/6 mice (n=3) prior to i.v. injection of 
20 ng of each mAb specific for a platelet surface molecule. Platelet numbers were 
assessed at 2 hr (blue) and 24 hr (red) post mAb injection. Bars represent SEM. 
Significant reductions in platelet numbers relative to baseline in mAb treated mice are 
shown as *ps0.05, ** psO.005. When another mAb was combined with the Gpllb-llla 
mAb, comparison made to % reduction with the mAb specific for Gpllb-llla alone. 
Table 4.1: The Level of Platelet Depletion Occurring In Wild-type and FcyR-/- Mice 
Following Injection of mAbs Specific for Different Platelet Proteins 
Antibody Target Antibody 
Isotype 
Platelet numbers (% baseline) ® 
C57BL/6 mice Wild-type mice'' FcyR -/- mice'' 
Gplba igGi 12.3 ± 0.9 (p< 0.005; ND" 
Gplba lgG2b 25.2 ± 5.4 (p < 0.05) 20.9 ± 1.5 (p = ns) 
Gpllb-llla lgGl 35.3 ± 3.8 (p < 0.005) ND 
Gpllb-llla lgG2b 7.8 ± 4.2 (p< 0.005; 78.4 ± 5.7 (p < 0.005) 
Gpla IgGi 25.6 ±7.1 {p<0.05) ND " 
Gpla lgG2a 3.5 ± 0.6 (p< 0.005; 62.4 ±4.1 {p< 0.005) 
GpV IgGi 72.1 ±2. 9 (p< 0.05; ND 
GpV lgG2b 94.0 ± 7.2 (p = ns) ND 
GplX IgGi 86.9 ± 6.8 (p = ns) ND 
PECAM-1 (CD31) IgGi 96.5 ± 2.7 (p = ns) ND 
BALB/c mice Wild-type mice FcyR-/- mice 
Gplba IgGi 12.0 ±2.1 {p< 0.005) 23.8 ± 2.9 (p < 0.05; 
Gpllb-llla igGi 29.3 ± 3.2 (p < 0.0005) 104.5 ± 4.3 (p< 0,005; 
Gpla IgGi 9.0 ± 1.0 (p< 0.0005; 87.5% ±9.6 {p<0.05) 
GpV IgGi 39.5 ± 5.5 (p < 0.05) 107.8 ±6.9 {p< 0.005) 
PECAM-1 (CD31) IgGi 86.3± 1.7 (p< 0.05; ND 
ND = Not determined 
^ Platelet numbers were measured at 2 hr and 24 hr following mAb injection and the 
lowest of these two measurements in WT mice is provided with statistical significance 
of the difference when compared to baseline platelet numbers. Platelet numbers in 
FcyR-/- mice at the equivalent time point are provided with statistical significance of the 
difference when compared to the WT value. 
" Data mean ± SEM (n=3) 
Determined in BALB/c mice 
Strong platelet depleting mAbs 
Weak platelet depleting mAbs 
Non-depleting mAbs 
producing a small but significant reduction in platelet numbers in BALB/c mice that was 
not seen in C57BL/6 mice (Table 4.1). 
To determine whether an increased level of platelet depletion occured when two mAbs 
specific for different platelet surface antigens were combined, 20 i^g of the IgGI mAb 
specific for Gpllb-llla and either the Gpla or the GplX-specific IgGI mAbs were injected 
simultaneously into C57BL/6 mice. The levels of platelet depletion observed, however, 
were not significantly greater than when the mAb to Gpllb-llla was administered alone 
(Figure 4.1 Panel A) suggesting that the mechanism of platelet depletion associated 
with administration of the Gpllb-llla specific IgGI mAb was functioning at maximum 
capacity. Additionally these data indicated that the GplX-specific mAb did not have 
inhibitory properties that could prevent ITP induced by the Gpllb-llla specific mAb. 
A similar pattern of ITP induction was observed with the four rat lgG2 mAbs as was 
seen with the rat IgGI mAbs of comparable antigen specificity, although there were 
some minor differences. Thus, when compared to their IgGI counterparts, the lgG2b 
mAbs specific for Gpllb-llla and Gpla induced a more rapid and greater level of platelet 
depletion, whereas the lgG2b mAb specific for Gplba induced somewhat less platelet 
depletion than the IgGI mAb of comparable specificity. Similarly, the lgG2a mAb 
specific for GpV did not induce platelet depletion whereas the comparable IgGI mAb 
was a weak platelet depletor (Figure 4.1 B; Table 4.1). Unfortunately, rat lgG2 mAbs 
specific for GplX and PECAM-1 could not be sourced. 
The extent of mAb binding to the platelet surface was considered a potential 
explanation for the variation in the degree of ITP induced by the different mAbs. The 
level of platelet surface binding of all the IgGI mAbs was, therefore, examined 
following incubation in vitro with C57BL/6 mouse platelets, with a mAb concentration 
(10 ng/ml) being used in vitro that closely corresponded with the in vivo concentration 
of the mAbs (Figure 4.2A). This study showed that the mAb specific for GplX bound 
platelets at the highest density followed, in order of decreasing density, by the mAbs 
specific for Gplba, GpV, Gpllb-llla, Gpla and PECAM-1. Clearly the data indicate that 
the density of mAb binding to platelets is not a simple explanation for the ITP-inducing 
ability of the mAbs. For example, the GplX-specific mAb, which does not induce ITP, 
exhibited the highest density binding, whereas the Gpllb-llla- and Gpla-specific mAbs 
that bind 3-6 fold less effectively than GplX induced ITP. It is possible, however, that 
the level of expression of the protein on the platelet surface and, hence, the density of 
bound mAbs influenced the rate of platelet depletion. For example, 50-80,000 copies of 
Gpllb-llla are expressed on the platelet surface and, following the administration of a 
Gpllb-llla-specific mAb to mice, the majority of platelets were seen to be depleted 
within 2 hr. In contrast, 2-4,000 copies of Gpla-lla are expressed on the platelet 
surface and, when a Gpla-specific IgGI mAb was administered to mice, maximum 
platelet depletion was not observed until 24 hr following mAb injection. 
To further validate the in vitro data, a comparison was made between the level of 
binding observed in vitro with that occurring when the mAbs were injected in vivo. Thus 
the level of platelet surface binding of the non-ITP inducing lgG1 mAbs specific for 
GplX and PECAM-1 was determined 2 hours following i.v. injection into C57BL/6 mice. 
The level of platelet surface binding of the GplX-specific mAb seen in vivo was 
identical to that obtained in the in vitro study whereas the level of binding of the mAb 
specific for PECAM-1 in vivo was less than that seen in the in vitro studies (Figure 
4.2B). This result is not surprising as PECAM-1 is expressed not only on platelets but 
also on leukocytes and the vascular endothelium. These studies clearly demonstrate 
that the density of binding of mAbs to the platelet surface does not correlate with the 
ability of the mAbs to induce ITP when injected into mice. 
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Figure 4.2 - Extent of mAb binding to platelets does not correlate with the ability of the 
mAbs to induce ITP. The extent of binding of the various rat IgGI mAbs to their platelet target 
antigens was determined using (A) all IgGI mAbs in-vitro and (B) the two IgGI non-depleting 
mAbs in-vivo (solid lines) and in-vitro (dotted lines). For in-vitro studies washed whole blood 
from C57BL/6 mice was incubated with the mAbs (10 ng/ml) for 30 mins at 37°C and for in-vivo 
studies C57BL/6 mice were injected with 20 ng of each mAb and blood collected 2 hr later. 
Extent of mAb binding was determined by flow cytometry using a FITC-conjugated mouse anti-
rat IgGI mAb. Data in Table shows the level of in-vitro binding of all the IgGI mAbs expressed 
as fold-binding vs isotype control as seen in Panel A. 
Another possibility is that the level of antigen saturation by mAbs on the platelet 
surface influences the ability of a particular mAb to induce ITP. In order to test this 
possibility mouse platelets were incubated with a range of mAb concentrations in vitro 
and the level of antigen saturation determined at 10 [xg/ml, the estimated in vivo 
concentration of the IgGI mAbs following a dose of 20 ^^g/mouse, i.e., the mAb dose 
used for the ITP studies. It was found that at a mAb concentration of 10 ng/ml, Gpllb-
llla and GpV were the least saturated, GplX and Gplba were almost saturated, and 
Gpla and PECAM-1 were beyond saturation (Figure 4.3). Thus, the degree of platelet 
antigen saturation also does not correlate with the ability of the different mAbs to 
induce ITP. 
4.3.2 Induction of ITP by platelet-specific mAbs is predominantly FcyR 
dependent and is regulated at the macrophage level. 
Since previous studies have suggested that FcyR play a key role in ITP, those 
antibodies causing significant platelet-depletion were administered to FcR common y-
chain deficient (FcyR-/-) mice. The IgGI mAbs were tested in FcvR-/- mice on a 
BALB/c background as it was on this strain background that more severe ITP was 
observed with the IgGI mAbs. The lgG2 mAbs were, in contrast, tested in FcyR-/- mice 
on a C57BL/6 background. In each case, comparisons of the level of ITP induction 
were made with wild-type (WT) mice of the same genetic background. 
In FcyR-/- mice, the platelet depleting ability of all the ITP inducing mAbs was 
dramatically inhibited except those mAbs specific for Gplba (Figure 4.4, Table 4.1). 
The extent of ITP induction observed following injection of both the IgGI and the lgG2 
mAbs specfic for Gplba was essentially unchanged in FcyR-/- mice. Interestingly, the 
lgG2b antibody specific for Gpla still caused 37.6% depletion of platelets at 2 hr in 
FcyR-/- mice, although this value was significantly less than the 96.5% depletion seen 
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Figure 4.3 - Ability of lgG1 mAbs to saturate their target antigens does not correlate 
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incubated for 30 min at 37°C with 2.5-40 ng/ml of the different platelet-specific rat IgGI mAbs, 
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Figure 4.4 - Induction of ITP by platelet-specific mAbs is predominantly FcyR 
dependent. Baseline platelet numbers were performed on WT (blue) and FcyR-/- (red) mice 
(n=3) prior to i.v. injection of 20 ^g of mAb to a platelet surface molecule. Data shows 
platelet numbers as a percentage of baseline at 24 hr post-injection of mAb. Bars represent 
SEM. Significant increases in platelet numbers in FcyR-/- mice relative to WT mice are 
shown as *ps0.05, ** psO.005. IgGI data was obtained from FcyR-/- on a BALB/c 
background as more severe ITP was observed in mice of this background with the IgGI 
mAbs. lgG2b data was obtained from FcyR-/-mice on a C57BL/6 background. Control values 
were obtained from WT of the same background. 
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in WT mice (Figure 4.4, Table 4.1). These data imply that FcyR uptake is the principal 
mechanism of antibody-mediated ITP. However, platelet depletion induced by the IgGI 
and lgG2b mAbs specific for Gplba was FcyR independent, whilst that occurring with 
the lgG2b mAb specific for Gpla was partially FcyR dependent. 
To confirm the role of macrophages in the uptake of antibody-coated platelets, 
peritoneal exudate cells were collected from C57BL/6 mice, labelled with a Per-CP 
conjugated CD11b-specific mAb, a mAb specific for myeloid cells, and incubated with 
CFSE-labelled platelets coated with rat IgGI mAbs specific for Gpllb-llla, GplX or an 
isotype control. Samples were then analysed for macrophage uptake of CFSE-labelled 
platelets (Figure 4.5A). Consistent with the in vivo experiments, platelets coated with 
the Gpllb-I I la-specific IgGI mAb induced a greater uptake of CFSE labelled platelets 
by the CD11b+ population than platelets coated with the GplX-specific IgGI mAb 
(p<0.0005)(Figure 4.5B). In fact, platelets coated with the GplX-specific mAb showed 
only a slight increase in phagocyte uptake above background. These data suggest 
that FcyR-mediated ITP induced by the binding of the various anti-platelet antibodies 
occurs at the level of the macrophage, although additional in vivo experiments would 
be required to definitively demonstrate this point. 
4.3.3 FcyR-independent mechanisms of ITP induction involve platelet 
disintegration or complement-mediated destruction 
Following the demonstration that administration of the IgGI and the lgG2b mAbs 
specific for Gplba still induced ITP in FcyR-/- mice, alternative mechanisms of platelet 
destruction were investigated. To determine the role of complement in the platelet 
depletion induced by these antibodies, the Gplba-specific IgGI mAb was administered 
to C3-/- mice (Figure 4.6). These data demonstrated that complement had no role in 
the platelet depletion mediated by the IgGI mAb specific for Gplba. 
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Figure 4.5 - Platelets are selectively opsonised for phagocyte uptake by an ITP 
inducing mAb specific for Gpllb-llla. Peritoneal exudate cells were collected from 
C57BL/6 mice, incubated with a Per-CP conjugated mAb specific for CD11 b, then incubated 
for 60 min at 37°C with CFSE-labelled platelets coated with rat IgGI mAbs specific for 
Gpllb-llla, GplX or an isotype control. (A) Representative histogram of samples analysed by 
flow cytometry for platelet uptake by CD11b+ myeloid cells gated for detection of CFSE 
fluorescence. (B) Combined results from 2 separate experiments consisting of a total of 5 
samples. Significant increases in the percentage of CFSE+ CD11b+ cells shown as 
*p<0.05 and "*p<0.0005. 
It has previously been demonstrated by Hoffmeister et al., that the chilling of platelets 
or, indeed, live mice, causes the clustering of the Gplba protein on the platelet surface. 
This neo-antigen is recognised by the Mac-1 (CD11b) receptor on macrophages and 
activates phagocytosis of the chilled platelets (Hoffmeister et al. 2003). To determine 
whether the Gplba-specific mAb was inducing a similar change to the Gplba protein 
and causing Mac-1 receptor-mediated phagocytosis, CD1 Ib(Mac-l)-/- mice were 
injected with the Gplba-specific IgGI mAb. It was found, however, that the maximum 
extent of platelet depletion in these mice was unchanged to that seen in WT mice 
(Figure 4.6). 
Experiments were also conducted to determine whether the binding of the mAb to 
Gplba was inducing a change in the expression of MHC class-l like molecules on the 
platelet surface that would allow their destruction by NK cells. |32-microglobulin 
deficient mice, which lack MHC class I molecules, were, therefore, injected with the 
Gplba-specific IgGI mAb, but, these mice were also found to be as susceptible to 
platelet depletion as WT mice (Figure 4.6). 
As Gplba binds P-selectin, it was also hypothesised that following Gplba-mAb binding 
platelets may be binding endothelial P-selectin constitutively expressed in the lungs 
and liver. The Gplba-specific IgGI mAb was, therefore, injected into P-selectin-/- mice. 
The maximum level of platelet depletion in these mice, however, was not significantly 
different to that observed in WT mice (Figure 4.6). 
To investigate whether the binding of the Gplba-specific IgGI mAb was causing direct 
activation and disintegration of platelets, washed whole blood was incubated for 30 min 
at 37°C with the Gplba-specific IgGI mAb, the Gpllb-llla-specific lgG2b mAb or the 
Gpla-specific lgG2b mAb and compared with a control sample containing no antibody. 
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Figure 4.6 - ITP induction by a Gplba-specific mAb does not involve complement, the 
macrophage receptor Mac-1, MHC-Class l-like molecules or P-selectin. Baseline platelet 
numbers were assessed for WT, C3-I-, CD11b-/-, PaM-/- and P-Sel-/- C57BL/6 mice (n=3) 
prior to I.v. injection of 20 ^g of an IgGI mAb specific for Gplba. Data shows platelet 
numbers as a percentage of baseline at 2 hr and 24 hr post-injection of mAb. Bars represent 
SEM. 
Following this, a FITC-conjugated antibody to P-selectin, a marl<er of platelet 
activation, was added. The samples were then analysed by flow cytometry for 
changes in platelet size, based on forward and side scatter, and P-selectin expression. 
In contrast to all the other treatments, platelets incubated with the Gplba-specific IgGI 
mAb became weakly positive for P-selectin expression (Figure 4.7A) and were clearly 
reduced in size (Figure 4.7B) thus indicating that the binding of the mAb to Gplba was 
causing platelet activation and fragmentation. This process was independent of 
complement as the platelets used in this experiment were washed free of serum, and 
ITP was demonstrated in complement deficient mice administered the Gplba-specific 
IgGI mAb (Figure 4.6). 
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Figure 4.7 - The ITP-inducing Gplba-specific mAb, but not ITP-inducing mAbs to other 
platelet surface molecules, directly activates platelets. Washed blood cells from wild-type 
C57BL/6 mice were incubated with rat IgGI mAbs to Gplba, Gpllb-llla or Gpla for 30 mins at 
37°C followed by a FITC-conjugated rat IgGI antibody specific for P-selectin, then analysed by 
flow cytometry for (A) surface expression of P-selectin and (B) alterations in platelet size (FSC) 
and granularity (SSC). 
Since ITP induced by the lgG2b mAb specific for Gpla was found to be partially 
independent of FcyR, this antibody was administered to WT and FcyR-/- mice depleted 
of C3 using cobra venom factor to determine whether complement-mediated platelet 
destruction was involved. Indeed, the induction of ITP was completely inhibited in the 
complement-depleted FcyR-/- mice indicating that platelet depletion by this mAb is 
partially complement dependent (Figure 4.8). A small but significant increase in 
platelet numbers was also seen at 2 hr after Gpla lgG2b mAb administration in 
complement-deficient WT mice when compared with complement-sufficient WT mice 
(32.9% ± 1.7 vs 15.2% ± 1.8; p < 0.005) (Figure 4.8). These data demonstrate that 
administration of the Gpla-specific lgG2b mAb induces platelet depletion via FcyR-
mediated phagocytosis and complement-mediated destruction. 
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Figure 4.8 - Induction of ITP by rat lgG2b mAb to Gpla is both FcyR and complement 
dependent. C57BL/6 WT and FcyR-/- mice (n=3) were depleted of complement via I.p. 
injection of cobra venom factor (CVF) 18 hr prior to i.v. injection of 20 fig of an lgG2b mAb 
specific for Gpla. Baseline platelet numbers were performed prior to injection of the Gpla 
mAb. Data shows platelet numbers as a percentage of baseline at 2 hr post injection of mAb. 
Bars represent SEM. Significant increases in platelet numbers are shown as *ps0.05 and 
"pfiO.005. 
4.3.4 Engagement of the phagocytosis inhibitor, SIRPa, prevents lgG1-
mediated, but not lgG2b-mediated, ITP 
The important question remaining was why some platelet antigen-specific mAbs induce 
ITP via FcYR-mediated phagocytosis while others do not. The working hypothesis was 
that the interaction of the ITP inducing mAbs with their platelet surface antigens was 
causing the loss of a self-recognition molecule on the platelet surface and, in doing so, 
triggering phagocytosis following FcyR engagement. As earlier studies have shown that 
antibody-mediated platelet depletion is enhanced in CD47-/- mice (Olsson et al. 2005), 
we examined whether the CD47-SIRPa recognition system may regulate ITP in our 
experimental model. Thus, experiments were performed to ascertain the role of the 
self-antigen, CD47, on platelets and its receptor, SIRPa, on macrophages in regulating 
the depletion of antibody-coated platelets. Initially CD47-/- mice (n=3) were injected 
with rat lgG1 mAbs specific for various platelet antigens and platelet numbers 
determined over time. In CD47-/- mice the lgG1 mAb specific for GplX was indeed able 
to induce a significant reduction in platelet numbers, an effect that was sustained for at 
least 48 hours (Figure 4.9A). In contrast to GplX, ITP was not observed in CD47-/-
mice receiving the non-depleting lgG1 and lgG2b mAb specific for GpV, nor the 
PECAM-1-specific lgG1 mAb (Figure 4.9B). However, a trend towards more severe 
ITP was seen in CD47-/- mice 24 hr following the injection of lgG1 mAbs specific for 
Gpllb-llla and Gpla, although these results did not reach statistical significance. 
The expression of CD47 on platelets following the binding of depleting and non-
depleting rat lgG1 mAbs specific for various platelet antigens was then investigated 
using flow cytometry. This study demonstrated that the level of CD47 surface 
expression was not reduced by any of the lgG1 mAbs compared with the level seen in 
the control sample. In fact, there appeared to be a slight increase in CD47 expression 
following anti-platelet mAb binding, although this increase did not correlate with the 
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Figure 4.9 - GplX specific mAb induces ITP in CD47-/- mice. (A) Wild-type (WT) and CD47-
/- C57BL/6 mice (n=3) were injected i.v. with 20 jig of a GplX-specific rat IgGI mAb and 
platelet numbers measured prior to, 2, 24 and 48 hr post mAb injection. (B) Ability of mAbs 
specific for various platelet antigens (20 |.ig i.v.) to affect platelet numbers 24 hr after 
administration to WT and CD47-/- C57BL/6 mice. Significant decreases in platelet numbers 
between WT and CD47-/- mice are shown as *ps0.05. Note that differences in panel B did not 
reach statistical significance. 
ability of the particular mAb to induce ITP (Figure 4.10). These data indicate that the 
binding of the various mAbs to platelet proteins was not selectively inducing a change 
in the level of expression of CD47 on the platelet surface that was inf luencing the 
induction of ITP. 
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Figure 4.10 - Surface detection of the SIRPa ligand, CD47, following binding of IgGI 
anti-platelet mAbs, does not correlate with ability to induce ITP in-vivo. Whole blood from 
wild-type mice was incubated for 30 mins at 37°C with a number of rat IgGI anti-platelet mAbs 
prior to the addition of a rat lgG2a anti-CD47 mAb or an isotype control. Extent of GD47 mAb 
binding was determined by flow cytometry using a RE conjugated mAb specific for rat lgG2a. 
(A) Representative FAGS plot for samples incubated with IgGI mAbs specific for Gpllb-llla 
and GplX. Data in table shows the level of CD47 mAb binding in the presence of different anti-
platelet mAbs expressed as fold-binding vs isotype control. 
Since the data described in this Chapter suggest that phagocytosis-inhibitory 
receptors, such as SIRPa, may be controlling ITP severity, we examined the ability of a 
SIRPa activating mAb to inhibit ITP. It was found that injection of such a mAb 1 hr prior 
to the injection of 20 ^g of the platelet-depleting rat lgG1 mAbs specific for Gpla 
(C57BL/6 mice), GpV (BALB/c mice) and Gpllb-llla (C57BL/6 mice) resulted in a 
complete inhibition of ITP induction (p<0.05 - p<0.0005 compared with isotype 
control)(Figure 4.11). Furthermore, the inhibition of ITP by SIRPa mAb treatment was 
similar to that observed in FcyR-/- mice (Table 4.2). 
Table 4.2: Comparison of Ability of SIRPa Activation or FcyR Deficiency to 
Prevent lgG1-induced ITP. 
Specificity of Anti- WT mice ^ WT mice treated with FcyR-/- mice ® 
Platelet mAb (lgG1) SIRPa specific mAb ® 
Gpllb-llla 35.3 ±3 .8 95.7 ±6.5 104.5 ±4.3 
Gpla 25.6 ±7.1 81.2 ±8.9 80.5 ± 8.8 
GpV (BALB/c) 39.5 ±5.5 103.5± 1.6 107.8 ±6.9 
® Mean platelet numbers expressed as % of baseline (± SEM) at 24 hr following anti-
platelet mAb injection (n=3). 
ediated F a' ' i Elir. 130 
Anti-platelet mAb alone 
Anti-platelet mAb + 50 |.ig SIRPa mAb 
Anti-platelet mAb + 50 ng Isotype control 
H I - Anti-platelet mAb + 5 j ig SIRPa mAb 
Anti-platelet mAb + 0.5 ^g SIRPa mAb 
Anti-platelet mAb + 0.5 ^g Isotype control 
5 10 15 20 25 30 0 5 10 15 20 25 30 
Hours post mAb Injection ^ 
Figure 4.11 - Treatment with low concentrations of a SIRPa-specific mAb prevents FcyR-
mediated ITP induced by rat IgGI mAbs (A & B) 50 ng of a rat lgG1 mAb to SIRPa or an 
isotype control was injected i.v. 1 hr prior to injection of 20 (.ig of a rat IgGI mAb specific for (A) 
Gpla in C57BL/6 mice and (B) GpV in BALB/c mice. (C) C57BL/6 mice were injected i.v. with 50-, 
5- or 0.5 ^tg of a SIR Pa-specific mAb or 50 ng or 0.5 ng of an isotype control 1 hr prior to i.v. 
injection of 20 ng of an IgGI mAb specific for Gpllb-llla. Platelet numbers were determined 1 hr 
prior to injection of the SIRPa mAb or the isotype control, and 2 hr and 24 hr following injection of 
the anti-platelet mAbs. Statistical comparisons made between equivalent doses of isotype control 
treated mice vs SIR Pa-specific mAb treated mice are shown as *ps0.05, ***ps0.0005. Data for 
mice treated with anti-platelet mAbs alone ( ) from Figure 4.1 A included to demonstrate 
reproducibility of ITP induced by each mAb. 
The minimum dose of the SIRPa-specific mAb required to prevent ITP was also 
investigated in mice administered the Gpllb-llla-specific mAb. C57BL/6 mice were 
injected with 5 or 0.5 i^ g of the SIRPa-specific mAb 1 hr prior to injection of 20 |j.g of 
the IgGI mAb specific for Gpllb-llla. The platelet preserving effect of the 5 ^g dose of 
the SIRPa mAb was found to be similar to that observed with a 50 i^g dose of the mAb, 
but a 0.5 ng dose was ineffective (Figure 4.11C). 
To determine whether the SIRPa-specific mAb could reverse pre-existing ITP, 
C57BL/6 mice were injected with 20 ng of the Gpllb-llla-specific IgGI mAb then 2 hr 
later with 50 or 5 ^g of the SIRPa-specific mAb. Platelet numbers were determined at 
baseline, 1, 3 and 24 hr following injection of the Gpllb-llla-specific mAb. Platelet 
numbers were significantly increased following treatment with the SIRPa-specific mAb 
at 3 hr (both doses p<0.05) and 24 hr after injection of the Gpllb-llla-specific IgGI mAb 
(5 (xg p<0.05 and 50 ng p<0.005) compared with mice receiving an isotype control 
(Figure 4.12). 
Additional experiments were conducted to determine whether the SIRPa-specific mAb 
could also prevent lgG2b mAb-induced ITP. Thus, WT C57BL/6 mice were injected 
with 50 ng of the SIRPa mAb or an isotype control 1 hr prior to the injection of 20 ng of 
the rat lgG2b mAb specific for Gpllb-llla. In stark contrast to the effect of SIRPa mAb 
treatment prior to the Gpllb-llla-specific IgGI mAb, ITP was not inhibited by SIRPa 
mAb treatment prior to the lgG2b mAb administration (Figure 4.13A). The ability of 
SIRPa mAb treatment to prevent ITP induced by the Gpla-specific lgG2b mAb was 
also investigated. As ITP induced by this mAb was previously demonstrated to be both 
FcyR and complement-mediated (Figure 4.8), WT and FcyR-Z-mice were depleted of 
complement using CVF and the WT mice subsequently injected with the SIRPa-
b-mediated Platelet Elimination - 1 3 2 
specific mAb or saline 1 hr prior to injection of the Gpla-specific mAb. However, as 
seen with the Gpllb-llla-specific igG2b mAb, SIRPa mAb treatment prior to Gpla-
specific lgG2b mAb administration did not result in ITP inhibiton (Figure 4.13B). These 
data contrast with the results seen in FcyR-/- mice administered these lgG2b mAbs 
(Figure 4.4) and implies that the inhibitory receptor, SIRPa, does not regulate the FcyR 
subclass that binds rat lgG2b mAbs. 
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Figure 4.12 - SIRPa-speclfic mAb treatment can reverse ITP induced by a Gpllb-llla 
specific IgGI mAb. C57BL/6 mice (n = 3) were injected i.v. with 20 |.ig of a rat lgG1 mAb 
specific for Gpllb-llla and 2 hr later with 50 or 5 ng of a SIRPa-specific mAb, or 5 ng of an 
isotype control. Platelet numbers were determined at baseline, 1, 3 and 24 hr post mAb 
Gpllb-llla injection. Significant increases in platelet numbers between the isotype control 
and the SIRPa-specific mAb treated mice are shown as *ps0.05 and **ps0.005. 
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Figure 4.13 - SIRPa-specific mAb is unable to prevent ITP induced by rat lgG2b mAbs 
specific for Gpllb-llla or Gpla either alone or when combined with complement 
depletion. (A) ITP observed in WT C57BL/6 mice (n = 3) injected i.v. with 20 (ig of a Gpllb-
llla-specific rat lgG2b mAb in the presence or absence of a SIR Pa-specific mAb (50 ng i.v.) 
injected 1 hr earlier. ITP induced by the Gpllb-l l la mAb in FcyR-/- mice is included for 
comparison. (B) ITP observed in WT C57BL/6 mice depleted of complement by CVF and 
injected i.v. with saline or 50 |.ig of a SIRPa-specific mAb 1 hr prior to i.v. injection of 20 ng of 
a rat lgG2b mAb specific to Gpla. ITP induced by the Gpla-specific mAb in CVF treated FcyR-
/- mice is included for a comparison. Platelet numbers were determined at baseline, 2 hr and 
24 hr post injection of the mAbs to Gpllb-l l la or Gpla. Data in (A) for WT mice ( ) from 
Figure 4 . IB . 
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4.3.5 Engagement of the inhibitory receptor, CD200R, on phagocytes 
fails to inhibit lgG1 or lgG2 mAb induced ITP 
There are other inhibitory receptors on macrophages in addition to SIRPa that could 
potentially regulate ITP. One of the best characterised is the CD200R, present on most 
leukocytes but at higher levels on macrophages. CD200R interacts with CD200, 
expressed by many cell types, and in doing so, inhibits macrophage activation (Barclay 
et al. 2002). Initially, the expression of the inhibitory ligand CD200 on mouse platelets 
was established by flow cytometry (Figure 4.14A), and the level of CD200 expression 
was shown to be unchanged following the binding of various mAbs specific for platelet 
surface proteins (Figure 4.14B). To determine whether CD200R could be stimulated 
by the administration of a specific mAb (0X2) in a similar manner to the SIRPa 
receptor, WT mice were injected with 50 |.ig of the 0X2 mAb 1 hr prior to the injection 
of the IgGI and the lgG2b mAbs specific for Gpllb-llla. Both 2 hr and 24 hr following 
Gpllb-llia-mAb injection, there was no significant difference in the ITP observed 
between the anti-CD200R (0X2) mAb treated mice and the control mice (Figure 4.15). 
It should be noted that previous studies have shown that the 0X2 mAb is a CD200R 
agonist and when used in vivo delayed the onset of experimental autoimmune 
encephalomyelitis (Voulgaraki et al. 2005) and lung inflammation following influenza 
infection in mice (Snelgrove et al. 2008) by inhibiting cytokine secretion. These data 
obtained in the ITP model imply that CD200R does not regulate FcyR-mediated uptake 
of antibody-coated platelets by phagocytes. 
4.3.6 ITP induction by the hamster mAb (1B5) to mouse Gpllb-llla 
involves FcyR and complement-independent platelet disintegration 
The mechanism of platelet depletion induced by the hamster mAb (1B5) specific for 
mouse Gpllb-llla used to deplete mice of platelets for the metastasis studies described 
in Chapter 3, was also studied. As shown in Figure 3.2, this hamster antibody caused 
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Figure 4.14 - The inhibitory ligand CD200 is expressed on the surface of mouse 
platelets and the level of expression remains unchanged following the binding of 
various mAbs specific for platelet surface proteins. (A) Whole blood from WT mice was 
incubated with a PE-conjugated CD200-specific mAb or a PE-conjugated isotype control. 
Samples were then analysed by flow cytometry. Duplicate histograms for each treatment are 
shown. (B) Isolated platelets were incubated with various mAbs specific for platelet surface 
proteins for 30 mins at 37°C then incubated with a PE-conjugated CD200-specific mAb or a 
PE-conjugated isotype control and analysed by flow cytometry for the level of CD200 mAb 
binding. Data in table represents the level of CD200 mAb binding in the presence of different 
anti-platelet mAbs expressed as fold-binding vs isotype control. 
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Figure 4.15 - Treatment with a CD200R-specific mAb does not prevent ITP induced by 
rat IgGI and lgG2b mAbs specific for Gpllb-llla. WT C57BL/6 mice were injected with 50 ng 
of a CD200R-specific mAb (0X2) 1 hr prior to injection of (A) 20 ng of a Gpllb-I I la-specific 
lgG1 mAb (n=3) or (B) 20 ng of a Gpllb-llla-specific lgG2b mAb (n=1). Platelet numbers were 
measured at 2 hr and 24 hr post Gpllb-llla mAb injection. Data for Gpllb-llla IgGI mAb ( ) 
and Gpllb-llla lgG2b mAb ( ) in control mice taken from Figure 4.1. 
rapid and extensive depletion of platelets when administered to mice. Experiments 
were performed to determine the contribution of FcyR, the FcyR regulatory protein, 
SIRPa, and complement in IBS-mediated depletion of platelets. WT mice administered 
20 ^ig of the 1B5 mAb experienced platelet reductions of -95% 2 hr following mAb 
injection as seen in previous experiments. Administration of 50 ng of the SIRPa-
specific mAb 1 hr prior to 1B5 mAb administration did not alter this outcome. When the 
1B5 mAb was administered to FcyR-/- mice, 70% of platelets were depleted within 2 hr. 
This was significantly less depletion than that observed in WT mice (p<0.005). When 
FcyR-/- mice were depleted of C3 using CVF prior to injection of the 1B5 mAb the 
outcome was essentially unchanged from untreated FcyR -/- mice (Figure 4.16A). 
The extent of platelet disintegration induced by the binding of the 1B5 mAb was also 
examined by incubating washed whole blood with the 1B5 mAb as in Figure 4,7. The 
platelet activating Gplba-specific lgG1 mAb and the non-activating Gpllb-llla-specific 
lgG1 mAb were included as controls. The results of this experiment demonstrated that 
the 1B5 mAb did indeed induce platelet loss similar to, but to a lesser extent than that 
induced by the Gplba-specific lgG1 mAb (Figure 4.16B). The 1B5 mAb therefore 
induces platelet depletion through both FcyR-mediated uptake and complement-
independent platelet disintegration. 
Figure 4.16 - ITP Induced by the hamster lgG3 mAb (1B5) specific for mouse Gpllb-llla 
occurs through an FcyR unaffected by SIRPa mAb treatment, with complement-
independent platelet fragmentation also playing a role. (A) ITP induced by injection (20 
t^g i.v.) of the hannster Gpllb-llla-specific lgG3 mAb, 1B5, in WT nnice in the presence or 
absence of a SIR Pa-specific mAb (50 |.ig i.v.) administered 1 hr earlier, and in FcyR-/- mice 
either depleted or not depleted of complement by CVF (n=3). Platelet numbers were 
measured at baseline, 2 hr and 24 hr post injection of the 1B5 mAb. Significant increases in 
platelet numbers in both complement sufficient or deficient FcyR-/- mice compared to WT 
mice are shown as *ps0.05 and **p<0.005. (B) Washed whole blood from WT G57BL/6 mice 
was incubated with the Gpllb-llla-specific hamster lgG3 mAb 185, the Gplba-specific rat 
IgGI mAb, or the Gpllb-llla-specific rat lgG2b mAb for 30 min at 37°G, washed twice in PBS 
and then analysed by flow cytometry for a reduction in platelet numbers. Significant 
reductions in platelet numbers compared to the no mAb control, are shown as *ps0.05 and 
"psO.005. 
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4.4 Discussion 
The key findings of the work described in this Chapter are: (i) the administration to 
mice of mAbs specific for different platelet membrane proteins does not always induce 
ITP, (ii) the ability of a mAb specific for a particular platelet antigen to induce ITP does 
not correlate with the density of binding on the platelet surface nor the degree of mAb 
saturation of the antigen, however, the rate of platelet depletion may be influenced by 
the density of the mAb on the platelet surface, (iii) the mechanism of antibody-
mediated platelet depletion is principally FcyR-mediated, but in some cases may occur 
through direct activation and fragmentation of platelets or via complement-mediated 
destruction, (iv) the level of FcyR-mediated platelet depletion is usually greater 
following the administration of lgG2b mAbs than lgG1 mAbs, (v) use of a mAb specific 
for the phagocytosis inhibitory protein SIRPa in vivo not only prevented, but reversed 
rat lgG1 mAb induced, Fc^'R-mediated ITP, although the SIRPa mAb could not prevent 
FcyR-mediated ITP induced by rat lgG2b mAbs, (vi) administration of the non-depleting 
GplX-specific lgG1 mAb to mice deficient in CD47, a SIRPa ligand, resulted in the 
induction of ITP and (vii) unlike SIRPa, the macrophage inhibitory receptor, CD200R, 
was found to probably not prevent ITP induced by rat lgG1 or lgG2b mAbs. 
The function of antibodies within the immune system is to bind foreign antigens, and in 
doing so, tag the antigen for identification and destruction by immune effector cells 
such as phagocytes, and opsonise the antigens for complement system activation. In 
the studies described herein, rat mAbs specific for different mouse platelet proteins 
were administered to mice in order to study the mechanisms of ITP, hence, the 
elimination of antibody-coated self-antigens was under study rather than foreign 
antigens. Auto-reactive antibodies are a key feature of many autoimmune disorders 
and, therefore, the findings of this work are relevant not only to ITP but to all antibody-
mediated pathologies. 
Three mechanisms of Ab-mediated platelet depletion were identified in these studies. 
The predominant pathway was found to be FcyR-mediated phagocytosis as ITP 
induction was inhibited in FcyR-/- mice with the majority of the mAbs under study. The 
second mechanism of platelet depletion identified was via the direct activation and 
fragmentation of platelets, a process that was independent of FcyRs, complement, 
Mac-1 and P-selectin. Antibody-mediated fragmentation of human platelets has 
previously been reported to occur in response to antibodies specific for CD9, Gplib-llla, 
GpIV and an additional two unidentified platelet antigens and the mechanism of platelet 
activation in these studies was demonstrated to occur as a result of Fc:FcR 
interactions (Horsewood et al. 1991). Human platelets express FcR whereas mouse 
platelets do not (McKenzie 2002). Therefore, from the studies of mouse platelets 
presented herein, the binding of mAbs to Gplba would appear sufficient to initiate 
signalling by this protein resulting in platelet activation and fragmentation. The third 
mechanism of Ab-mediated platelet depletion was through complement activity, 
however, this was seen to play a partial role with only one of the antibodies under 
study, an lgG2b mAb specific for Gpla. These data suggest that complement 
regulatory proteins on the surface of platelets are effective in preventing complement-
mediated lysis and that steric hindrance of these regulatory proteins may have resulted 
in the complement activity induced by the lgG2b mAb specific for Gpla. 
In order to further comprehend the implications of our data, it is necessary to have a 
thorough understanding of the function of the different FcyRs. Mice express four FcyR 
subtypes that vary in their interactions with IgG isotypes and may inhibit or activate 
cellular effector functions (Table 4.3). The nomenclature of the IgG subclasses is not 
consistent between species, however, genetic, structural and functional studies have 
enabled the comparison of mouse and rat IgG subclasses and the FcyR with which 
they interact (Hulett and Hogarth 1994). Unfortunately, the same information is not 
available for hamster IgG isotypes. The rat mAbs used in the studies described in this 
Chapter included the IgGI, lgG2a and lgG2b isotypes. Rat IgGI and lgG2a are 
reported to be most similar to murine IgGI and bind to the murine low-affinity activating 
receptor, FcyRIII, and the murine low-affinity inhibitory receptor, FC7RIIB (Table 4.3). 
Rat lgG2b, on the other hand, is reportedly similar to murine lgG2a and binds the high-
affinity activating receptor, FcyRI, the low-affinity activating receptor, FcyRHI, the low-
affinity inhibitory receptor FcyRIIB, and, most likely, the recently identified intermediate-
affinity activating receptor, FcyRIV (Nimmerjahn et al. 2005). The response of the 
effector cell is determined by the balance of the activation and inhibitory signals 
received via the different Fc^-Rs (Ravetch and Bolland 2001). 
Table 4.3: Murine Fey Receptors and Their Interactions 
FcyR subclass Effector 
Function 
Mouse IgG Isotypes 
Bound 
Equivalent Rat Isotype/s 
1 Activating lgG2a 
(high affinity) 
lgG2b 
MB Inhibitory IgGI, lgG2b, lgG2a 
(low affinity) 
IgGI, lgG2a, lgG2b 
III Activating IgGI, lgG2b, lgG2a 
(low affinity) 
IgGI, lgG2a, lgG2b 
IV Activating lgG2a and lgG2b 
(intermediate affinity) 
lgG2b (?) 
Table generated from data presented in Fridman, 1991, Coding, 1996, and Nimmerjahn et 
al, 2005. 
In the ITP studies described herein, a greater extent of FcyR-mediated platelet 
depletion was observed when lgG2b mAbs specific for Gpllb-llla and Gpla were 
administered to mice than was seen with their lgG1 counterparts. This result is 
consistent with the notion that rat lgG2b mAbs bind the murine high-affinity FcyR 
whereas lgG1 mAbs bind the low-affinity activating receptor, thus, a much stronger 
pro-phagocytic signal occurs in response to lgG2b mAbs. As platelets are flowing in 
the bloodstream past FcyR-bearing effector cells, high-affinity FciPcyR binding would 
more likely result in a sustained interaction between platelets and effector cells. In 
contrast, low-affinity FciFcyR binding may result in platelet release from the effector 
cell, although this is less likely if multiple low-affinity interactions occur. This effect may 
explain the different rates of platelet depletion observed when mice were administered 
the lgG1 mAbs specific for Gpllb-llla and Gpla. As Gpllb-llla is present on the surface 
of platelets in very high numbers, when bound by lgG1 mAbs, multiple low-affinity 
interactions with the effector cells would promote a sustained interaction with rapid 
platelet clearance. Gpla-lla, however, is present on the platelet surface in low 
numbers and, therefore, interactions with low-affinity FcyR would be fewer in number, 
and, therefore, less likely to be sustained, resulting in a reduced rate of platelet 
clearance. 
The lack of ITP induction observed following the administration of some lgG1 mAbs 
implied that platelet clearance by FcyRs was being inhibited. As platelet-depleting and 
non-platelet-depleting mAbs were of the same isotype, the potential mechanism of 
inhibition was considered to be other than inhibitory FcyR. Having demonstrated that 
the non-ITP inducing mAbs were binding to the platelet surface, in the case of the 
GplX-specific mAb to a greater level than the ITP-inducing mAbs, we hypothesised that 
the gain or loss of a secondary signal on the platelet surface must also be required to 
trigger phagocytosis. 
The self-recognition, inhibitory protein pairs CD47:SIRPa and CD200:CD200R were 
considered as possible regulators of FcyR-mediated depletion of antibody-coated 
platelets and, therefore, were investigated. It is useful to review the current 
understanding of the role of these regulatory protein pairs in the context of platelets 
and ITP, in order to better understand the implications of the data. CD47, also known 
as the integrin-associated protein (lAP), is a widely expressed membrane protein and 
present on the surface of platelets in association with Gpllb-llla (allbpS) and Gpla-lla 
(a l ip i ) (Chung et al. 1997; Chung et al. 1999). The receptor for CD47, SIRPa, is 
expressed on hematopoietic stem and/or progenitor cells, monocytes, granulocytes, 
and dendritic cells (Seiffert et al. 2001). CD47:SIRPa signalling in macrophages results 
in the activation of SHP-1 phosphatase which dephosphorylates myosin MA preventing 
the formation of a phagocytic cup (Tsai and Discher 2008). The SIRPa:CD47 
interaction has been demonstrated to regulate the half-life of platelets, with CD47-/-
and SIRPa mutant mice having a shorter platelet lifespan than WT mice (Yamao et al. 
2002; Olsson et al. 2005). Furthermore, CD47-/- mice were more sensitive to Ab-
mediated ITP than wild-type mice when injected with a mouse IgGI mAb, known as 
6A6, to an unidentified platelet antigen. In vitro experiments using IgG opsonised 
platelets demonstrated an enhanced uptake of CD47-/- platelets, however, when 
SIRPa was blocked using a specific mAb, the rate of uptake of WT platelets increased 
to that of CD47-/- platelets (Olsson et al. 2005). A further piece of evidence implicating 
CD47 in the regulation of ITP was the finding that in a mouse model of ITP induced by 
shiga-toxin producing £. coli infection, CD47 expression on platelets was 
downregulated (Guo et al. 2009). CD200 is a member of the Ig superfamily and is 
expressed on thymocytes, neurons, endothelium, follicular dendritic cells in all 
lymphoid organs, a subset of CD34+ progenitor cells and at low levels on some smooth 
muscle cells and B lymphocytes. It is reportedly expressed in very low levels or absent 
on NK cells, monocytes, granulocytes and platelets in humans (Kretz-Rommel et al. 
2008) but we found detectable levels of the protein on mouse platelets. The interaction 
between CD200 and CD200R inhibits the activation of, and cytokine secretion by 
granulocytes and macrophages (Hoek et al. 2000). To our knowledge, the role of 
CD200R in the inhibition of phagocytosis, has not been studied. 
Following the demonstration that expression of CD47 on platelets was not reduced 
subsequent to the binding of the various lgG1 mAbs to platelet antigens, we 
hypothesised that steric hindrance of the interaction between CD47 and SIRPa, 
caused by antibody binding, was likely determining whether an lgG1 mAb caused 
platelet depletion or not, and that steric hindrance was more likely to occur with mAbs 
specific for proteins with which CD47 is closely associated. The data supports this 
hypothesis in that the lgG1 mAbs to Gpllb-lla and Gpla, with which CD47 is known to 
associate, induced the most marked FcyR-mediated ITP. Furthermore, when CD47-/-
mice were administered the non-platelet depleting GplX-specific lgG1 mAb a 
significant reduction in platelet numbers of ~50% was observed. GplX is a non-integrin 
and is not known to be associated with CD47. Consequently, binding of the mAb 
specific for this protein would not hinder the interaction between CD47 and SIRPa in 
WT mice. It is intriguing that a slow reduction over 24 hr in platelet numbers to 50% 
baseline was observed in the CD47-/- mice rather than a rapid reduction within 2 hr as 
seen with the Gpllb-llla-specific lgG1 mAb. This suggests that despite the significant 
level of binding of the GplX-specific mAb to the platelet surface, only a proportion of 
these mAb are able to interact with FcRs. When reviewing the structure of the Gplb-IX-
V complex (Figure 4.17), it is feasible that the large ectodomains of the 2 Gplba chains 
impeded the interaction between bound GplX-specific mAbs and FcyRs. This factor 
may also explain why the GpV-specific IgGI and lgG2a mAbs were weak and non-
depletors, respectively, in WT and also in GD47-/- mice. An alternative explanation for 
the partial induction of ITP by the GplX-specific IgGI mAb in CD47-/- mice and the lack 
of ITP induction by the mAbs specific for GpV is the presence of additional inhibitory 
mechanisms controlling phagocytosis. This inhibitory effect may be due to differential 
binding of the mAbs to FcyRIIB. Although this was initially considered unlikely as the 
mAbs were of the same isotype, it is possible that differences in the glycosylation of the 
mAbs influences their binding affinity for the inhibitory FcyR (Raju 2008). It is 
interesting to note that BALB/c mice administered the lgG1 mAbs to GpV, Gpla and 
PECAM-1 had more severe ITP than that observed in C57BL/6 mice receiving these 
mAbs, suggesting strain differences in the expression of inhibitory FcyR or 
polymorphisms affecting their function (Jiang et al. 2000). To summarise this section, it 
is suggested that the lack of ITP induction by some anti-platelet lgG1 mAbs may have 
been due to the inability of Fc:FcR interactions to occur due to steric hindrance 
imposed by neighbouring surface proteins, differences between the mAbs in their 
affinity for inhibitory FcyR, and/or due to the ability of CD47:SIRPa interactions to occur 
thus inhibiting phagocytosis. 
As ITP induction by an anti-platelet lgG1 mAb appeared to be determined by the 
balance of activating and inhibitory phagocytosis signals delivered via FcyRs and 
SIRPa, we investigated the possibility of preventing Ab-mediated ITP induction by 
pushing the balance towards an inhibitory phagocytosis signal. It has been previously 
observed that the in vivo administration of mAbs specific for receptors or their ligands 
may result in the activation of the receptor through cross-linking (Boyman et al. 2008). 
This appeared to be the case with the mAb specific for SIRPa as mice pre-treated with 
this antibody were resistant to ITP following administration of the lgG1 mAbs specific 
for Gpllb-llla and Gpla, in C57BL/6 mice, and GpV, in BALB/c mice. Treatment with 
the SIRPa mAb could not only prevent but also reverse lgG1 mAb-induced ITP. 
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Figure 4.17: Structure of the Gplb-IX-V complex. 
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The lgG2b mAbs specific for Gpllb-llla and Gpla induced a greater level of platelet 
depletion than their lgG1 counterparts, probably due to high-affinity FcyR binding. ITP 
induced by the lgG2b mAb specific for Gpllb-llla was completely inhibited in FcyR-/-
mice whereas ITP induced by the Gpla-specific lgG2b mAb was only completely 
inhibited in FcyR-/- mice depleted of complement. Studies performed to determine 
whether pre-treatment with the mAb specific for SIRPa could prevent ITP induced by 
these lgG2b antibodies were unsuccessful, indicating that, unlike the low-affinity 
FcyRs, CD47:SIRPa inhibitory signalling is unable to override the pro-phagocytic 
signals of the higher affinity FcyRs. The combination of a SIRPa-specific mAb with 
pooled immunoglobulin (IVIg) may provide sufficient inhibitory signalling to overcome 
the high affinity activating FcyRs and prevent ITP. 
Studies investigating the role of the CD200:CD200R interaction in the regulation of ITP 
induction indicated that, despite CD200 being expressed on mouse platelets and this 
expression remaining unchanged following the binding of the various lgG1 mAbs to 
platelet antigens, this interaction appears to play no role in regulating phagocytosis of 
rat lgG1 and lgG2b mAb-coated platelets. It is not only possible, but likely, that other 
inhibitory receptors exist on the surface of macrophages and are involved in the 
regulation of phagocytosis induced by high-affinity FcyR engagement. 
The hamster anti-mouse Gpllb-llla mAb, 1B5, belongs to the lgG3 isotype and was 
used in Chapter 3 to deplete mice of platelets for tumour metastasis studies. The 
relationship between hamster IgG isotypes and murine isotypes is unknown, however, 
data described in this Chapter demonstrated that platelet depletion induced by the 1B5 
mAb occurs partially via complement independent platelet fragmentation and partially 
via FcyR-mediated phagocytosis. As 1B5 induced FcyR-mediated uptake could not be 
prevented through pre-treatment with the SIRPa-specific mAb, this suggests the 
antibody binds to high-affinity FcyRs. 
In conclusion, the destruction of antibody-bound platelets principally occurs via FcyR-
mediated phagocytosis but may also occur through complement-mediated destruction 
or through an FcyR- and complement-independent process of platelet fragmentation. 
Use of a SIRPa-specific mAb in vivo can prevent or reverse lgG1 mAb-induced, FcvR-
mediated ITP but is insufficient to override the pro-phagocytic signals delivered by 
lgG2 mAbs interacting with high-affinity activating FcyRs. The ligand for SIRPa, CD47, 
is present on platelets associated with the integrins Gpllb-llla and Gpla thus an 
attractive hypothesis is that mAb binding to these proteins sterically inhibit the 
SIRPa:CD47 interaction thereby removing the inhibitory phagocytosis signal. Based on 
this hypothesis, the capacity of an antibody to induce ITP via Fo/R-mediated 
phagocytosis would, therefore, be determined in the first instance by the ability of the 
Fc portion of the antibody to overcome physical barriers and interact with FcyRs; in the 
second instance by the isotype and glycosylation of the mAb and, therefore, the affinity 
of the FcyRs with which it binds; and in the third instance, in the case of mAbs binding 
low-affinity FcyRs, by the steric hindrance of the CD47:SIRPa interaction. The results 
of these studies provide a greater understanding of the pathogenic pathways of ITP 
and how the self-recognition system, expressed by phagocytic cells may be 
manipulated to prevent antibody-mediated tissue damage. 

Chapter 5 
Monitoring platelet and erythrocyte lifespan 
kinetics using in vivo CFSE labelling 
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5.1 Abstract 
The factors determining platelet and erythrocyte lifespan are not completely 
understood despite extensive study. The lack of success may be attributed to the 
methods used to measure lifespan kinetics, all of which require processing of cells prior 
to analysis, and the inconsistent and potentially inappropriate use of mathematical 
models for data analysis. The aims of this study were to establish an in vivo platelet 
and erythrocyte labelling method using CFSE, determine the most appropriate 
mathematical model for lifespan analysis, and apply both to the study of factors that 
control platelet and erythrocyte lifespans. Control and platelet-deficient c-mpi-l- and 
BCI-XL mutant mice were injected with CFSE and platelet and erythrocyte fluorescence 
followed over time. Data sets were analysed using linear, exponential, multiple-hit and 
lognormal mathematical models. It was found that in vivo CFSE labelling of platelets 
and erythrocytes requires no post-collection processing, proved to be stable, non-toxic 
and non-immunogenic, and the lifespans obtained were highly reproducible. 
Mathematical modelling revealed the lognormal model gave a robust fit to control and 
extreme data sets when either extrinsic or intrinsic factors determined lifespan. Using 
these methods, platelet lifespans were found to be significantly shortened in 
thrombopoietin-receptor deficient mice independent of blood loss, and the anti-
apoptotic protein BCI-XL was shown to play a role in prolonging erythrocyte lifespans. 
Thus, the simultaneous study of platelet and erythrocyte lifespans using in vivo CFSE 
labelling with lognormal modelling yielded insights into common intrinsic and extrinsic 
platelet and erythrocyte lifespan determinants and provides an improved methodology 
for use in this field of research. 
5.2 Introduction 
The work described in this chapter arose when attempting to deplete mice of platelets 
for the purpose of tumour cell metastasis studies. Subsequent to the administration of 
an antibody treatment that we anticipated would reduce platelet numbers in mice, an 
unexpected increase in platelet numbers was observed. It was not clear whether the 
treatment had induced an increase in platelet production from the marrow or whether it 
had prolonged the lifespan of platelets within the bloodstream. Upon reading the 
literature, it became apparent that little progress had been made in identifying factors 
that determine the production, lifespan and destruction of platelets and it occurred to us 
that this lack of progress may be due to deficiencies in the methodologies available for 
measuring these parameters. It also became clear that prior work in this area focused 
on either platelet- or erythrocyte lifespans but not both despite the likelihood of there 
being molecular pathways common to both and the potential for one to affect the other. 
We, therefore, set out to establish a new method for the simultaneous in vivo labelling 
and tracking of platelets and erythrocytes, and to determine the most appropriate 
mathematical model for the analysis of platelet and erythrocyte lifespan data. 
Previously, lifespan measurements have been achieved using radioisotopes, biotin-
labelling or labelling with fluorescent compounds (Van Putten 1958; Goodman and 
Smith 1961; Hoffmann-Fezer et al. 1991; Heilmann et al. 1993; Michelson et al. 1996; 
Baker et al. 1997). The shortcomings of methods using radioisotopes include the risks 
to researchers associated with radiation and the difficulty of its disposal. Furthermore, 
methods that require in vitro labelling of isolated cells of interest prior to injection into 
the animal may cause cellular damage or activation that have the potential to influence 
lifespan. Biotin labelling in vivo has overcome these problems, but post-collection 
fluorescent labelling and centrifugation is required prior to analysis. Additionally, as 
biotin labels cell surface proteins there is the potential for interference with normal 
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function (Magnusson et al. 1998). Biotin has also been demonstrated to be highly 
immunogenic inducing anti-biotin antibodies, therefore, studies repeated in the same 
animal may be compromised (Berger 1975; Dale et al. 1994; Muzykantov et al. 1996). 
In addition to the shortcomings of the labelling techniques mentioned above, published 
mathematical models for the analysis of platelet and erythrocyte survival data are 
numerous, of questionable suitability and applied inconsistently, thus comparisons 
between studies are difficult to perform (Lotter et al. 1986; Hoffmann-Fezer et al. 1993; 
Baker et al. 1997; Mason et al. 2007). The multiple-hit model (MHM) is recommended 
for use when analysing platelet survival data by the International Committee for 
Standardization in Hematology (1988), although it was not recommended for use when 
platelet survival time was very short (Lotter et al. 1986). The MHM assumes that 
lifespan is determined by the number and rate of damaging hits that platelets receive 
within the circulation (Murphy and Francis 1971). However, the advent of END {N-
ethyl-A/-nitrosourea) mutagenesis and genetically modified animals has resulted in the 
identification of intrinsic factors, such as pro- and anti-apoptotic proteins, that play a 
role in determining platelet lifespan kinetics (Carpinelli et al. 2004; Mason et al. 2007). 
Thus, a mathematical model that makes no prior assumptions about biological events 
and that is suitable for use with a diversity of survival times is preferable, as is a rapid 
and cost-effective method for the screening of lifespans in mutant animals to hasten 
progress in this field of research. 
This chapter describes a safe, easy, reliable and cost-effective method for 
simultaneous in vivo labelling and measurement of platelet and erythrocyte lifespans 
and the application of this method in wild type, c-mpN- and BCI-XL mutant mice. The 
method is based on carboxyfluorescein diacetate succinimidyl ester (CFSE), a 
fluorescent dye that covalently links to intracellular molecules and overcomes the 
problems associated with previous labelling procedures (Quah et al. 2007). CFSE 
labelling allows the simultaneous identification of both aged and young platelets or 
erythrocytes, and since it is non-immunogenic, allows repeat studies in the same 
animal to be performed. Mathematical modelling of the survival data obtained using 
the CFSE labelling procedure in the wild type and mutant mouse strains revealed that 
the lognormal model very accurately fits platelet and erythrocyte data, even when 
survival times were very short and, moreover, when lifespans were dictated by either 
cell intrinsic or extrinsic factors. The simultaneous analysis of platelet and erythrocyte 
lifespans in wild type, c-mpi-/- and BCI-XL mutant mice revealed that a lack of 
thrombopoietin signalling, known to dramatically reduce platelet production, was shown 
to also significantly shorten platelet lifespans independent of blood loss, and reduced 
BCI-XL signalling was demonstrated to decrease erythrocyte lifespans in conjunction 
with the previously established reduction in platelet lifespans. 
5.3 Results 
5.3.1 In vivo CFSE labelling of platelets and erythrocytes is stable, non-
toxic and non-immunogenic 
Initial studies investigated whether CFSE, a fluorescent dye that has been used 
extensively to label lymphocytes and follow their migration and proliferation, could be 
administered in vivo to label erythrocytes and platelets. A simple FSC/SSC gating 
strategy was used to identify platelets and erythrocytes with a PE-conjugated anti-
Gpllb/llla antibody confirming platelet identity and reference beads being used to 
quantify platelet and erythrocyte numbers (Figure 5.1 A). It was found that the 
intravenous injection of mice with CFSE resulted in the fluorescent labelling of platelets 
and erythrocytes present in the bloodstream at the time of injection (Figure 5. IB and 
5.1C). Fluorescent labelling of both platelets and erythrocytes was highly stable 
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Figure 5.1: Flow cytometry analysis of carboxyfluorescein diacetate succinimidyl 
ester (CFSE)-labelled platelets and erythrocytes in mice for determination of lifespan. 
Following intravenous injection of CFSE into C57BL/6 mice, anticoagulated blood was 
collected at various time points, exposed to a phycoerythrin (PE)-conjugated monoclonal 
antibody to Gpllb-llla and analysed by flow cytometry. (A) Gating strategy for platelets 
using forward (FSC) and side scatter (SSC) parameters and Gpllb-llla-PE staining. CFSE 
bright and dull populations were then determined (data shown for 32 hours post-CFSE 
injection). (B) Characteristic CFSE profiles obtained with platelets at 3 hours to 120 hours 
following CFSE injection, demonstrating the appearance of a CFSE dull peak and the 
diminution of the CFSE bright peak. (C) Characteristic profiles obtained with erythrocytes. 
Numbers in flow cytometry histograms represent percentage of platelets (B) or erythrocytes 
(C) that are CFSE dull or CFSE bright. 
allowing platelets to be tracked for 5 days (Figure 5.1 B) and erythrocytes for 50 days 
(Figure 5.1C) post labelling. Furthermore, platelets and erythrocytes released from the 
bone marrow subsequent to the CFSE injection had a substantially lower level of CFSE 
fluorescence, thus enabling measurement of the rates of production and destruction of 
each cell type and allowing lifespans to be easily determined (Figure 5.1 B and 5.1C). 
Mice were kept for 8 months following CFSE injection with no evidence of ill-health. 
Additionally, histological examinations performed by a pathologist at 1 and 10 days 
post CFSE injection showed no evidence of renal or hepatic toxicity. In a group of mice 
receiving a subsequent injection of CFSE 12 weeks after the first, an identical 
erythrocyte lifespan was obtained thus demonstrating the reproducibility of the labelling 
method and, importantly, the lack of immunogenicity of CFSE in C57BL/6 mice (Figure 
5.2). 
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Figure 5.2: Reproducibility and lack of immunogenicity of the in-vivo CFSE-
labelling procedure. C57BL/6 mice were given a second intravenous injection of 
CFSE 12 weeks after the first injection. Percentage of CFSE bright erythrocytes was 
determined at each time point following CFSE injection as outlined in Figure 5.1, The 
mean percent of CFSE bright erythrocytes for all mice is shown with error bars 
representing the standard error of mean (n=4). 
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5.3.2 Platelet and erythrocyte lifespans in wild type and platelet-deficient 
mouse strains 
The availability of highly accurate platelet and erythrocyte tracking data, obtained using 
the CFSE-labelling method, allowed us to analyse various mathematical models of 
platelet and erythrocyte lifespans. Model fits to the percentage of CFSE labelled 
platelets and erythrocytes in C57BL/6 mice assuming a linear fit (yellov\/), exponential 
fit (red) and lognormal model (green) are shown in Figure 5.3A (platelets) and Figure 
5.3C (erythrocytes). The corresponding lifespan distributions of platelets are shown in 
Figure 5.3B and of erythrocytes in Figure 5.3D. It is clear that the lognormal model is 
superior to both the exponential and linear fits for both the platelet and erythrocyte data 
sets as it is able to capture both the initial linear decrease (which an exponential 
function cannot capture) and the curved tail (which is missed by a linear fit). The 
superiority of the lognormal model is clear both from a visual inspection of the quality of 
the fits obtained (Figure 5.3A and C) and from a comparison of the weighted mean 
squared error generated from the three fits {Platelets: lognormal - 0.45; linear - 8.90; 
exponential - 72.92 and Erythrocytes: lognormal - 13.73; linear - 126.62; exponential -
718.72). Thus, all subsequent analyses of the data used the lognormal model to 
calculate lifespans. 
Platelet and erythrocyte lifespans obtained in wild type C57BL/6 mice using in vivo 
CFSE labelling and curve fitting using the lognormal model were 87.2 ± 2.3 hr (mean ± 
SEM) and 35.0 ± 0.5 days respectively (Figure 5.4A and 5.4E; Table 5.1). In 
comparison with C57BL/6 mice, the platelet lifespan was shorter (67.7 ± 1.8 hr) and the 
erythrocyte lifespan was longer (42.5 ± 0.4 days) in BALB/c wild type mice (Figure 5.4B 
and 5.4E; Table 5.1) demonstrating that significant strain-specific differences in 
lifespans can occur. It should be noted that the lifespan values obtained using the 
CFSE labelling technique are highly reproducible between experiments (15 x C57BI/6 
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Figure 5.3: Mathematical modelling of labelled platelet and erythrocyte (RBC) data from 
wild-type C57BL/6 mice. Mean values for proportion of labelled platelets (A) and erythrocytes 
(C), present in C57BL/6 mice following in-vivo carboxyfluorescein diacetate succinimidyl ester 
(CFSE) labelling, were fitted using linear (yellow), exponential (red), and lognormal (green) 
distribution models. The lifespan distribution obtained with these models is shown in (B) for 
platelets and (D) for erythrocytes with the left-hand Y-axis representing the exponential fit and 
lognormal model, and the right-hand Y-axis representing the linear fit. It can be seen that the 
lognormal model gave a superior fit to the platelet and erythrocyte survival data and was 
therefore used for subsequent analyses. 
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Figure 5.4: Lognormal modelling of labelled platelet and erythrocyte survival data in wild-type, 
c-mpI knockout (KO), and Plt20 mutant mouse strains. Mice received an intravenous injection of 
carboxyfluorescein diacetate succinimidyl ester (CFSE) and blood samples were collected at the time 
points indicated in each X axis. Platelets and erythrocytes were identified and counted by flow 
cytometry as in Figure 5.1, and the CFSE-labelled populations of each followed over time. The 
lognormal model was applied to the data to generate the curves shown in this figure and to estimate 
mean lifespans (Table 5.1). Mean values of experimental groups are shown with error bars 
representing standard error of mean. (A) Labelled platelet data over 5 days in wild-type C57BL/6 
mice, c-mpI KO mice with mean platelet levels 14% that of controls, and c-mpI KO mice with mean 
platelet levels 3% that of controls. (B) Labeled platelet data in wild-type BALB/c and BALB/c Plt20 
mutant mice (platelets 30% that of control levels) during a 5-day period. (C) Labelled platelet data in 
Plt20 mutant mice during a 24-hours period. (D) Platelet lifespan distribution calculated using the 
lognormal model with datasets for wild-type C57BL/6, c-mpI KO (platelets 14% and 3% normal) and 
Plt20 mutant mice. (E) Labelled erythrocyte data in wild-type C57BL/6, c-mpI KO (platelets 14% 
normal), wild-type BALB/c and BALB/c Plt20 mutant mice. (F) Labelled erythrocyte data for individual 
c-mpI KO mice (platelets 3% normal). 
mice in Figure 5.4A representing 3 separate experiments) and are within the range of 
lifespan values previously published, although these values vary significantly most 
probably due to the different methodologies and mouse strains used (Van Putten 1958; 
Goodman and Smith 1961; Abbrecht and Littell 1972; Ault and Knowles 1995; Baker et 
at. 1997; Bergeref a/. 1998; Marinkovic etai 2007). 
In contrast to wild type C57BL/6 mice, in c-mpN- mice that lack thrombopoietin (TPO) 
receptors, platelet and erythrocyte lifespans varied depending upon the baseline 
platelet levels of the mice. Two phenotypes commonly arise within the same litter of 
the c-mpl-l- mouse strain, one with extremely low platelet numbers which are 
approximately 3% of normal levels, and the other with platelet numbers that are 
approximately 14% of normal levels. This phenotypic variation is not genetically stable 
as the breeding of mice with extremely low platelet levels results in offspring with 
platelet numbers either 3% or 14% of normal. The explanation for this variation is 
unknown and has been observed by others (personal communication Dr Ben Kile, 
WEHI, Australia). 
Mice with platelet levels 14% that of wild type controls had a substantially shorter mean 
platelet lifespan (61.8 ± 2.9 versus 87.2 ± 2.3 hr), a difference that was highly 
significant (p < 0.0001 )(Figure 5.4A, Table 5.1). In contrast, the mean erythrocyte 
lifespan in these mice was not significantly different from control values (36.4 ± 1.4 
versus 35.0 ± 0.5 days)(Figure 5.4E, Table 5.1), indicating that the shortened platelet 
lifespan in these mutant mice is due to an intrinsic defect resulting from a lack of c-mpi 
signalling and not due to blood loss. Platelet lifespans in c-mpl-l- mice with very low 
(3% of control) endogenous platelet numbers had an even shorter mean platelet 
lifespan (32.1 ± 6.6 versus 87.2 ± 2.3 hr, p < 0.0001), which was accompanied by a 
significantly (p<0.02) reduced erythrocyte lifespan (18.7 ± 4.1 days compared with 35.0 
± 0.5 days), a result indicative of blood loss (Figures 5.4A and 5.4F, Table 5.1). Thus, 
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in these highly thrombocytopenic mutant mice, platelet lifespan is determined by both 
extrinsic and intrinsic factors. Platelet production in c-mpl-l- mice was, as would be 
expected, dramatically reduced when compared with wild type mice (Figure 5.5A), but 
no impairment in erythrocyte production was seen (Figure 5.5B). 
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Figure 5.5: Platelet and erythrocyte production in wild-type, c-mpi KO and Plt20 mutant 
mouse strains. Mice received an intravenous injection of CFSE and blood samples were 
collected at the time points indicated on each X axis. Platelets and erythrocytes were identified 
and counted by flow cytometry as in Figure 5.1, and the CFSE-dull population of each followed 
over time. (A) Platelet production (cumulative total of absolute numbers x 10^/i.iL) in wild-type 
C57BL/6 and c-mpI KO mice (platelets 14% normal). (B) Erythrocyte production (cumulative 
total of absolute numbers x 10%iL) in wild-type C57BL/6, c-mpI KO (platelets 14% normal) c-
mpl KO (platelets 3% normal), wild-type BALB/c and BALB/c Plt20 mutant mice. 
Table 5.1: Platelet and erythrocyte lifespans In wild-type and platelet-deficient mouse strains 
Mouse Strain Platelet Lifespan 
hr (mean +/-
SEM) 
Erythrocyte Lifespan 
days (mean +/- SEM) 
P-value vs wild-type 
(platelets; erythrocytes) 
Wild-type C57BL/6 87.2 ±2.3 35.0 ±0,5 NA 
c-mpI KO C57BL/6 (14%) 61 .8±2.9 36.4 ±1.4 p < 0.0001; p = ns 
C-mpI KO C57BL/6 (3%) 32.1 ±6.6 18.7±4.1 p < 0.0001; p < 0.02 
Wild-type BALB/c 67.7 ±1.8 42.5 ±0,4 p < 0.0001 ®;p< 0.0001 ® 
Plt20 BALB/c mutant 11.0 ±0.7 37.2 ± 1.1 p < 0.0002; p < 0.0017 
Lifespan values obtained from lognormal curve fitting of data as shown in Figure 5.3. 
SEM indicates standard error of the mean; NA indicates not applicable. 
® Compared with wild-type C57BL/6. 
Plt20 mice, generated by ENU mutagenesis, have a shortened platelet lifespan due to 
the production of an unstable BCI-XL protein resulting in a pro-apoptotic phenotype 
(Mason et al. 2007). Platelet lifespan in the Plt20 mutant strain was found to be 
substantially shorter (p < 0.0002) than wild type BALB/c mice (11.0 ± 0.7 versus 67.7 ± 
1.8hr) (Figures 5.4B and 5.4C, Table 5.1) which is consistent with previously published 
work (Mason et al. 2007). The erythrocyte lifespan in the Plt20 mutant mice (Figure 
5.4E, Table 5.1) was also slightly but significantly (p = 0.0017) shorter than in the 
BALB/c controls (37.1 ±1 .1 versus 42.5 ± 0.4 days). 
The shortened platelet lifespans measured in the Plt20 mutant mouse and c-mpl-l-
mice allowed us to test the ability of the lognormal model to accurately describe 
extreme platelet data sets. Fits using the lognormal model are shown in Figure 5.4A (c-
mpl 3% and c-mpi 14%) and Figure 5.4B and 5.4C (Plt20 mice). We observed that the 
lognormal model is able to the fit the c-mp114%, c-mpI 3% and Plt20 platelet data sets 
extremely well. Additionally, the erythrocyte survival data obtained from the c-mpl-l-
mice with very low platelet numbers was extremely variable between individual mice. 
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This gave us an ideal opportunity to test the curve fitting ability of the lognormal model 
using extreme data sets from individual mice. It can be seen in Figure 5.4F that, in 
each case, the lognormal model accurately fitted the erythrocyte survival data. 
5.3.3 Aged-Associated Changes to Etvthrocytes 
The CFSE labelling method can not only be used to track platelet and erythrocyte 
lifespans, but can also be used to follow the changes in the flow cytometry 
characteristics of old and new erythrocytes. New erythrocytes were determined as 
those with negligible CFSE fluorescence (CFSE dull) and, therefore, 10 days following 
CFSE injection were between 0 and 10 days of age. Old erythrocytes were determined 
as those erythrocytes that still exhibited high CFSE fluorescence (CFSE bright), 40 
days following CFSE injection and were therefore 40+ days of age. When the FSC and 
SSC parameters of these erythrocyte populations were examined it was found that the 
old erythrocytes had a significantly reduced mean FSC (p = 0.0001) and coefficient of 
variation of SSC (p = 0.0079) compared with young erythrocytes (Figure 5.6). These 
results suggest that aged erythrocytes are smaller in size and have a reduced 
intracellular complexity, a result consistent with earlier studies of aging erythrocytes 
(Waugh et at. 1992; Willekens et al. 2003). 
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Figure 5.6. Ability of the in-vivo CFSE labelling method to detect age-related changes to 
erythrocytes. Erythrocytes (RBCs) were studied for changes in forward (FSC) and side scatter 
(SSC) parameters at 10 days and 40 days following in-vivo CFSE labelling, with erythrocytes being 
gated as in Figure 5.1 A. (A) Selection of newly generated, CFSE dull RBCs (Blue Gate) at 10 days 
post injection, and old, CFSE bright RBCs (Red Gate) at 40 days post injection. Numbers represent 
the percentage of CFSE dull and CFSE bright erythrocytes. (B) Comparison of SSC and FSC 
histograms between New and Old RBCs in a single mouse. (C) Comparison of coefficient of 
variation (CV) of SSC, and mean FSC between New and Old RBCs in C57BL/6 mice. Values 
represent the mean and error bars represent the SEM (n = 5). 
5.4 Discussion 
The in vivo labelling of platelets and erythrocytes with CFSE is advantageous over in 
vivo biotin labelling in that post-collection processing is not required, the label is 
internal and therefore less likely to interfere with surface protein function and, of 
particular importance, CFSE is non-immunogenic. We have also shown that CFSE 
injected intravenously is non-toxic and cell populations of different ages may be 
studied. The production rates and lifespan of platelets and erythrocytes are generally 
not studied together. In vivo CFSE labelling, however, enables both entities to be 
studied simultaneously, and allows valuable information to be gained, such as 
evidence of blood loss that may significantly impact upon lifespan. 
The lognormal model was used to calculate average platelet and erythrocyte lifespans 
and good fits to experimental data were obtained. A lognormal distribution of cell 
lifespans implies that many cells have similar lifespans (indicated by a peak in the 
distribution - Figures 5.3B and D) but that there is some variance in lifespans around 
this most common value. Some cells have a slightly shorter lifespan while others have 
a longer lifespan. Such a distribution has been proposed previously to model cell 
lifespans by Dowling et al (Dowling et al. 2005). Furthermore, the lognormal model is 
able to fit both the normal and more extreme platelet and erythrocyte survival data sets 
very well. 
A number of other functions have been used previously to model platelet lifespans, 
from simple linear and exponential functions (Hoffmann-Fezer et al. 1993; Baker et al. 
1997), to more complicated models (Lotter et al. 1986). Like the lognormal model, a 
linear fit to labelled data also assumes that cell destruction is age dependent. However, 
a linear fit assumes that all cells die after exactly one lifespan, L. In contrast, a 
lognormal distribution allows for variation in the platelet lifespan about the most 
common value of L. The result is that the survival curves for the lognormal model have 
what appears to be a linear early part followed by a curved tail that matches well with 
experimental data. It was also found that a far better fit to the experimental data was 
obtained by assuming that cell lifespans have a lognormal, rather than an exponential 
distribution. This is clear both from a visual inspection of the quality of the fits obtained 
(Figures 5.3A and C) and from a comparison of the mean squared error generated 
from both fits. It should also be noted that many of the more complicated models that 
have been proposed (Lotter et al. 1986) do not have a biological basis. The lognormal 
model, however, corresponds well to a scenario where platelets are created with a 
certain 'most common' lifespan, but where there is some biological variance about this 
value. 
A multiple-hit, or gamma model has also been used to model platelet lifespans (1977; 
Tsukada and Tango 1980; Lotter et al. 1986; Baker et al. 1997). We found that the 
multiple-hit model gave similar lifespan estimates to the lognormal model, however the 
fitting procedure took far longer to run. This increase in processing time was not 
associated with any increase in the accuracy of the fit. Furthermore, the multiple-hit 
model is based on the assumption that platelet lifespan is determined by a number of 
injurious hits occurring within the circulation. When fitting data using the multiple-hit 
model there appeared to be little consistency within each data set between the number 
of hits required for platelet destruction or the waiting time between these hits. This calls 
into question the biological validity of the model's assumptions. 
It is likely that a combination of intrinsic and extrinsic factors determine platelet and 
erythrocyte lifespan, hence, a mathematical model that makes no assumptions about 
the events causing platelet destruction but that has a biological basis would be more 
appropriate for widespread use. The excellent fit of the lognormal model to the 
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extremely thrombocytopenic c-mpl-l- mice and the Plt20 mutant mice demonstrates the 
versatility of this model in describing lifespans determined by either intrinsic or extrinsic 
biological events, and hence its use is recommended over the multiple-hit model. 
Comparisons between C57BL/6, c-mpl-l- and wild type littermate controls 
demonstrated that the platelet levels within these mice significantly influence the 
lifespan of platelets and erythrocytes. We infer from the results obtained that when 
platelet numbers are extremely low (3% of normal), vascular integrity is compromised 
and microscopic bleeding occurs resulting in reduced platelet and erythrocyte 
lifespans. This is consistent with the findings of a correlation between platelet lifespan 
and platelet count in patients with bone marrow hypoplasia (Hanson and Slichter 
1985). However, when platelet levels in the c-mpl-l- mice are 14% of normal, vascular 
integrity is maintained, as reflected by a normal erythrocyte lifespan and production 
rate. The reduced platelet lifespan in these mice, however, suggests that TPO 
signalling may play some role in the determination of platelet lifespan. It is known that 
TPO acts as a survival signal for stem cells, megakaryocytes and platelets, and 
it is proposed to do so by altering the intracellular environment to promote cell cycling 
and proliferation and inhibit apoptosis by altering the balance of proteins such as cyclin 
D, c-myc, p27, FKHR, BCI-XL and Bad (Geddis ef al. 2002; Majka et al. 2002). It is 
likely, therefore, that in the absence of TPO-R signalling, the few platelets produced 
have a shortened lifespan, predominantly due to a decrease in Bcl-Xtthus accelerating 
the Bak-mediated pathway of apoptosis (Mason et al. 2007). 
As expected, the rate of platelet production in the c-mpl-l- mice was considerably 
reduced and is consistent with the finding that megakaryocyte numbers within the 
marrow of these mice are very low (Alexander et al. 1996). The erythrocyte production 
rate, however, was not compromised in the c-mpl-l- mice despite the finding that there 
are reduced numbers of erythroid progenitor cells in the marrow and spleen of this 
mouse strain (Alexander et at. 1996). In c-mpl-l- mice with platelet levels 3% of 
normal, we found elevated rates of erythrocyte production compared to controls, which 
is consistent with our inference of microscopic blood loss occurring due to a loss of 
vascular integrity. 
In the Plt20 mutant mouse strain, the platelet lifespan was dramatically shortened 
when compared with normal controls. This is consistent with the findings of Mason et 
al (Mason et al. 2007) and has been explained by a reduction of BCI-XL signalling 
causing a pro-apoptotic phenotype in the platelets. The erythrocytes in these mice had 
a slightly, but significantly, shorter lifespan than their wild type controls. As these mice 
have a platelet count approximately 30% of normal levels, and the rate of erythrocyte 
production was not significantly different to that of the wild type controls, it is unlikely 
that the shortened erythrocyte lifespan was due to microscopic blood loss. A previous 
study of erythrocytes in vitro demonstrated a potential role for membrane-bound BCI-XL 
in erythrocyte survival (Walsh et al. 2002). Furthermore, studies on conditional bcl-x-/-
mice demonstrated apoptosis of a large majority of late-stage erythroblasts and 
evidence for premature lysis of mature erythrocytes (Wagner et al. 2000; Rhodes et al. 
2005). Our in vivo studies of erythrocyte lifespan in the Plt20 mutant mouse would 
suggest that BCI-XL is involved in determining the lifespan of mature erythrocytes as 
well as late-stage erythroblasts. 
Mammalian platelets and erythrocytes are both anucleate in their mature forms, 
however, platelets retain their mitochondria whereas erythrocytes do not. Platelets 
therefore have the capacity to utilise mitochondrial-dependent pathways of apoptosis. 
Indeed, the gross structural alterations occurring in megakaryocytes prior to platelet 
production, including cytoskeletal alterations, membrane condensation and ruffling, 
have been compared to cells undergoing apoptosis. The process of programmed cell 
death in erythrocytes, termed eryptosis, is characterised by a reduction in cell volume. 
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decoupling of the cytoskeleton from the plasma membrane causing membrane 
blebbing, the activation of proteases and exposure of phosphatidylserine on the outer 
membrane following calcium-dependent activation of scramblase (Poller et al. 2008). 
Erythrocyte senescence or aging is characterised by a reduction in cell volume and 
loss of haemoglobin, cholesterol and phospholipids through vesiculation, the 
generation of a senescent-specific antigen and exposure of phosphatidylserine (Waugh 
et al. 1992; Willekens et al. 2003; Bosman et al. 2005). As eryptosis and senescence 
have similar features it has been suggested that erythrocyte senescence represents an 
apoptotic pathway(Bosman et al. 2005). Our studies of age-associated changes within 
the erythrocytes demonstrated a reduction in size and cellular complexity consistent 
with the changes ascribed to senescence and eryptosis. 
In conclusion, in vivo labelling of erythrocytes and platelets with CFSE overcomes 
several technical and safety concerns of previously published labelling methods. 
Additionally, the in vivo injection of CFSE in mice was demonstrated to be non-toxic 
and non-immunogenic. The application of the lognormal model to platelet and 
erythrocyte survival data using the CFSE labelling method gave an excellent fit to both 
normal and extreme datasets when lifespan was determined by intrinsic or extrinsic 
factors. The use of both CFSE labelling and the lognormal model is therefore 
recommended for future research into erythrocyte and platelet lifespans. Using these 
novel approaches in c-mpl-l- and BCI-XL mutant mice it was also demonstrated that 
TPO-signalling increases platelet lifespan and BCI-XL signalling increases erythrocyte 
lifespan, with both findings having potential clinical relevance. 
Chapter 6 
Final Discussion 
This chapter summarises the major findings arising from the experimental data 
presented in Chapters 3, 4 and 5 and discusses their implications in terms of current 
concepts, future research directions and potential avenues for translation. 
6.1 Introduction 
Platelets are cytoplasmic fragments present in large numbers within the bloodstream 
that contain a multitude of proteins. For a long time, platelet function was believed to 
be limited to the essential functions of haemostasis and thrombosis. However, it has 
become clear in the last decade that platelets play significant roles in both innate and 
adaptive immunity, inflammatory responses including leukocyte migration, tissue 
regeneration and angiogenesis. Parallelling the revelation of the diverse physiological 
functions of platelets, however, has been the association of exacerbated platelet 
function with numerous thrombotic and chronic inflammatory diseases (Barnes 2002; 
Klinger 2002; von Hundelshausen and Weber 2007; Jennings 2009; Solanilla et al. 
2009; Yoshida and Granger 2009). 
The aims of this thesis were to examine in detail the following three platelet-associated 
biological processes: 
(i) The role of platelets in tumour cell metastasis, in particular, the kinetics and 
interrelationship of the pro-metastatic role of platelets and the anti-metastatic role of 
NK cells, and the relevant contributions to the metastatic process of platelet P-selectin 
and endothelial P-selectin. 
(ii) The determinants and mechanisms of antibody-mediated platelet elimination and 
the role of inhibitory self-recognition systems in this process. 
(iii) The factors influencing platelet and erythrocyte lifespan by establishing appropriate 
experimental and analytical methodologies. 
6.2 The role of platelets in tumour cell metastasis 
Platelets have long been implicated in haematogenous tumour cell metastasis, with the 
purported mechanisms of action including the formation of a thrombus around the 
tumour cell thus affording protection from haemodynamic stresses, linking tumour cells 
to the vascular endothelium via adhesion molecules such as P-selectin, assisting the 
migration of tumour cells across the blood vessel wall through the release of 
degradative enzymes, and the provision of growth and angiogenic factors enabling the 
establishment of secondary tumours (Karpatkin and Pearlstein 1981; Karpatkin 2002; 
Erpenbeck and Schon 2010). It has also been suggested that the only role of platelets 
in tumour cell metastasis is the provision of a protective cloak from recognition and 
destruction by immune cells, principally NK cells (Nieswandt et al. 1999; Palumbo et al. 
2005). 
The results presented in Chapter 3 obtained using an experimental metastasis model 
in mice, demonstrated that platelets promoted, whilst NK cells inhibited the lung 
metastasis of B16F1 melanoma and 4T1.2 breast cancer cell lines. On further 
examination using the B16F1 melanoma, the pro-metastatic action of platelets and the 
anti-metastatic action of NK cells were shown to be chronologically distinct and the 
kinetics of the NK-cell effect was unchanged in the presence or absence of platelets. 
These data, therefore, unequivocally demonstrate that the role of platelets in tumour 
cell metastasis occurs within 1 hr of tumour cell entry into the bloodstream and is 
independent of NK cells. Equally, the anti-metastatic effect of NK cells occurs between 
1 and 24 hr following tumour cell injection and is independent of platelets. Previous 
work on the role of NK cells in the elimination of intraperitoneal B16 melanoma cells 
also showed an early time frame (3-5 days following injection) for the infiltration and 
anti-tumoral actions of NK cells (Kurosawa et al. 1993). Furthermore, the important role 
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of IFN-Y produced by early-entry N K cells in activating the anti-tunnoral responses of 
macrophages and T cells was demonstrated (Kurosawa et al. 1995; Abe et al. 1998). 
The data described in Chapter 3 also raise the question of the location of NK cell 
destruction of tumour cells and suggests that it may be occurring soon after tumour cell 
attachment to the blood vessel wall. It is possible that endothelial activation, occurring 
as a result of tumour cell attachment, triggers the recruitment of NK cells to the region 
of invasion. Indeed, endothelial cells have been demonstrated to secrete TNFa 
(Imaizumi et al. 2000), the principal cytokine for NK cell recruitment into normal and 
tumour-bearing tissue (Pilaro et al. 1994; Smyth et al. 1998). The secretion of TNFa 
also induces the expression of E-selectin on endothelium enabling leukocyte adhesion 
to the blood vessel wall, however, E-selectin is also implicated in aiding tumour cell 
metastasis (Biancone et al. 1996). Studies by Fogler et al also indicate that the VCAM-
1:VLA-4 interaction, that is enhanced by TNFa, is likely to support the initial rolling and 
adhesion of NK cells to the endothelium in the lung, liver and B16 melanoma tumours 
(Fogler et al. 1996). In order to further define the timing and location of NK cell action 
against metastasising tumour cells, studies in mice with additional time points of NK 
depletion, such as 6 hr and 12 hr following tumour cell injection, and also NK cell 
replenishment, such as 48 hrs following tumour cell injection, may be beneficial. Intra-
vital microscopy studies may also assist in answering these questions. 
To our knowledge, these are the first studies that examine the mechanisms of lung and 
liver metastasis simultaneously. Using the B16F1 melanoma cells as a model, it was 
observed that in the absence of platelets, although lung metastasis was significantly 
reduced, liver metastasis increased. This effect became very obvious in mice depleted 
of NK cells. Using 4T1.2 breast cancer cells as an additional model, lung metastases 
decreased in the absence of platelets, however liver metastases remained 
undetectable even in the absence of NK cells. These results provide additional 
evidence that platelets arrest tumour cells within the lung vasculature and, in their 
absence, a greater number of tumour cells are carried within the bloodstream to the 
capillary beds of downstream organs. Of equal significance, these data imply that 
platelets are not required for B16F1 melanoma tumour cell metastasis to the liver and 
that 4T1.2 breast cancer cells are incapable of metastasising to, or growing within, 
hepatic tissue. These findings are of particular clinical importance as they suggest that 
the use of platelet inhibitors to prevent metastasis may result in the redistribution rather 
than diminution of metastatic spread. Additionally, these results confirm the influence of 
vascular anatomy, haemodynamic forces and 'seed and soil' interactions on metastatic 
spread. 
Previous studies have consistently demonstrated P-selectin to be involved in tumour 
cell metastasis, however, this has been attributed to platelet-derived P-selectin (Kim et 
at. 1998) although one study also suggests a possible role for endothelial P-selectin 
(Ludwig et al. 2004). The results of the metastasis experiments described in Chapter 3 
clearly demonstrate that both endothelial and platelet-derived P-selectin play significant 
roles in B16F1 melanoma lung metastasis, and endothelial P-selectin in B16F1 
melanoma liver metastasis. These data add to the already substantial evidence 
supporting the targeting of P-selectin in therapeutic trials to prevent metastasis. Borsig 
et al have studied a number of anticoagulant and non-anticoagulant heparin-like 
molecules that bind selectins and their administration to mice proved effective in 
reducing experimental lung metastasis (Stevenson et al. 2007). Additionally, low-
molecular weight heparins have proven beneficial in a number of human trials in 
cancer patients with the beneficial effects not only being due to the inhibition of selectin 
binding, but also the inhibition of the endoglycosidase, heparanase, as well as 
inhibition of a range of biological processes, such as coagulation, angiogenesis and 
immune effector function, and induction of apoptosis (Falanga 2004). 
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The experiments with NK cell and platelet-depleted mice revealed some additional 
intriguing results that raise further questions. Firstly, a significant number of tumours 
occurred in the lungs of mice depleted of both NK cells and platelets that were absent 
from the lungs of mice depleted of platelets alone. This result indicates that a 
significant population of tumour cells were capable of metastasising to the lungs 
without the assistance of platelets. The experiments conducted in P-selectin deficient 
and WT mice depleted of platelets demonstrated that endothelial P-selectin is capable 
of supporting both lung and liver metastasis in the absence of platelets. However, 20-
25% of metastasis to the liver and lungs was observed to occur independently of both 
platelets and P-selectin. Potential mechanisms of platelet and P-selectin independent 
metastasis include the physical entrapment of single tumour cells or tumour cell 
aggregates due to size restrictions within a small capillary despite inherent 
haemodynamic pressures, and the interaction of other adhesion protein pairs, such as 
E-selectin with sialylated fucosylated lactosaminoglycans (Biancone et al. 1996), VLA-
4 with VCAM-1, and hyaluronic acid with CD44 (Zetter 1993). 
The role of L-selectin in the promotion of metastasis is of interest when relating the 
findings of Laubli et al to our data on the timing of NK cell anti-metastatic activity. Using 
B16F1 melanoma cells in an experimental lung metastasis model, these investigators 
found that L-selectin promoted tumour cell survival, an effect that occurred 12-24 hr 
following tumour cell injection and could not be attributed to B or T cells as the same 
results were seen in NOD-SCID mice. However, despite NK cells also expressing L-
selectin, in the experiments by Laubli et al, NK cell numbers in lung tissue appeared to 
be unaffected by L-selectin deficiency. It was proposed, therefore, that L-selectin 
positive leukocytes (granulocytes and/or monocytes) assisted the migration of tumour 
cells across the vessel wall and the induction of inflammation may provide a protective 
and nurturing environment for the tumour cells. (Laubli et al. 2006). 
Taken together, the results described in Chapter 3 suggest a model of lung metastasis 
wherein tumour cells are dependent upon platelets to a large extent, to assist in 
establishing resistance to the inherent velocity of blood flow within the lung vasculature 
and aid attachment to the endothelium. The platelet adhesion molecule, P-selectin, 
probably plays a dominant cross-linking role in this model through interactions with 
mucin proteins expressed by tumour cells and PSGL-1 expressed by endothelial cells. 
A proportion of tumour cells are capable of metastasising independently of platelets 
and are aided by endothelial P-selectin interactions with tumour-derived mucins. 
Physical entrapment and other adhesion molecules may also play a role. The majority 
of tumour cells that succeed in the early stages of metastasis to the lung are rapidly 
eliminated by NK cells, with only a very small proportion of tumour cells exhibiting NK 
cell resistance (Figure 6.1). Metastasis to the liver would appear to occur 
independently of platelets, most likely due to the inherent slow flow of blood and 
fenestrated endothelium within the hepatic vasculature, and is aided by endothelial P-
selectin. Physical entrapment and other adhesion molecules are also likely to play a 
role. Again, however, NK cells have a major negative impact upon the success of liver 
metastasis. 
6.3 Antibody-mediated platelet depletion and its inhibition 
The production of auto-antibodies to platelet surface proteins manifests in a condition 
known as immune thrombocytopenic purpura (ITP) which affects all age groups and 
leaves sufferers susceptible to life-threatening haemorrhage. Current treatment 
strategies have considerable side-effects or associated risks and treatment failures are 
not uncommon. The predominant mechanism of platelet depletion in ITP is FcR-
mediated uptake of antibody-coated platelets by immune effector cells. However, a 
study by Nieswandt et al indicated that FcR-independent mechanisms of platelet 
depletion existed that were dependent upon the target antigen (Nieswandt et al. 2000). 
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Figure 6.1: B16F1 melanoma metastasis to tl ie lungs may occur through platelet-
dependent and independent pathways that involve endothelial P-selectin. (A) Within 
the bloodstream, activated platelets bind B16F1 melanoma cells via P-selectin:mucin 
interactions. P-selectin on activated platelets and tumour cell (TC) mucins (e.g. sialyl 
Lew/is *) interact with PSGL-1 and P-selectin, respectively, on endothelial cells. Additional 
platelets recruited to the TC provide resistance to haemodynamic forces enabling TC 
attachment to the blood vessel wall. TNFa released from activated endothelial cells recruit 
highly-effective anti-tumoral NK-cells that destroy >90% attached TC. (B) In the absence 
of platelets, a proportion of TC interactions with endothelial P-selectin are sufficiently 
strong to resist haemodynamic forces thus enabling TC attachment to the vessel wall. A 
proportion of TC will also attach to the vessel wall through platelet and P-selectin 
independent processes involving other adhesion proteins or physical entrapment (not 
shown). Unattached TC are swept through the lung capillary bed to downstream organs 
such as the liver. 
Furthermore, studies by Olsson et al using a mAb to an unidentified platelet antigen 
implicated the self-recognition protein pair, CD47:SIRPa, in the regulation of ITP 
(Olsson et al. 2005). 
The results of experiments described in Chapter 4, conducted to investigate both of the 
above findings in greater detail, yielded several significant findings. The mechanism of 
platelet depletion induced by the majority of mAbs studied was principally FcyR-
mediated, but in some cases occurred through direct activation and fragmentation of 
platelets or via complement-mediated destruction. Furthermore, the level of FcyR-
mediated platelet depletion was usually greater following the administration of lgG2b 
mAbs than lgG1 mAbs. Direct activation and fragmentation of platelets was observed 
following the administration of both IgGI and lgG2b mAbs to Gplba and this process 
was shown to be both FcyR and complement independent. It is likely, therefore, that 
mAb binding to Gplba triggered the receptor resulting in platelet activation and 
degranulation. Interestingly, the fragmentation of -80% of the platelet population within 
a 2 hr period did not have any apparent health consequences such as thrombosis or 
acute inflammation. A similar effect of platelet fragmentation following Ab binding has 
been observed in human studies and was attributed to the engagement of the FcyR 
present on human platelets but absent on mouse platelets (Nardi et al. 2001; Li et al. 
2008). This appears to be the first report, however, of the involvement of Gplba in this 
process of mAb-induced platelet activation. With the majority of mAbs studied, 
complement did not play a role, suggesting that complement-inhibitory proteins present 
on the platelet surface prevented complement-mediated destruction. In the case of the 
lgG2b mAb targeting Gpla, however, complement was shown to play a significant role 
in platelet destruction. Therefore, in treatment refractory cases of ITP, the trial of 
complement inhibitors may be worthwhile. Treating ITP that involves mAb-induced-
platelet fragmentation, however, may prove a much greater challenge. 
The more severe ITP induced by rat lgG2b mAbs compared to their rat lgG1 
counterparts suggested the preferential binding of rat igG2b mAb to high-affinity FcyR 
and rat lgG1 mAbs to low-affinity FcyR. Structural comparisons between mouse and 
rat IgG confirmed that this was more than likely the case (Hulett and Hogarth 1994). 
The administration to mice of mAbs specific for different platelet membrane proteins 
did not always induce ITP and this effect appeared to be antigen specific. Upon further 
investigation, the ability of a mAb specific for a particular platelet antigen to induce ITP 
did not correlate with the density of binding of the mAb to the platelet surface nor the 
degree of saturation of the platelet surface antigen by the mAb. However, the rate of 
platelet depletion induced by IgGI mAbs appeared to be influenced by the density of 
the mAb on the platelet surface. These data suggested that, in the situation of a non-
depleting mAb, the Fc portion of the mAb was incapable of interacting with FcR due to 
steric hindrance, the mAb exhibited a higher binding affinity for the inhibitory than the 
activating FcyR, or that FcR-mediated uptake of the mAb coated platelets was being 
regulated by the presence of additional inhibitory signals. 
The most well described self-recognition protein pairs involved in the regulation of the 
effector function of macrophages are CD47:SIRPa and CD200:CD200R. Since in most 
cases ITP appears to be induced by FcyR-dependent phagocytosis of mAb coated 
platelet by macrophages, the function of these inhibitory protein pairs in the regulation 
of ITP was investigated. Administration of the non-ITP inducing GplX-specific mAb to 
mice deficient in CD47 resulted in ITP although at a relatively slow rate of induction. 
These data suggested that the inhibition of CD47:SIRPa interactions by mAb binding 
may have been a determinant of ITP induction. Indeed, CD47 is associated on the 
surface of platelets with the integrins Gpllb/llla and Gpla thus it is possible that ITP 
induction by IgGI mAbs specific for these CD47-associated proteins occurred as a 
result of the disruption of the CD47:SIRPa interaction. This hypothesis could be tested 
by assessing the capacity of recombinant SIRPa to bind to platelets in the presence of 
a panel of anti-platelet mAbs including the IgGI mAbs specific for Gpla and Gpllb/l l la. 
The effect of stimulating the inhibitory receptor, SIRPa, using a specific mAb in vivo to 
prevent FcyR-mediated ITP was investigated and discovered to not only prevent, but 
reverse rat IgGI mAb induced, FcyR-mediated ITP. This effect was not observed, 
however, with ITP induced by rat lgG2b mAbs. 
The mechanism by which SIRPa signalling inhibits phagocytosis was elucidated by 
Tsai and Discher (Tsai and Discher 2008). Their studies on the phagocytosis of foreign 
cells have demonstrated that in response to FcR engagement, actin and non-muscle 
myosin fibres are recruited in the formation of the phagocytic cup. The binding of 
autologous CD47 with SIRPa results in the inactivation of myosin through 
dephosphorylation thus preventing this process from occurring (Tsai and Discher 2008) 
(Figure 6.2). 
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Figure 6.2: Inhibition of phagocytosis by CD47:SIRPa signalling. (A) Foreign cells deficient 
in CD47 are opsonised by IgG and subsequent FciFcyR interactions on macrophages initiates 
the assembly of paxillin, F-actin, and nonmuscle myosin IIA in the formation of a phagocytic cup. 
(B) In contrast, CD47 present on IgG-opsonised 'self cells signals through SIRPa to inhibit 
myosin assembly through dephosphorylation thus preventing phagocytosis. 
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The results in Chapter 4 imply that signalling induced by the SIRPa mAb regulates low-
affinity activating FcyR and that triggering this receptor with a specific mAb or chimeric 
CD47 protein may be an effective treatment for pathologies involving the binding of 
low-affinity FcyR. Unlike the low-affinity activating FcyR, SIRPa signalling clearly does 
not regulate high-affinity activating FcyR. Furthermore, the macrophage inhibitory 
receptor, CD200R, did not appear to regulate low- or high-affinity activating FcRs. The 
identification of proteins that negatively regulate high-affinity activating FcyR would be 
of significant clinical benefit in the treatment of antibody-mediated pathologies including 
ITP and, therefore, represents a vital area for future research. Until the identification of 
other such inhibitory proteins, future studies should assess the efficacy of combination 
therapy using a SIRPa-specific mAb and intravenous pooled immunoglobulin to 
overcome the pro-phagocytic signalling mediated by both low affinity and high-affinity 
activating FCYR. 
An important limitation of the mouse models of ITP described in this thesis is that 
mouse platelets lack FcR whereas human platelets express FCYRIIA. This limitation 
could be overcome by using transgenic human FcyRIIA mice which are available and 
possess FcyRIIA bearing platelets (McKenzie 2002). Furthermore, patients with ITP 
generally have anti-platelet antibodies of more than one IgG isotype and against 
several platelet antigens. The translation of these findings into information that can be 
directly related to ITP in humans will require studies to be performed with human tissue 
in vitro, although the results of experiments in vitro often do not correlate with 
outcomes in vivo. For example, in vitro the SIRPa-specific mAb blocked SIRPa 
signalling by CD47 whereas our in vivo experiments using the same antibody appeared 
to trigger SIRPa signalling (Olsson et al. 2005). The use of a chimeric human/mouse 
model, as has recently been developed by Liang 6t a/ for the study of drug-induced 
thrombocytopenia (Liang et at. 2010), in combination with human FcyRIIA transgenic 
mice, may help to overcome such experimental quandaries. 
Taken together, the results of Chapter 4 suggest a model of FcyR-mediated ITP 
whereby anti-platelet mAbs binding low-affinity FcvR-binding will induce ITP if they 
sterically hinder CD47:SIRPa interactions. If, however, CD47:SIRPa interactions 
prevail the balance of signalling from activating and inhibitory FcyR will determine 
whether phagocytosis occurs. In either of the above scenarios, use of a SIRPa-specific 
mAb in vivo restores the inhibitory signalling pathway thus preventing phagocytosis 
(Figure 6.3). 
6.4 In vivo CFSE labelling and mathematical modelling of 
platelet and erythrocyte lifespans 
Little progress has been made in identifying factors that determine the production, 
lifespan and destruction of platelets and it occurred to us this may be due to 
deficiencies in the methodologies available for measuring these parameters. It also 
became clear that prior work in this area focused on either platelet- or erythrocyte 
lifespans but not on both despite the likelihood of there being common molecular 
pathways and the potential for one to affect the other. We, therefore, set out to 
establish a new method for the simultaneous in vivo labelling and tracking of platelets 
and erythrocytes, and to determine the most appropriate mathematical model for the 
analysis of platelet and erythrocyte lifespan data. 
The results described in Chapter 5 demonstrate that in vivo CFSE labelling of platelets 
and erythrocytes requires no post-collection processing, proved to be stable, non-toxic 
and non-immunogenic, and the lifespans obtained were highly reproducible. CFSE 
has been used extensively in the study of the migration and division of lymphocytes 
Figure 6.3: Potential role of SIRPa signalling in the inhibition of 
phagocytosis induced by mAbs binding low-affinity FcyR- (A) Following mAb 
binding to a platelet antigen, Fc portions of the Ab interact with both low-affinity 
activating (green) and low-affinity inhibitory (red) FcyRs and CD47 on the platelet 
surface (orange) interacts with SIRPa on the immune effector cell (orange). The 
balance of signalling is inhibitory and therefore phagocytosis does not occur. (B) If 
the anti-platelet mAb is specific for a protein closely associated with CD47, such 
as Gpllb-llla and Gpla, steric hindrance of the CD47:SIRPa interaction shifts the 
balance of signals towards a pro-phagocytic outcome. (C) Use of a SIRPa-
specific mAb triggers the inhibitory SIRPa receptor restoring the inhibitory 
signalling and thus preventing phagocytosis. 
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(Weston and Parish 1990; Lyons and Parish 1994), however, this is the first report of 
its use to label platelets and erythrocytes in vivo. Assessment of the kidneys and livers 
of mice following CFSE injection by an independent pathologist revealed no signs of 
organ toxicity. The advantages of CFSE labelling over in vivo biotin labelling, 
therefore, is that post-collection processing is not required prior to flow cytometric 
analysis and the lack of immunogenicity, hence, pre-and post-treatment studies may 
be performed in the same experimental animal. 
Mathematical modelling, performed by collaborators, revealed the lognormal model 
gave a robust fit to control and extreme data sets when either extrinsic or intrinsic 
factors determined lifespan and was superior to the linear, exponential and multiple-hit 
models. Using these methods, both platelet and erythrocyte lifespans were found to be 
significantly shortened in thrombopoietin-receptor deficient mice, independent of blood 
loss, and the anti-apoptotic protein BCI-XL was shown to play a role in prolonging 
erythrocyte lifespans. Thus, the simultaneous study of platelet and erythrocyte 
lifespans using in vivo CFSE labelling with lognormal modelling yielded insights into 
common intrinsic and extrinsic platelet and erythrocyte lifespan determinants and 
provides an improved methodology for use in this field of research. This methodology 
has many potential applications such as to determine the circulation kinetics of tumour 
cells and to assess the impact of therapeutic agents upon the rate of bone marrow 
production, the lifespan and the senescence of platelets and erythrocytes. Examples of 
such agents, in the context of this thesis, include modified antibodies targeting specific 
platelet protein interactions with tumour cells and growth factor mimetics aimed at 
boosting platelet or RBC production and/or longevity. 
6.5 Conclusion 
Platelets are critical for the preservation of life through their maintenance of vascular 
integrity, immunity, inflammation, wound repair and angiogenesis. The experimental 
data presented in this thesis has shed some light on three aspects of platelet biology, 
namely, proving their NK cell independent role in the promotion of tumour cell 
metastasis that closely resembles their role in assisting leukocyte migration; identifying 
not only likely determinants and mechanisms of immune-mediated platelet destruction 
but also an inhibitor of this process that may have therapeutic potential; and the 
development of robust methods that may be used to better understand those factors 
influencing the production, lifespan and senescence of platelets. As with most 
research, whilst the results presented in this thesis have answered some questions, 
they have also raised many more upon which future research may be based. 
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